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ABSTRACT 
 
In recent decades, the prevalence of obesity and type 2 diabetes has risen dramatically. 
Strategies to reduce the incidence of these diseases are of great clinical relevance. The 
contribution of dietary fat has been central to that debate. In particular, the 
composition of dietary fat can influence skeletal muscle metabolism and the sensitivity 
to feeding and exercise adaptations. Polyunsaturated omega-3 fatty acids are linked 
with beneficial effects on skeletal muscle metabolism and function while saturated 
fatty acids have been linked with metabolic dysfunction. It is still poorly understood 
how differences in fatty acid structure can have contrasting effects in skeletal muscle. 
 
It is known that omega-3 fatty acids are incorporated into skeletal muscle lipid pools, 
however, it is unknown what specific lipid species omega-3 fatty acids are incorporated 
into. In Chapter 2 of this thesis, the effects of EPA and DHA on the lipidomic profile of 
skeletal muscle myotubes were explored. Although similar in structure, EPA and DHA 
treatment resulted in divergent lipid profiles. EPA increased the content of DPA, while 
DHA reduced arachidonic acid. Both omega-3 fatty acids significantly increased the 
saturated fatty acid content. EPA and DHA incorporated into myotubes were largely 
directed towards phospholipid species. The changes in lipid profiles following EPA 
treatment were associated with increased basal and insulin dependent glucose uptake. 
This increase in glucose uptake was not driven by changes in the protein abundance of 
glucose transporters or mitochondrial respiration. DHA did not have any impact on the 
metabolic measures made. These data show for the first time that EPA and DHA 
differentially affect glucose uptake in skeletal muscle and this effect may be associated 
with the differential changes in lipid profiles. 
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Previous studies have shown that omega-3 supplementation increase mTORC1 
signalling and protein anabolism following feeding. There is evidence to suggest that 
EPA is the dominant n-3 fatty acid that drives muscle anabolism. These anabolic effects 
of omega-3 fatty acids may be driven by changes in the proteomic profile which 
increases sensitivity to extracellular stimuli. In chapter 3, the effects of EPA and DHA 
on protein turnover and protein expression are explored. Neither, EPA or DHA did not 
altered basal protein synthesis. The activation of the mTORC1 pathway in response to 
a combined stimulus of amino acids + serum was not altered by either EPA or DHA. 
EPA reduced protein breakdown and this was not related to a reduction in 
ubiquitinated proteins. Proteomic analysis showed that EPA and DHA differentially 
altered the abundance of a number of proteins. Given the significant incorporation into 
phospholipids, we explored how changes in membrane lipid content altered the 
proteins associated with membrane compartments. DHA treatment resulted in the 
decreased association of ribosomal proteins with the membrane while EPA induced a 
small increase in ribosomal proteins associated with the membrane. Gene ontology 
analysis showed that proteins involved in protein folding associated with cell 
membranes were enhanced following EPA treatment of myotubes. These results led us 
to hypothesis that EPA may enhance myotube protein content by altering protein 
fidelity 
 
In contrast to omega-3 fatty acids, saturated fatty acids such as palmitate are linked 
with the dysfunction of a number of metabolic systems. A number of studies have 
demonstrated that palmitate causes skeletal muscle insulin resistance through the 
generation of lipid intermediates, such as ceramides and diacylglycerols, which inhibit 
insulin action. Palmitoleate, a fatty acid analogous to palimate with the addition of a 
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single double bond, can protect against the deleterious effect of palmitate and 
intrinsically improve glucose uptake. To date, no study has assessed the impact of 
palmitate and palmitoleate on lipid profiles. Treatment of myotubes with palmitate and 
palmitoleate respectively significantly increased the content of each fatty acid with 
myotubes, while, only modestly altering the abundance of other fatty acid species. 
Palmitate reduced insulin dependent glucose uptake and palmitoleate did not have any 
effect. PKB activation in response to insulin was unaltered by either fatty acid. Both 
palmitate and palmitate increased maximal mitochondrial respiration when used at a 
dose of 250µM but increasing concentration substantially reduced coupled respiration 
and increased proton leak. These data show that accumulation of palmitate specifically 
and not general lipid accumulation attenuates normal insulin action. The data also 
suggests that reduction in PKB activation may not be the critical mechanism for the 
loss of insulin stimulated glucose uptake following palmitate incorporation. 
 
Obesity and acute increases in circulating fatty acids are linked with a reduction in the 
muscle protein synthetic response to insulin and amino acids. It was hypothesised that 
PA and PAO would have different effects on protein turnover through changes in 
protein synthesis and breakdown.  Incorporation of palmitate into myotubes resulted 
in the significant decrease in the basal protein synthesis while protein breakdown was 
unchanged. PAO did not alter protein synthesis or breakdown. Palmitate increased 
phosphorylation of ribosomal protein S6, a readout of P70S6K1 activity despite 
reduced protein synthesis. Eif2α phosphorylation was not altered by either fatty acid, 
indication no changes in endoplasmic reticulum stress. Proteomic analysis revealed 
that both fatty acids altered the protein abundance of a number of different proteins 
but no changes in proteins associated with muscle anabolism were detected. Despite 
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increasing anabolic signalling, increasing palmitate accumulation resulted in 
depressed protein synthesis independent of changes in ER stress. 
Collectively, these data show that minor differences in fatty acid structure can elicit 
divergent metabolic activities in skeletal muscle. This may occur by altering the cell 
microenvironment through changes in lipid profiles, protein abundance and associated 
with cell membranes. The addition of a just a single double bond in the fatty acyl chain 
can prevent deleterious effects on glucose and protein metabolism.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart Jeromson: PhD thesis                                                                                                           V 
THANK YOU 
 
I would like to thank my supervisors Lee and Iain for giving me the opportunity to 
pursue a PhD and for their support and guidance throughout. A special thanks to Chris 
and Lee for getting me started in the lab and stimulating my fascination in skeletal 
muscle metabolism.  I consider myself lucky to have been part of such a promising 
research group, it made my time in Stirling so much more enjoyable and I have learned 
so much from everyone. Thanks to all the collaborators, without them, it would not 
have been possible to undertake this project. 
 
To all the past and present members of 4B142, thanks, it was always a great laugh and 
a continued source of support. Thanks to everyone I’ve worked alongside in the lab for 
putting in the hard work and for their expert help. 
 
 
 
Lastly, and most importantly, my family, for your continued help and support and 
instilling in me the qualities to make it through a PhD – Thank you most of all. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart Jeromson: PhD thesis                                                                                                           VI 
TABLE OF CONTENTS 
ABSTRACT I 
THANK YOU V 
TABLE OF CONTENTS VI 
LIST OF FIGURES IX 
LIST OF TABLES XI 
ABBREVIATIONS XII 
LIST OF PUBLICATIONS XIV 
CHAPTER 1: General introduction 1 
1.0 Introduction 1 
1.1. Dietary fatty acid sources and lipid metabolism in skeletal muscle                                    2 
1.3. Omega-3 PUFAs and  Skeletal muscle anabolism 7 
1.4. Omega-3 PUFAs and insulin sensitivity 13 
1.5. Summary of Omega-3 research 22 
1.6. Saturated fatty acids and metabolic health 23 
1.7. Saturated fatty acids and insulin sensitivity 25 
1.8. SFA and skeletal muscle anabolism 29 
1.9. Summary of SFA/MUFA research 34 
1.10. Remodelling the lipidome 35 
    1.11.     Mass spectrometry approaches in biology                                                                 37 
1.12. Conclusion 43 
1.13. Aims and objectives                                                                                                                       44  
CHAPTER 2:  Lipid remodelling may influence the differential effects of EPA and DHA on 
skeletal muscle glucose uptake. 46 
2.0. Abstract 46 
2.1. Introduction 47 
2.2. Materials and methods 50 
2.2.1. Materials 50 
2.2.2. Cell culture 50 
2.2.3. FAME analysis 51 
2.2.5. Phospholipid profiling of C2C12 myotubes 52 
2.2.6. Glucose uptake 53 
2.2.7. Cellular respiration. 53 
2.2.8. Cell processing 54 
2.2.9. Western blotting 55 
2.2.10. Statistics 55 
2.3. Results 56 
2.3.1. EPA and DHA substantially increase the abundance of omega-3 species but have 
different effects on individual omega-3 fatty acids 56 
2.3.2. EPA and DHA divergently alter myotube lipid profiles 57 
2.3.3. EPA enhances basal and insulin stimulated glucose uptake independent of 
increased PKB phosphorylation 58 
2.3.4. EPA and DHA do not alter the  protein abundance of glucose transporters or 
hexokinase 59 
2.3.5. N-3 fatty acids do not alter mitochondrial respiration 60 
 
Stewart Jeromson: PhD thesis                                                                                                           VII 
2.3.6. Global lipidomic analysis reveals that EPA and DHA transition into 
phospholipids and divergently remodel the phospholipidome 62 
2.3.7. Targeted phospholipid analysis reveals that EPA and DHA increase the fraction 
of lipid species containing long chains and 5 or more double bonds at the expense of 
shorter chain less saturated species. 65 
2.4. Discussion 68 
Chapter 3: EPA and DHA alter the membrane proteome and may drive the differential 
effects on protein turnover. 74 
3.0. Abstract 74 
3.1. Introduction 75 
3.2. Materials and Methods 77 
3.2.1. Materials 77 
3.2.2. Cell culture 77 
3.2.3. Cell preparation 77 
3.2.4. Protein content 78 
3.2.5. Muscle protein synthesis and breakdown 78 
3.2.6. P70S6K1 signalling in response to a serum stimulus 79 
3.2.7. Western blotting 80 
3.2.8. Stable isotope labelling of amino acids in cell culture 80 
3.2.9. Treatment protocol 82 
3.2.10. Mass spectrometry 82 
3.2.11. Quantification and bioinformatics analysis 83 
3.2.12. Serum dialysis 84 
3.2.13. FAME analysis 85 
3.2.14. Data analysis and statistics 85 
3.3. Results 86 
3.3.1. Serum dialysis increases the omega-3 content in donor horse serum 86 
3.3.2. EPA enhances protein accretion through a reduction in breakdown while DHA 
has a neutral effect. 87 
3.3.3. N-3 fatty acid treatment does not alter the P70S6K1 signalling response to a 
serum stimulus. 89 
3.3.4. EPA and DHA differentially alter global proteome profiles 89 
3.3.5. Altered composition of phospholipids changes the membrane-associated 
proteome. 92 
3.4. Discussion 94 
3.5. Supplementary figures 101 
Chapter 4: Palmitate induces insulin resistance despite conserved insulin driven PKB 
phosphorylation. 104 
4.0. Abstract 104 
4.1. Introduction 105 
4.2. Materials and methods 107 
4.2.1. Cell culture 107 
4.2.2. FAME analysis 107 
4.2.3. Glucose uptake 108 
4.2.4. Cell respiration 108 
4.2.5. Cell processing 109 
4.2.6. Western blotting 109 
4.2.7. Data analysis and statistics 110 
4.3. Results 110 
4.3.1. Palmitate and Palmitoleate exert similar effects on lipid profiles 111 
4.3.2. Palmitate causes insulin resistance despite normal PKB phosphorylation 112 
4.3.3. Palmitate disrupts mitochondrial function 113 
 
Stewart Jeromson: PhD thesis                                                                                                           VIII 
4.4. Discussion 117 
Chapter 5: Palmitate attenuates protein synthesis despite an increase in anabolic signalling.
 123 
5.0. Abstract 123 
5.1. Introduction 124 
5.2. Materials and methods 126 
5.2.1. Cell culture 126 
5.2.2. Cell processing 126 
5.2.3. Western blotting 127 
5.2.4. Muscle protein synthesis and breakdown 127 
5.2.5. Stable isotope labelling of amino acids in cell culture 129 
5.2.6. Mass spectrometry 129 
5.2.7. Quantification and bioinformatics analysis 130 
5.2.8. Data analysis and statistics 131 
5.3. Results 131 
5.3.1. Palmitate attenuated protein synthesis but not protein breakdown 131 
5.3.2. Altered rates of protein turnover results in divergent proteomic profiles 133 
5.4. Discussion 134 
Chapter 6: General discussion 140 
6.0. General discussion 140 
References 164 
 
  
 
Stewart Jeromson: PhD thesis                                                                                                           IX 
LIST OF FIGURES 
 
Figure 1.1. Proposed mechanisms of omega-3 PUFA action. 23 
Figure 1. 2 Accumulation of FFA and increased Palmitate can disrupt insulin signalling by 
attenuating PKB activity. 29 
Figure 1. 3  Experimental design 45 
 
Figure 2. 1 EPA and DHA enhance n-3 abundance but differentially alter the abundance of 
individual omega-3 fatty acids. 57 
Figure 2. 2 Lipid alterations in response to EPA and DHA are not limited to omega-3 fatty acids.
 58 
Figure 2. 3 EPA and DHA have differential effects on muscle glucose uptake despite similar PKB 
signalling.                                                                                                                                              59 
Figure 2. 4 EPA and DHA do not alter total protein abundance of glucose transporters and 
hekokinase 1 and 2.    60 
Figure 2. 5 N-3 fatty acids do not alter mitochondrial oxygen consumption                   61 
Figure 2. 6  Omega-3 treatment does not alter the abundance of proteins involved in the 
electron transport complex. 62 
Figure 2. 7 PCA scores plots of lipid profiles generated by LC-MS in (A) positive ion and (B) 
negative ion modes. 62 
Figure 2. 8. Positive ion OPLS-DA scores plots for (A) BSA vs DHA and (B) BSA vs EPA  64 
Figure 2. 9 Targeted phospholipid analysis indicates preferential incorporation of long chain 
polyunsaturated fatty acids into specific phospholipid classes                                           65 
Figure 2. 10 EPA and DHA cause significant remodelling of phospholipid species.         67 
 
Figure 3. 1 SILAC workflow. 82 
Figure 3. 2 EPA enhances protein accretion. 87 
Figure 3. 3 The effect of EPA and DHA on muscle protein anabolism. 88 
Figure 3. 4 EPA or DHA does not alter the P70S6K1 signalling response to a serum stimulus.
 89 
Figure 3. 5. Descriptive summary of global proteome. 91 
Figure 3. 6 Over representation analysis. 91 
Figure 3. 7. Ribosomal protein association with membranes. 94 
Figure 3. 8 Abundance of a) collagen proteins and b) P62, detected in the global proteomic 
screen. 98 
 
Stewart Jeromson: PhD thesis                                                                                                           X 
Figure 3. 9 STRING diagram representing protein-protein interactions.  99 
 
Figure 4. 1 Palmitate and Palmitoleate induced lipid profiles in C2C12 myotubes. 111 
Figure 4. 2. Differential changes in fatty acids species following PA or PAO incorporation 112 
Figure 4. 3  Palmitate inhibits insulin sensitive glucose uptake with no change in PKB 
phosphorylation. 113 
Figure 4. 4. Acute changes in oxygen consumption. 113 
Figure 4. 5. Mitochondrial oxygen consumption traces. C2C12 myotube oxidative capacity was 
assessed using a seahorse bioanalyser and mitochondrial stress test. 114 
Figure 4. 6.Effects of Palmitate and Palmitoleate on parameters of mitochondrial funtion         
116                         
Figure 4. 7 . Protein abundances of electron transport chain complexes. 117 
 
Figure 5. 1 Effect of PA and PAO on protein anabolism. 132 
Figure 5. 2 Venn diagram of common and divergent changes in protein abundance 
following PA/PAO treatment. 134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart Jeromson: PhD thesis                                                                                                           XI 
LIST OF TABLES 
 
 
Table 1. 1 Summary of studies characterising the impact of omega-3 PUFAs on skeletal muscle 
metabolism. 13 
Table 1. 2 Summary of studies characterising the impact of omega-3 PUFAs on glucose 
homeostasis. 21 
 
Table 3. 1 Pathway activation prediction analysis 91 
Table 3. 2 Overrepresented biological processes in EPA treatment group. 92 
Table 3. 3 Overrepresented biological processes in DHA treatment group 93 
 
Table 5. 1 List of proteins altered by PA 134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart Jeromson: PhD thesis                                                                                                           XII 
ABBREVIATIONS 
 
4E-BP1 – Eukaryotic translation initiation factor 4E binding protein 1  
AA – Arachidonic acid 
ADP – Adenosine diphosphate 
ALA – alpha linoleic acid 
AMPK – AMP activated protein kinase 
ATF6 – Activation transcription factor 6 
BiP – Binding immunoglobin protein 
Bnip3 - BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 
BSA – Bovine serum albumin 
CAMKII – Calmodulin dependent kinase 2 
CD36 – Cluster of differentiation 36 
COX – cyclooxygenase 
CVD – Cardiovascular disease 
DAG – Diacylglycerol 
DHA – Doxosahexaenoic acid 
DHS – Donor horse serum 
DM – Differentiation media 
DMEM – Dulbeccos modififed eagles medium 
DPA – Docosapentaenoic acid 
Eif2a – Eukaryotic initiation factor 2alpha 
Elovl2 – Elongase 2 
EPA – Eicosapentaenoic acid 
ER – Endoplasmic reticulum 
ESI MS/MS – Electron spray ionisation double mass spectrometry 
FAME – Fatty acyl methyl esters 
FATP – Fatty acid transporter proteins 
FBS – Foetal bovine serum 
FCCP - Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
Foxo03 – Forkhead box transcription factor 3 
GLUT4 – Glucose transporter 4 
GLUT1 – Glucose transporter 1 
GM – Growth media 
GPR120 - G protein coupled receptor 120 
GTP – Guanidine triphosphate 
Ikbα – NF-kappaB inhibitor alpha 
IMCL – Intramyocellular lipid 
IR – insulin resistance 
IRS1 – Insulin receptor substrate 1 
LA – Linoleic acid 
LC/MS - Liquid chromatography mass spectrometry 
LOX – lypooxygenase 
LPC – Lyso-phosphatidylcholine 
LPE – Lyso-phosphatidylethanolamine 
MPB – Muscle protein breakdown 
MPS – Muscle protein synthesis 
mRNA – Messenger ribonucleic acid 
mTOR – Mechanistic target of Rapamycin 
mTORC1 – Mechanistic target of rapamycin complex 1 
 
Stewart Jeromson: PhD thesis                                                                                                           XIII 
MUFA – Mono unsaturated fatty acid 
MURF-1 – Muscle ring finger protein 1 
NF-Kb – Nuclear factor kappa B 
NRF1 – Nuclear respiratory factor 1 
OCR – oxygen consumption rate 
OPLS-DA – Orthogonal partial least squares – discriminant analysis 
PA – Palmitate 
PBS – phosphate buffer saline 
PC – Phosphatidylcholine 
PE – Phosphatidylethanolamine 
PERK – Protein kinase R-like Er kinase 
PGC-1 alpha – Peroxisome proliferator activated coactivator 1 
PGF2α – Prostaglandin 2F alpha 
Pi3K – Phosphoinositide-3 kinase 
PI – Phosphatidylinositol 
PKB - Protein kinase B 
PKC – Protein kinase C 
PP2A – protein phosphatase 2A 
PPARγ – Peroxisome proliferator activated receptor gamma 
P70S6K1 – Ribosomal S6 protein kinase 1 
PS - Phosphatidylserine 
PUFA – polyunsaturated fatty acid                                                                           
SFA – Saturated fatty acid 
SILAC – stable isotope labelling of amino acids in cell culture 
SKM – Skeletal muscle 
SPT-1 – Serine Palmitoyl transferase 1 
TAG – Triacylglycerol 
TCA – Trichloroacetic acid 
T2D – Type 2 diabetes 
TFAM – Mitrochondrial transcription factor A 
TNF-a – Tumour necrosis factor alpha 
UPR – Unfolded protein response 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stewart Jeromson: PhD thesis                                                                                                           XIV 
LIST OF PUBLICATIONS 
 
-  Jeromson S, Mackenzie I, Doherty MK, Whitfield PD,Bell G, Dick J, Shaw AS, Rao 
F, Ashcroft SP, Philp A, Galloway S,Gallagher I,Hamilton DL (2016) Lipid 
remodelling and an altered membrane proteome may drive the effects of EPA 
and DHA treatment on skeletal muscle glucose uptake and protein accretion. 
American journal of physiology – endocrinology and metabolism. Under 
revision. 
- Jeromson S, Gallagher IJ, Galloway SDR, Hamilton DL. (2015) Omega-3 fatty 
acids and skeletal muscle health. Marine drugs. 13(11) 6977-7004. 
- Shaw A*, Jeromson S*, Watterson KR, Pediaini JD, Gallagher IJ, Whalley T, 
Dreczkowski G, Brooks NE, Galloway SDR, Hamilton DL. (2016) Multiple AMPK 
activators inhibit L-carnitine uptake in C2C12 skeletal muscle myotubes. 
American journal of physiology – cell physiology.* Both authors contributed 
equally to this work. 
- Impey SG, Hammond KM, Shepherd SO, Sharples AP, Stewart C, Limb M, Smith 
K, Philp A, Jeromson S, Hamilton DL, Close GL, Morton JP. (2016) Fuel for the 
work required: a practical approach to amalgamating train-low paradigms for 
endurance athletes. Physiological reports. 4(10) e12803. 
- Hammond KM, Impey SG, Currell K, Mitchell N, Shepherd SO, Jeromson S, 
Hawley JA, Close GL, Hamilton DL, Sharples AP, Morton JP. (2016) Post exercise 
high-fat feeding suppresses p70S6K1 activity in human skeletal muscle. 
Medicine & science in sports & exercise.  
- Philp A, Schenk S, Perez-Schindler J, Hamilton DL, Breen L, Laverone E, 
Jeromson S, Phillips SM, Baar K. (2015) Rapamycin does not prevent increases 
 
Stewart Jeromson: PhD thesis                                                                                                           XV 
in myofibrillar and mitochondrial protein synthesis following endurance 
exercise. Journal of physiology. 593(18) 4275-84.  
- Hamilton DL, Beall C, Jeromson S, Chevtzhoff C, Cuthbertson DJ, Ashford ML. 
(2014) Kv 1.3 inhibitors have differential effects on glucose uptake and AMPK 
activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle. Journal 
of Physiological Sciences. 64(1) 13-20. 
- MacNaughton LS, Wardle SL, Witard OC, Mcglory C, Hamilton DL, Jeromson S, 
Lawrence CE, Wallis GA, Tipton KD. (2016) The response of muscle protein 
synthesis following whole-body exercise is greater following ingestion of 40g 
than 20g ingested whey protein. Physiological reports.  
- Da Boit M, Sibson R, Sivasubramaniam S, Meakin JR, Greig CA, Aspden RM, Thies 
F, Jeromson S, Hamilton DL, Speakman JR, Hambly C, Mangoni AA, Preston T, 
Gray SR. (2016) Fish oil supplementation increases muscle function and quality 
in response to resistance exercise training in older women but not men: a 
randomized control trial. American journal of clinical nutrition.. 
- Jeromson S, Hunter DJ. (2014) Influencing mitochondrial membrane 
composition and bioenergetics through omega-3 supplementation. Journal of 
physiology. 592(9). 1913-14 
 
 
 
 
 
 
General introduction                                                                                                                             1 
CHAPTER 1: General introduction 
 
 
 
1.0 Introduction 
 
In the last three decades global obesity has almost doubled to over 1.4 billion, meaning 
that as much as one third of westernised populations are classed as overweight/obese 
(World Health Organisation, 2008). Concurrent with the increase in obesity rates is an 
increase in obesity related disorders such as type 2 Diabetes (T2D), sarcopenic obesity 
and cardiovascular disease making obesity one of the major healthcare issues facing 
the world (World Health Organisation report, 2000). Being overweight/obese 
increases the risk of developing diabetes by up to 30% [1]. The cost of primary diabetes 
care for the UK National Health Service (NHS) is currently at £9.8 billion/annum and is 
expected to continue rising (NHS). Skeletal muscle is a major site of glucose disposal, 
accounting for approximately 30% of postprandial glucose disposal [2]. Maintaining 
skeletal muscle metabolic health is therefore key to maintaining glycaemic control. 
Strategies that improve skeletal muscle metabolic function and insulin sensitivity could 
therefore have a major impact on the obesity induced development of insulin 
resistance and diabetes and reduce health care costs and improve quality of life. 
Skeletal muscle mass maintenance is not only crucial to the maintenance of metabolic 
function, but also through the control of locomotion it is also critical to the maintenance 
of physical function. Skeletal muscle (depending on adiposity levels) accounts for 
approximately 40% of total body mass and is highly adaptable to environmental 
changes such as diet and physical activity levels [3], [4]. Loss of muscle mass with 
progressing age is an inevitable aspect of the aging process [5]. Reductions in skeletal 
muscle mass and metabolic function can have detrimental effects on overall health and 
 
General introduction                                                                                                                             2 
is a major contributing factor to the onset of disease with age [6]. Loss of muscle mass 
and subsequent physical function not only places the individual at greater risk of 
chronic disease but leads to frailty and reduced quality of life [6]. From the age of 
approximately 50, skeletal muscle mass declines by 0.2–0.5%/year and this loss is 
accelerated in a diseased state [7]. Moreover, as little as a 5% decrease in skeletal 
muscle mass has been associated with increased morbidity [8]. If the rate of sarcopenia 
(age related loss of muscle mass) can be reduced by 10% this would translate to a 
saving in US health care costs of $1.1 billion per year [9]. Therefore, it is of great clinical 
relevance to find effective therapies for improving muscle mass and metabolic 
function. Recent evidence suggests that manipulating the lipid content of skeletal 
muscle has the capacity to alter muscle function and metabolism. For instance, 
enhancing the omega-3 polyunsaturated acid (PUFA) content of skeletal muscle may 
enhance protein anabolism and muscle strength [10], [11]. This introduction will focus 
on the role of multiple lipid species in skeletal muscle metabolism and function. This 
will be split into two sections, first the effect of omega-3 PUFAs will be reviewed and 
the second part will review the effects of saturated fatty acids (SFA) and 
monounsaturated fatty acids (MUFA). 
1.1. Dietary fatty acid sources and lipid metabolism in skeletal muscle  
 
As previously mentioned, skeletal muscle is highly adaptable or mal-adaptable to 
changes in diet composition. In particular, diets high in saturated fat have been linked 
with the onset of both obesity and T2D [12], [13]. However, diets high in 
polyunsaturated fatty acids such as the Mediterranean diet have been linked to 
beneficial outcomes, such as improved cardiovascular health [14], [15]. Furthermore, 
the traditional diet of Inuit populations which is high in omega-3 PUFAs and low in 
omega-6 fatty acids is associated with a lowered risk of cardiovascular disease and 
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improved insulin sensitivity despite being a diet very high in fat [16], [17]. Therefore, 
the amount and type of fat in the diet can play an important role in regulating whole 
body metabolic health. 
Fatty acid species are classified by their varying degrees of saturation into three 
main classes; saturated fatty acids (SFA), monounsaturated fatty acids (MUFA) and 
polyunsaturated fatty acids (PUFA). SFAs are a simple carbon chain containing no 
double bonds, MUFAs contain one double bond and PUFAs are classified as carbon 
chains containing two or more double bonds. The differences in the chemical structure 
of these different classes can lead to different physiological effects. For example, SFA 
has been linked with the development of metabolic dysfunction while conversely some 
MUFAs and PUFAs have positive effects on metabolic function [18], [19]. 
At a cellular level, fatty acids are not only structurally important, as the main 
component of cellular membranes, but also have an important function in a number of 
metabolic processes such as regulating the activity of certain enzymes and by acting as 
signalling molecules [20]. Therefore, alterations in the composition of the muscle lipid 
pool may have profound effects on skeletal muscle metabolic and physical function. It 
is well established that skeletal muscle is sensitive to changes in dietary lipids, with a 
minimum 2-week alteration in dietary intake needed to significantly alter muscle lipid 
composition [21]–[23]. The change in cellular function brought about by changing lipid 
composition is possibly due to the fact that different species of fatty acids display a 
diverse array of structures ranging from simple saturated carbon chains to highly 
unsaturated carbon chains, these differences in structure are a large determinant of 
function. Before fatty acids can have an impact on cellular metabolism they must first 
be transported into the cell. However, fatty acid transport and metabolism must be 
tightly regulated as high intracellular levels of free fatty acids can be highly toxic due 
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to lipid peroxidation, theoretically, highly unsaturated fatty acids will be most readily 
oxidized. As a result, there are a number of transporter proteins (CD36/FATP/FABPpm) 
and cytosolic proteins (FATPc) that regulate uptake and subcellular localisation of fatty 
acids, allowing for them to be stored or metabolised effectively [24]. Fatty acid uptake 
is analogous to glucose uptake, in which CD36 vesicles translocate from intracellular 
stores to the sarcolemma and is sensitive to insulin stimulation and contraction 
induced activation of AMPK [24]. These transporter proteins are also known to play a 
role in the regulation of mitochondrial fatty acid oxidation [25]. Once transported into 
the cell a number of intracellular fates are possible, mainly, β-oxidation, storage in 
discrete lipid droplets or incorporation into cell membranes. In skeletal muscle the 
approximate ratio of storage to oxidation is 2:1 although this is variable depending on 
a number of factors such as energy expenditure and muscle fibre type [26]. Up to 90% 
of fatty acids transported into the cell are either stored or oxidized in soleus muscle 
[26]. Alternatively, fatty acids are incorporated into cellular membranes; the length of 
the carbon chain, number and position of double bonds of the fatty acids composing 
the membrane determine the physico-chemical properties such as fluidity [27]. 
Membranes which contain phospholipids lacking any double bonds pack tightly 
together reducing fluidity whereas the cis-kinks in the carbon chains caused by double 
bonds in unsaturated fatty acids pack less tightly and increase the deformability and 
fluidity of the membrane [28]. A change in membrane fluidity can alter the activity of 
membrane associated proteins, membrane receptors and vesicle budding and fusion 
[29], [30]. 
1.2. Omega-3 Polyunsaturated fatty acids 
The omega-3 fatty acids are a group of polyunsaturated fatty acids defined by a 
double bond at the third carbon from the methyl end of the carbon chain. Humans do 
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not possess the necessary omega-3 desaturase to add a double bond at the 15th carbon 
of a long chain fatty acid and are, therefore, unable to endogenously synthesize alpha-
linoleic acid (ALA 18:3n-3) and linoleic acid (LA 18:2n-6) making them essential fatty 
acids. Omega-6 PUFAs are also essential fatty acids and generally have metabolically 
distinct effects to omega-3 PUFAs. While the human body cannot synthesize omega-3 
and omega-6 PUFAs, it does have the capacity to further metabolize these fatty acids 
through stages of elongation and desaturation. ALA can be metabolized to 
eicosapentaenoic acid (EPA 20:5n-3) and docosahexaenoic acid (DHA 22:6n-3) by ∆6 
desaturase and ∆5 desaturase respectively, while LA is converted to arachidonic acid 
(AA 22:4n-6). However, the conversion of ALA to DHA is very inefficient with <10% 
conversion in females and <3% in males [31], [32]. While ALA is the preferred 
substrate for ∆6 desaturase, an abundance of dietary linoleic acid has been shown to 
suppress conversion of ALA to DHA [33], which may be a confounding factor in these 
studies. There is recent evidence to suggest that supplementing with stearidonic acid 
(18:3n-3) may improve the efficiency of conversion to DHA, indicating ∆6 desaturase 
as a rate limiting step [34]. There is also a degree of individual variation in the lipidome 
following omega-3 supplementation in humans which may be a factor in the equivocal 
metabolic changes measured in many human supplementation trials [35]. 
It is thought that hominids’ diets during the Paleolithic era were high in seafood and 
low in seeds and vegetable oils, which led to an omega-3/omega-6 ratio of 
approximately 1:1 [36]. Given the likelihood that early human ancestors’ diets were 
already high in omega-3 intake it may not have conferred any evolutionary benefit to 
develop the ability to synthesize omega-3 PUFAs. During the agricultural revolution, 
with changes to food production in the Neolithic era this n-3/n-6ratio began to diverge 
and now in the typical western diet is thought to be as much as 20:1, with omega-3 
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PUFA intake predominantly from ALA [37]. Although unlikely to be a primary driver, 
the divergence in the n-3/n-6 ratio has happened concurrently with the rise in CVD and 
states of chronic inflammation. Briefly, omega-6 PUFAs are associated with the 
production of pro-inflammatory mediators while omega-3 PUFAs produce less potent 
inflammatory mediators and inflammatory resolving proteins and so manipulating this 
ratio may bring about positive health outcomes. 
The potential therapeutic benefit of a diet with high omega-3 content was first 
observed due to the lower incidence of CVD in Greenland Inuit populations [17]. 
Subsequent studies observed that a period of omega-3 supplementation reduced risk 
factors associated with CVD, such as the lowering of plasma triacylglycerides (TAGs) 
and an increase in high density lipoproteins at the expense of low density lipoproteins, 
as well as decreasing in platelet aggregation  [35], [38], [39]. Yet, when end point 
measures such as cardiovascular disease are taken together in a meta-analysis the 
results of omega-3 supplementation are equivocal [40]–[43]. We hypothesize that 
while a given period of omega-3 supplementation leads to a significant increase in 
omega-3 content of various tissues it may not be sufficient to dramatically reduce the 
n-3/n-6 ratio. 
The results of studies in animals in which the n-3/n-6 ratio is substantially reduced 
have been largely positive regarding insulin sensitivity and resolving inflammation. A 
particularly effective model for assessing the impact of n-3/n-6 ratios is the fat-1 
transgenic mouse model which can endogenously synthesize omega-3 PUFAs from 
omega-6 PUFAs [44]. The ability to convert omega-6 fatty acids to omega-3 leads to an 
n-3/n-6 ratio of approximately 1:1. This model allows for the same diet to be used in 
all conditions and for the comparison of two significantly different n-3/n-6 ratios. It is, 
however, difficult to discern whether any effects are due to a reduction in the overall 
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n-3/n-6 ratio or an increase in omega-3 PUFAs alone. Reductions in the n-3/n-6 ratio 
are associated with an improvement in whole body glucose tolerance, as well as 
preventing the age related decline in glucose tolerance [45], [46]. Fat-1 mice were also 
protected from obesity related inflammatory activity and decrements in insulin 
sensitivity [47]. As well as improving glucose clearance, lowering the n-6/n-3 ratio also 
led to an increase in insulin secretion [48]. These studies demonstrate that a balance 
between omega-6 and omega-3 PUFAs within the lipid pool, may have a potential role 
in determining the metabolic effects of omega-3 PUFAs. Studies attempting to address 
this ratio in humans, however, would be difficult to adequately control. A human trial 
investigating a Mediterranean type diet which led to a reduction in the n-3/n-6 ratio 
observed that this reduction alongside other variables may confer some protection 
against metabolic dysfunction, providing some evidence that alterations in fatty acid 
content may have an effect on human health [15]. 
1.3. Omega-3 PUFAs and Skeletal muscle anabolism 
There is now growing evidence that omega-3 PUFAs also have intrinsic anabolic/anti-
catabolic properties in skeletal muscle. Muscle protein balance is regulated by changes 
in the ratio of muscle protein synthesis (MPS): muscle protein breakdown (MPB). An 
increase in MPS or a decrease in MPB will lead to a positive balance and ultimately 
hypertrophy [49]. Muscle disuse due to illness or injury is associated with severe 
skeletal muscle loss [50] . However, omega-3 supplementation has been shown in 
human, rodent and cell models to blunt the loss of skeletal muscle mass during disuse 
or injury [51]–[53]. It is well established that increasing amino acid availability 
stimulates a rise in MPS [54] and omega-3 supplementation may potentiate this 
response to anabolic stimuli [61] [62]. In a randomised controlled trial in healthy 
elderly individuals, it was observed that omega-3 PUFAs potentiated the muscle 
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protein synthesis (MPS) response to simulated feeding (hyperinsulemia-
hyperaminoacidemia clamp) following an 8-week supplementation period (1.86 g EPA, 
1.5 g DHA/day), independent of increased glucose action. Importantly, omega-3 
supplementation had no effect on basal rates of MPS [56]. A follow on study also 
observed the same effect in the effect of omega-3 PUFA on MPS in young and middle 
aged healthy individuals [55]. It is proposed that the changes in these studies in MPS 
were independent of anti-inflammatory activity due to the healthy status of the 
participants. Measures of  c-reactive protein, TNFα and interleukin-6 in plasma did not 
show any changes with fish oil supplementation. The lack of changes in plasma does 
not mean that changes in inflammation within the localised muscular environment did 
not change. The anabolic effects of omega- PUFAs is thought to be partially mediated 
through an increased phosphorylation of mechanistic target of rapamycin (mTOR) and 
downstream signalling target P70S6K1, a key regulatory pathway of protein synthesis 
and, by extension, muscle mass [57], [58]. Upstream of mTORC1 no changes were 
detected in PKB in either study, suggesting a potential direct sensitisation of mTORC1 
and P70S6K1 to amino acid stimulation or alternatively an interaction of omega-3 
PUFAs with other kinases involved in the activation of mTORC1. In young healthy men, 
8 weeks omega-3 supplementation caused a reduction in mTOR, P70S6K1 and AMPK 
kinase activity following combined resistance exercise and feeding. Furthermore, 
omega-3 fatty acids did not enhance the MPS response to exercise and feeding, 
suggesting that the effects of omega-3 on MPS my specific to feeding [59]. This study 
was conducted in young healthy males, where the combination of exercise and feeding 
may have saturated MPS precluding the ability to see any effect of fish oil 
supplementation. Taken together, these studies suggest that omega-3 PUFAs improve 
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muscle anabolism through an enhanced sensitivity to a nutritional stimulus likely 
independent of PKB activity. 
A recent cell based study has suggested that EPA, and not DHA, is responsible for the 
anabolic effects of omega-3 PUFAs [60]. C2C12 myotubes treated with EPA showed 
elevated MPS 25% greater than the control with no effect of DHA despite P70-S6K1 
phosphorylation being significantly elevated in both treatments [60]. A weakness of 
the study is that basal protein synthesis was not shown so the change in protein 
synthesis following leucine stimulation is unknown.  Furthermore, leucine is a strong 
stimulus for mTOR signaling but does not increase protein synthesis or net protein 
accretion in C2C12 myotubes [61]. Meaning leucine may not be a suitable stimulus to 
assess changes in protein synthesis in C2C12 These data would suggest that the effect of 
EPA on protein synthesis is likely independent of an enhanced anabolic signal through 
p70S6K1.  Kamolrat et al. (2013) [60] and others studies in cell models  [62]–[64] have 
shown that EPA and DHA may play a role in attenuating the rate of protein degradation. 
The mechanism behind this effect appears to be through the inhibition of the NF-kB 
pathway [63]. EPA inhibits the degradation of the NF-kB complex by reducing 
phosphorylation of lkBα [65]. This action prevents translocation of NF-kβ to the 
nucleus where it can induce expression of the muscle ring finger-1 gene (MURF-1) [62]. 
Knockdown of PPARγ significantly reduced the effect of EPA on NF-kB signalling. NF-
kB is an important pathway linked with the loss of skeletal muscle mass as MURFF-1 
facilitates ubiquitination of muscle proteins, effectively tagging them for degradation 
[66], [67]. Animal models that lack MURF-1 expression are protected from atrophy 
[67], [68]. Further support for a role of EPA in preserving muscle mass through 
inhibition of the atrophy pathways, comes from earlier work in a mouse cancer 
cachexia model. Treatment with EPA attenuated the loss of muscle mass through the 
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suppression of the ubiquitin proteasome pathway [69]. Inhibition of this pathway 
could play an important role in the maintenance of skeletal muscle mass by offsetting 
periods of depressed MPS, a key contributing factor to atrophy. Contrary to other 
studies which observed no effect of DHA on protein breakdown, Wang et al. (2013) [70] 
observed that DHA attenuated protein degradation through the same mechanisms as 
EPA but with greater efficiency. These in vitro studies indicate a role for EPA and DHA 
in both protein synthesis and breakdown but few studies have made integrated 
measures of synthesis, breakdown and protein accretion. 
There is in vivo evidence in humans that omega-3 PUFAs enhance the MPS response to 
feeding, and evidence from in vitro and rodent cancer models that omega-3 PUFA 
supplementation reduces muscle protein breakdown. Yet, it was unclear if long term 
omega-3 supplementation could improve muscle function. Rodacki et al. (2012)[11] 
were the first to assess if omega-3 supplementation could improve muscle function in 
the elderly when combined with resistance training [11]. They supplemented 45 
subjects for 90 days with 2 g/day omega-3 fatty acids in combination with a 90 day 
progressive resistance exercise program. They found that muscle strength and 
neuromuscular function was significantly improved when omega-3 supplementation 
was combined with resistance exercise, but omega-3 alone had no effect. A potential 
mechanism for omega-3 PUFAs improving contractile function may be an enhanced 
sensitivity of the muscle to acetylcholine, a neurotransmitter that stimulates muscle 
contraction. It has previously been observed that fish oil supplementation led to an 
increase in contractility in rats [71]. Strategies to improve or maintain neuromuscular 
function are of great interest as decrements in motor unit number and stability may 
precede functional changes in muscle [72]. A study using both elderly male and female 
participants observed that the beneficial effects of omega-3s may be specific to females 
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as no effects on muscle strength were observed in older women [73]. Maintaining 
neuromuscular function may be an important factor in offsetting muscle loss, and there 
is some promising initial evidence that omega-3 PUFAs may be effective in maintaining 
both muscle mass and function in typically atrophic conditions. Indeed, a higher dose 
of omega-3 PUFAs than the dose used by Rodacki and colleagues (2012) [11] 
demonstrated that supplementing elderly individuals with 4 g of omega-3 PUFAs daily 
for six months preserved muscle mass and function, not due to exercise induced effects, 
attenuating the normal declines associated with aging [10].  The mechanisms behind 
this preservation in muscle mass and function may be a combination of increases in 
postprandial MPS and improved neuromuscular function. 
Despite several studies demonstrating the beneficial effect of EPA and DHA on muscle 
anabolism, a study in Sprague-Dawley rats suggested that omega-3 supplementation 
may blunt muscle recovery following a period of atrophy inducing immobilization [74]. 
The results showed that while fish oil blunted the loss of muscle mass during 
immobilization, muscle recovery was reduced at 3 days following remobilization, 
however, 13 days following remobilization muscle to body weight ratio and Myosin 
Heavy Chain had returned to similar levels. The early phase response inhibition was 
attributed to a reduction in PGF2α, a prostaglandin derived from arachidonic acid 
which has been shown to be important for muscle protein synthesis [75], [76]. The 
reduction in PGF2α occurred simultaneously with a reduction in P70S6K1. Thus, it may 
be hypothesized omega-3 fatty acids may inhibit anabolic processes by reducing 
PGF2α.  This may indicate that in healthy organisms without the presence of low grade 
inflammation that omega-3 PUFA supplementation may delay regeneration of muscle 
following damage.  
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Taken together, these studies suggest omega-3 PUFAs, particularly EPA, play a 
beneficial role in maintaining total protein balance (Table 1.1). It is thought that one 
of the main underlying causes of muscle wasting conditions, such as sarcopenia, is an 
impaired MPS response to anabolic stimuli [77]. Omega-3 PUFAs may be of potential 
relevance to the clinical setting as a non-pharmacological method of reducing muscle 
loss. Further long-term human trials are necessary to address whether omega-3 
supplementation leads to muscle hypertrophy and consequent functional gains. 
Furthermore, the question remains whether omega-3 PUFAs not only improve the MPS 
response to nutrition but also increase MPS following an acute bout of resistance 
exercise. A recent study observed a rise in the total protein content in focal adhesion 
kinase, a mechanically sensitive protein, and mTOR which may indicate an enhanced 
capacity to respond to resistance exercise [23]. Experiments from tissue culture 
models indicate that EPA may be the significant contributor to changes in MPS rather 
than DHA, however, it has yet to be confirmed in humans if EPA underpins the changes 
in muscle mass and function. 
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Table 1. 1 Summary of studies characterising the impact of omega-3 PUFAs on skeletal muscle 
metabolism. 
 
 
1.4. Omega-3 PUFAs and insulin sensitivity 
 
Skeletal muscle is a primary site of insulin stimulated glucose disposal [2], [80] and 
any dysfunction in this process can lead to the development of insulin resistance (IR), 
preceding T2D. A reduced sensitivity of skeletal muscle to insulin stimulation is one of 
the primary defects leading to the development of T2D [81]. T2D is characterized in 
skeletal muscle by a reduction in glucose uptake, decreased glycogen synthesis, down 
Study Model Protocol Key findings 
Smith et al. 
(2011)[55] 
Human 
(Young) 
8 weeks, 1.86 g EPA, 
1.5 g DHA daily. 
Augmented MPS and enhanced mTOR and 
p70S6K1 signalling in response to a 
hyperaminoacidemic-hyperinsulinemic clamp 
in young volunteers. 
 
Smith et al. 
(2011)[78] 
Human 
(Elderly) 
8 weeks, 1.86 g EPA, 
1.5 g DHA daily. 
Augmented MPS and enhanced mTOR and 
p70S6K1 signalling in response to 
hyperaminoacidemia-hyperinsulinemia in 
elderly volunteers. 
 
Rodacki et al. 
(2012)[11] 
Human 
(Elderly) 
60 days pre training 
and 90 days during 
training, 0.4 g EPA, 
0.3 g DHA. 
potentiated training increase in peak torque 
and rate of torque development (Knee 
extensor,flexor,plantar and dorsiflexor). 
 
Smith et al. 
(2015)[10] 
Human 
(Elderly) 
6 months, 1.8 g EPA, 
1.5 g DHA daily. 
Ameliorated age related declines in lean 
muscle mass. Increased handgrip strength and 
1-RM muscle strength. 
You et al. 
(2010)[74] 
Rodent 
14 days enriched 
with 5% cod liver oil 
followed by 14 days 
immobilisation. 
Reduced Myosin heavy chain loss during 14 
days of hindlimb immobilsation. 
Kamolrat et al. 
(2013)[60] 
Rodent 
8 weeks of chocolate 
derived sweets, 
49.6% EPA, 50.4% 
DHA 
Increased phosphorylation of Pi3K and 
p70S6K1 during aminoacidemic-insulinemic 
clamp. 
Gingras et al. 
(2007)[79] 
Steers 
5 weeks infusion 4% 
menhaden oil 
Enhanced insulin action alongside an increase 
in amino acid disposal and increased mTOR-
p70S6K1 in response to hyperinsulinemic-
euglycaemic-euaminoacidemic clamp. 
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regulation of fat oxidation and an expanded intramuscular (TAG) pool  [82]–[84]. Lipid 
induced IR can be observed after only a few hours of increased plasma free fatty acids 
in vitro and in skeletal muscle within three weeks of a high fat diet in rodents [85]–
[87]. In particular, an overabundance of SFA (e.g. palmitate (PA 16:0) can induce IR 
through the accumulation of lipid derivatives including DAGs, ceramides and long 
chain acyl-coAs in the cytosol, which in turn can interfere with IRS1-PKB signalling  
[88]–[93]. However, our understanding of the role lipid metabolites has in a clinical 
context are still poorly understood. Increases in these lipid derivatives, particularly 
ceramides, can lead to the activation of PKC isoforms which lead to the 
phosphorylation of serine residues on insulin receptor substrate-1(IRS) and 
attenuating PKB activation [94], [95]. In response to insulin, targets downstream of 
PKB initiate translocation of GLUT4, an insulin sensitive glucose transporter, to the 
membrane to facilitate transport. One of the prominent features of IR is the reduction 
of glucose uptake, caused by a reduction of GLUT4 at the cell surface despite no changes 
in total GLUT4 content [96], [97]. Compared to SFA it appears that omega-3 PUFAs 
appear to at least have a neutral effect on skeletal muscle insulin sensitivity with some 
studies also showing a beneficial effect. While meta-analyses detect little or no impact 
of marine derived omega-3 PUFAs on insulin sensitivity or reduction in risk of 
developing T2D [98]–[100] there are a number of human, animal and cell studies which 
support a potential role of omega-3 PUFAs in the treatment of IR/T2D.  
Through alterations in muscle metabolism, and omega-3 PUFAs may protect against 
some of the metabolic defects induced by a high fat diet [101]. A high omega-3 index 
(erythrocyte concentrations of EPA and DHA) is associated with higher insulin 
sensitivity and lower fasting insulin levels [102]. The results of current human clinical 
trials however are equivocal with some showing a beneficial effect [103], [104] while 
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some show no effect or adverse effects [105]–[107]. Yet, a recent study has observed 
that addition of omega-3 PUFAs to an intravenous lipid infusion attenuated the decline 
in insulin stimulated glucose action in muscle as well as an increased glucose disposal 
compared to an omega-6 infusion, these effects were independent of changes in acyl 
carnitine levels; a marker of mitochondrial overload [108]. During the infusion in this 
study intramyocellular lipids (IMCL) significantly increased by nearly 50% in the 
omega-3 group suggesting that omega-3 PUFAs promote the incorporation of fatty 
acids in complex lipids, instead of being directed towards β-oxidation [108]. Rodents 
fed a 10 week high fat diet with added fish oil attenuated the decline in glucose 
tolerance compared to a high fat diet and this effect was accompanied by a reduction 
in long chain acyl-coa species as well as in some ceramide species, although the 
abundance of these intracellular lipids were still elevated compared to the control diet 
[101]. These data may be explained by the findings that pre-treatment of C2C12 cells 
with EPA increased the incorporation of labelled oleate into TAGs and phospholipids, 
with no changes in β-oxidation observed [109]. Wensaas & colleagues (2008) [110] also 
observed a marked increase in TAG synthesis following EPA treatment in isolated 
skeletal muscle myotubes and this effect was more pronounced in myotubes isolated 
from T2D individuals. EPA also reduced the amount of C:18-2 coA beyond that of 
control and again this effect was more pronounced in T2D myotubes. While increased 
levels of fatty acyl-coA in general are associated with IR and C18:2-coA accumulation 
is a potential indicator of IR [90], [92]. The ability of EPA to apparently increase 
incorporation of free fatty acids into TAGS may improve insulin sensitivity by 
preventing the accumulation of lipid intermediaries and the potential interference of 
these lipids on insulin signalling pathways. The potential for omega-3 PUFAs to 
increase complex lipid species in skeletal muscle is in contrast with data from other 
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tissues where lipid droplet formation is suppressed [111]. Increasing intracellular 
TAGS has previously been shown to protect against lipotoxicity in states of lipid 
overload [112], [113].  
As well as increasing complex lipid formation, EPA may also improve both basal and 
insulin stimulated glucose uptake in a manner independent of PKB signaling [109], 
[114]. The ability to clear blood glucose is diminished in IR/T2D individuals and 
sustained levels of high blood glucose can lead to negative health outcomes. Aas et al. 
(2006) observed that a 24-hour treatment of skeletal muscle cells with EPA increased 
basal glucose uptake 2.4-fold, however, the increase with insulin stimulation was 
similar to that of the control. The changes in glucose uptake are likely independent of 
any changes in PKB signalling as  Hessvik et al. (2010) and Aas et al. (2005) [109], [115] 
do not detect any differences in basal and insulin stimulated PKB phosphorylation. One 
study observed that despite phosphatidylinositol-3-kinase (PI3K) activity being down 
regulated PKB phosphorylation remained intact in response to insulin [116]. 
Potentially indicating the omega-3 PUFAs may reduce the activation threshold for 
signalling in response to external stimuli. DHA is also known to play a role in glucose 
metabolism; preventing the deleterious effects of PA on PKB phosphorylation and 
glucose uptake [117]. Furthermore, increased transcription of genes involved in 
glucose regulation may also influence the metabolic effects of EPA and DHA. Coupled 
with an increase in glucose uptake observed by Aas et al. (2006) [109] was an increase 
in mRNA content of GLUT1 , which is involved in the regulation of basal glucose uptake 
[118]. Addition of fish oil to mice fed a high fat diet increased transcription of GLUT4 
and IRS-1 [101]. Multiple studies have observed an increase in GLUT4 expression  
[114], [119], however, whether this is reflected at the protein level is still unclear with 
one study showing no change in GLUT4 content with a low dose of omega-3 PUFAs 
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[116]. These data suggest a potentially beneficial role for both EPA and DHA in glucose 
metabolism. Assessment of the effects of omega-3 PUFAs on cell and rodent models 
have returned largely positive results, however, this has yet to translate into consistent 
health benefits in human trials. 
An alternative mechanism explaining the insulin sensitising effects of omega-3 PUFAs 
is through the reduction in inflammatory markers. Briefly EPA and, to a lesser extent, 
DHA are natural ligands for Peroxisome proliferator-activated Receptor γ(PPARɣ) and 
following activation of PPARγ NF-Kb activity is suppressed reducing the release of pro-
inflammatory cytokines [63]. Tumour necrosis factor-α (TNF-α) is also known to 
induce IR through the phosphorylation of IRS-1 on serine 307 similar to lipid 
intermediates [120]  and EPA reduces TNF-α expression [114]. Furthermore, in 
macrophages and adipocytes the G-protein coupled receptor GPR120 is an omega-3 
sensitive receptor that exhibits anti-inflammatory properties through the suppression 
of TNF-activation [121]. While this may be an important factor in clinical trials and 
rodent models, GPR120 expression is negligible in skeletal muscle and would therefore 
not explain the changes induced by omega-3 PUFAs in tissue culture models [121]. In 
rodents, knockout of AMPK subunit alpha 2 abrogates the improvement in hepatic 
insulin sensitivity by omega-3 PUFAs during a high fat diet despite studies observing 
little interaction between omega-3 PUFAs and AMPK [122]. It may be of interest to 
assess the importance of AMPK on insulin sensitizing effects of omega-3 PUFAs in 
skeletal muscle [123]. Skeletal muscle is highly adaptable to alterations in substrate 
availability and can switch between fat and glucose oxidation in response to changes 
in environmental conditions. Skeletal muscle mass comprises up to approximately 
40% and is a significant determinant of metabolic rate. In older women, 12 weeks of 
omega-3 supplementation increased resting metabolic rate(14%) and energy 
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expenditure during exercise (10%). Moreover, fat oxidation was increased in both the 
resting (19%) and exercise (27%) state [124].  A follow up study in young healthy 
males did not find any impact of fish oil supplementation on metabolic rate or substrate 
metabolism  
The ability to switch between different fuel sources, termed metabolic flexibility, is 
diminished by obesity and T2D at rest and during exercise [125], [126]. Studies have 
observed that the ability to oxidize fat in particular is blunted by T2D [127], [128]. In 
cultured muscle cells EPA and DHA treatment improved the ability to switch between 
fat and glucose oxidation depending on which substrate was available [115]. The 
studies on the effect of omega-3 PUFAs on substrate metabolism have not yielded 
consistent results. In healthy individuals, three weeks of omega-3 supplementation 
increased fat oxidation by 35% at the expense of glucose utilization in response to a 
bolus of glucose [129]. While a follow up study indicated a tendency towards increased 
fat oxidation during exercise (60% VO2 max), however, differing modes and intensity 
of exercise would likely alter these results [130]. The shift towards fat utilization 
during exercise may be a characteristic of all PUFAs as omega-6 fatty acids suppress 
activation of pyruvate dehydrogenase (PDH) at the onset of exercise [131]. However, 
to the authors’ knowledge it has yet to be determined if omega-3 also suppresses PDH 
activity. Another group observed time dependent changes in resting substrate 
selection in T2D subjects with fish oil increasing glucose utilization after one week, 
however, after nine weeks fat oxidation was enhanced [132]. Yet, in diabetic but non 
obese rats EPA alone reduced total fat oxidation by 50%, instead fatty acids were 
directed towards storage [114]. Furthermore, a combination of EPA and DHA in 
rhabdomyosarcoma cells reduced the ratio between the oxygen consumption rate: 
extracellular acidification rate indicating a shift towards an increase on glycolytic 
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reliance [119]. These data demonstrate a lack of consistency in an organism’s 
metabolic response to omega-3 PUFA supplementation.  
There has been much debate on whether mitochondrial defects are a primary factor 
in the development of insulin resistance (IR). Initial studies observed a reduction in 
mitochondrial content and size in insulin resistant and T2D individuals, accompanied 
by a reduction in expression of genes involved in mitochondrial biogenesis and 
oxidative phosphorylation [133], [134]. Yet, it has also been reported that feeding 
rodents a short term high fat diet increases mitochondrial content and oxidative 
capacity despite the development of IR [135], [136]. A number of studies have also 
reported normal mitochondrial function in insulin resistant populations [137], [138]. 
Studies which have induced severe mitochondrial dysfunction actually observe an 
increase in insulin sensitivity. Despite these studies indicating that mitochondrial 
dysfunction is not a primary driver of IR, increases in mitochondrial content and 
oxidative capacity may help prevent the lipid accumulation associated with the onset 
of IR. There is some evidence that omega-3 PUFAs may stimulate mitochondrial 
biogenesis through the increased mRNA expression of transcription factors such as 
PCG1-alpha, TFAM and NRF1 [101], [139]. This study observed an increase in 
mitochondrial abundance and oxidative capacity in response to a high fat diet without 
any added effect of fish oil [101]. Outwith the context of a high fat diet, 12 weeks of 
omega-3 PUFA supplementation (2 g EPA, 1 g DHA) did not alter mitochondrial 
abundance in humans, however, did increase ADP sensitivity [140]. It is unclear at 
present how the increased ADP sensitivity will alter mitochondrial function in the long 
term. In insulin resistant individuals omega-3 PUFAs did not alter mitochondrial 
abundance, maximal ADP respiration or peripheral insulin sensitivity [141]. In an aged 
mouse model replacing 3.4% of kcal with EPA but not DHA attenuated age related 
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declines in mitochondrial function through the maintenance of mitochondrial protein 
quality, independent from changes in mitochondrial abundance [142]. There is also 
evidence that both LA and ALA in an obese animal model preserve insulin signalling 
and oxidative capacity through differential mechanisms [140]. Interestingly, the 
authors observed an increase in the abundance of electron transport chain sub-units 
in the subsarcolemmal mitochondrial pool independent of changes in mitochondrial 
content with ALA [140]. This study provides some evidence that some omega-6 PUFAs 
have similar protective effects to omega-3 PUFAs. The currently available data suggests 
that any insulin sensitising effects of EPA or DHA are unlikely to occur through 
increases in skeletal muscle mitochondrial abundance or oxidative capacity.  
Taken together, these studies suggest that both EPA and DHA may have a protective 
effect against fatty acid induced insulin resistance, with some potential EPA or DHA 
independent effects. A summary of the results from human trials on glucose 
homeostasis can be seen in Table 1.2. These effects may be mediated by anti-
inflammatory actions and the increased incorporation of potentially harmful fatty acid 
species into complex lipids, thereby reducing the interference with signalling pathways 
involved in glucose metabolism. Predominantly, fatty acid accumulation induces IR 
partially through a reduction in PKB related signalling and the data would suggest that 
EPA and DHA may protect against the blunting of PKB signalling rather than 
intrinsically increasing PKB activity. As such, several studies have shown 
improvements in glucose uptake with EPA, but not DHA, independent of changes in 
PKB phosphorylation. As well as potential improvements in peripheral insulin 
sensitivity, there is some evidence that omega-3 PUFAs may improve hepatic insulin 
sensitivity. Changes in hepatic insulin sensitivity are of great clinical relevance as the 
liver is a major contributor to postprandial glucose disposal. Lalia et al. (2015) [141] 
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and colleagues observed small reduction in endogenous glucose production while 
subset analysis of a meta-analysis indicated an increase in hepatic insulin sensitivity 
[99]. 
 
 
Table 1. 2 Summary of studies characterising the impact of omega-3 PUFAs on glucose homeostasis. 
Study Model Protocol Key findings 
Delarue et al. 
(1996)[129] 
Human (healthy) 
3 weeks. 1.1g EPA, 
0.7g DHA daily. 
Reduction in insulinemia with 
an increase in non-oxidative 
glucose metabolism. Shift 
towards fat oxidation 
following a glucose load. 
Delarue et al. 
(2006)[103] 
Human (healthy) 
3 weeks. 1.1g EPA, 
0.7g DHA daily. 
Reduction in glucose fluxes 
during exercise (60% VO2 
max). Tendency towards 
increase in fat oxidation 
during exercise. 
Lalia et al. 
(2015)[141] 
Human (insulin 
resistant) 
6 months 3.9g 
EPA/DHA daily. 
No change in peripheral 
insulin sensitivity compared 
to control. Small reduction in 
hepatic gluconeogenesis. 
Fasching et al. 
(1991)[105] 
Human (impaired 
glucose tolerance) 
2 weeks, 3.8g EPA, 
2.5g DHA daily (30 
ml fish oil). 
No changes in fasting plasma 
glucose or insulin levels. No 
change in glucose or insulin 
during hyperinsulemic clamp. 
Glauber et al. 
(1988)[106] 
Human (T2D) 
4 weeks, 18g fish oil 
daily. 
Increase in fasting plasma 
glucose and in response to 
feeding. Increased hepatic 
glucose production. Reduction 
in insulin secretion. 
Popp-snijders et al. 
(1987)[104] 
Human (T2D) 
8 weeks, 3g 
EPA/DHA daily. 
Enhanced glucose clearance 
during steady state infusion of 
glucose and insulin. 
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1.5. Summary of omega-3 research 
The results from omega-3 supplementation trials have often been mixed, yielding 
null responses when combined in meta-analyses. We hypothesize that one of the 
primary variables that may limit the effect of omega-3 fatty acids is a high n-6/n-3 ratio. 
Evidently the relationship between omega-3 and omega-6 PUFAs is not simply 
antagonistic and different effects of fatty acids within each subclass adds to the 
complexity. Further studies should aim disseminate the interaction between omega-3 
and omega-6 PUFAs and how this may impact metabolism. The currently available 
evidence suggests that omega-3 PUFAs EPA and DHA may be effective in preventing 
the deleterious effects of atrophic conditions or low-grade inflammation (Figure 1.1). 
The research has focused predominantly on EPA and DHA, yet it is now emerging that 
DPA has also been shown to have similar, and in some cases, more potent effects. There 
is emerging evidence that different omega-3 PUFAs has divergent metabolic functions, 
and further research is required to understand the different mechanisms underpinning 
these effects. The recent advances in the ‘omic’ techniques and mass spectrometry 
technology will allow for a comprehensive and sensitive approach to analysing the 
metabolic changes induced through omega-3 uptake. Currently, omega-3 PUFAs are 
mainly derived from marine sources. Given the increasing environmental pressures on 
fish populations, it brings into question the sustainability of fish as a suitable resource 
of omega-3. It is estimated by 2050 that the human population will reach 9.1 billion 
and global warming will reduce the omega-3 content in algae, reducing the total 
omega-3 content in fish [143]. This highlights the need to understand the mechanisms 
of omega-3 PUFA action which may lead to the development of an omega-3 mimetic 
and provide a sustainable long-term source. Further study is necessary to understand 
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the link between enriching omega-3 PUFAs EPA and DHA in the lipid pool with the 
effects on glucose and protein metabolism. 
 
Figure 1.1. Proposed mechanisms of omega-3 PUFA action. This figure highlights the mechanisms of 
action by which omega-3 fatty acids may exert cellular effects. Protein synthesis in response to amino 
acids is enhanced through increased phosphorylation of proteins in the mTOR pathway. Omega-3 fatty 
acids may also reduce inflammation and protein breakdown by inhibiting the translocation of key 
transcription factors (NF-Kb and MURF1) to the nucleus.  
. 
 
1.6. Saturated fatty acids and metabolic health 
 
Ever since Randle & colleagues (1963) [144]  proposed that accumulation of fatty acids 
was linked to dysfunction in carbohydrate metabolism there has been a great deal of 
debate over the role of fatty acids in metabolic health. Central to that debate is the link 
between saturated fatty acids and a number of pathologies including cardiovascular 
disease and diabetes. In comparison to the PUFAs discussed in the previous sections, 
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saturated fatty acids are causally linked to the disruption of key anabolic processes 
such as protein accretion and glycogen synthesis. 
It is commonly asserted that a diet high in saturated fatty acids are associated with 
impaired insulin sensitivity. However, the data available from human studies suggest 
a more ambiguous relationship. Meta-analyses indicate that replacing saturated fat 
with MUFA or PUFAs can have favourable effects on glucose and insulin homeostasis 
[145]. Yet, studies using the euglycemic-hyperinsulinemic clamp to assess insulin 
sensitivity have not found a significant link between SFA intake and reduced insulin 
sensitivity. One of the most commonly cited studies supporting the SFA hypothesis is 
the KANWU study [12]. This study compared diets rich in either MUFAs or SFAs for 3 
months in 162 subjects (mean total fat intake was 37%). The authors found that in the 
SFA diet insulin sensitivity declined by 10%. Although post intervention insulin 
sensitivity was not significantly different from the MUFA diet group and there was no 
control group for comparison. As a result, the KANWU study does not provide 
conclusive evidence that SFA induces insulin resistance. This was a free living study 
where fat intake was not clamped and an interesting sub set analysis revealed that the 
difference in insulin sensitivity between SFA and MUFA was accentuated when fat 
intake was below 37%, while regardless of dietary status fat intakes of above 37% 
reduced insulin sensitivity. Furthermore, other studies have also observed the same 
results but in different populations. The LIPGENE study, reduced the dietary SFA 
content in 417 Europeans with metabolic syndrome and did not find any effect on the 
HOMA-IR index or plasma inflammatory markers [146]. Moreover, a smaller scale diet 
analysis study in obese individuals found no difference between diets rich in SFA or 
MUFA on glycemic control in spite of differential inflammatory adipose tissue gene 
expression [147]. Overall, the human studies do not demonstrate a clear consensus on 
 
General introduction                                                                                                                             25 
the effects of dietary SFA on insulin sensitivity.  As discussed below, studies from tissue 
culture commonly demonstrate that the negative effects of PA are dampened when 
incubated with other fatty acids such as oleate, PAO and other unsaturated species 
[19], [148], [149]. In human trials the negative effects of PA may be offset by the 
balance of lipid species in the diet. Another confounding factor may lie in the greater 
susceptibility of skeletal muscle isolated from obese individuals to the deleterious 
effects of PA on glucose uptake compared to lean individuals [150]. Furthermore, these 
studies last for time periods in the range of 3 months and it is possible that only a 
sustained intake of SFAs may attenuate insulin sensitivity, potentially through the 
build-up of low grade inflammation.  
 
1.7. Saturated fatty acids and insulin sensitivity 
Evidence for the deleterious effects of PA on insulin sensitivity are mainly derived from 
animal and tissue culture studies. There is a large body of evidence demonstrating that 
incubation of skeletal muscle myotubes with PA(500-750µM) attenuates the action of 
insulin on glucose uptake [19], [93], [151]. The disruption of glucose homeostasis can 
be mitigated by co-incubation with unsaturated fatty acids species such as PAO [19].  
Oversupply of PA in skeletal muscle leads to the generation of lipid intermediates such 
as ceramides and diacylglycerols (DAG). Palmitoyl-CoA is a substrate for Serine 
Palmitoyl transferase-1, which condenses palmitoyl-CoA to 3-ketohydrosphingosine 
and is then acylated to form dihydroceramide. Ceramide is then produced through the 
desaturation of dihydroceramide. Ceramide accumulation results in the inhibition in a 
number of cellular processes such as glucose uptake and glycogen synthesis. The 
inhibitory action on PKB by ceramides act downstream of IRS/PI3K and occurs through 
alternative mechanisms in different cell types [152]. In L6 myotubes, PKB activity is 
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downregulated through activation of PKC isoforms while in C2C12 myotubes protein 
phosphatase 2A (PP2A) is activated increasing the de-phosphorylation of PKB. The 
mechanism of PKB inhibition by ceramide is dependent on the abundance of ceramide 
enriched micro domains [152]. Inhibition of SPT-1 prevents the accumulation of 
ceramide and is sufficient to prevent the deleterious effects of PA [153]–[155]. 
Ceramides are a prominent candidate for driving insulin resistance, however, not all 
studies report a relationship between ceramide levels and insulin sensitivity. Skovbro 
and colleagues (2008) [156] assessed muscle ceramide content across healthy, 
impaired glucose tolerance, T2D and endurance trained individuals and found that 
ceramide levels were similar across all groups, despite differing levels of insulin 
sensitivity. Furthermore, pharmacological/genetic inhibition of ceramide synthesis 
channels PA towards greater DAG synthesis resulting in impaired insulin action [157]. 
Alternatively, it has been observed that DAG levels, and not ceramides, are associated 
with acute insulin resistance following a lipid infusion in humans [88], [91]. DAG’s also 
inhibit PKB but, unlike ceramides, act at the level of IRS/PI3K. DAGs activate PKC 
isoforms that increase IRS-1 serine phosphorylation which subsequently reduces IRS-
1 tyrosine phosphorylation. Whether ceramide or DAG drive insulin resistance may be 
dependent on the lipid type.  Whilst in some cell types PA induction of insulin 
resistance appears to be primarily ceramide driven, oversupply of linoleate (an 
unsaturated fatty acid) appears to induce insulin resistance through DAG mediated 
mechanisms [155]. It therefore appears that oversupply of a range of lipid types to a 
tissue with limited storage capacity can induce insulin resistance. Yet, in some contexts, 
unsaturated fatty acids can offset the deleterious effects of saturated fatty acids. 
In a range of studies utilising a number of different cell types, unsaturated fatty acids 
have been shown to offset the inhibition of insulin action induced by saturated fatty 
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acids [19], [64], [158]. Indeed, the incubation of primary cells with a fatty acid mixture 
does not cause insulin resistance (as assessed by insulin induced PKB 
phosphorylation), even when PA is the predominant fatty acid [148]. Even minor 
differences in structure such as one double bond in PAO (16:1) and two extra carbons 
and a double bond in oleate (18:1) can have opposing effects to PA. For instance, 
incubation of L6 myotubes with PAO not only completely attenuated the inhibitory 
effects of PA on glucose uptake but also intrinsically increases glucose uptake when 
incubated in isolation. However, whilst basal glucose uptake was stimulated by PAO, 
the insulin induced response is lost  [19]. Additionally, other unsaturated fatty acids 
such as oleate (18:1) and linoleate (structure) enhance insulin stimulated PKB and 
ERK1/2 activation [159]. It appears that one of the ways that unsaturated fatty acids 
reduce the effects of saturated fatty acids is by increasing the channelling of fatty acids 
into neutral lipid stores [112]. The importance of this mechanism is evident from 
experiments in which Triglyceride synthesis is disrupted. In the context of inhibited 
TAG synthesis, linoleate results in lipotoxicity. Given that the ability of skeletal muscle 
to store lipids is limited, channelling excess lipids into TAG would reach a saturation 
point where it is no longer beneficial. Yet, the channelling of SFA into neutral lipid 
stores may also offset some of the inflammatory effects of PA. Work from the Hundal 
laboratory showed that PA induced NF-Kb activation and elevated interleukin-6 mRNA 
levels. This effect was regulated by the extracellular regulated kinase (ERK) as 
inhibition ameliorated the activation of NF-Kb. Yet, the inhibitory effect of PA on 
glucose uptake persisted, demonstrating independent properties of PA which induce 
insulin resistance. Further work built on this data, showing that PAO potently 
repressed these inflammatory effects. This protective effect was due to increased 
neutral lipid storage and increased oxidative capacity. Whilst there is a limited storage 
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capacity for lipid in skeletal muscle, skeletal muscle does have the capacity to 
dramatically increase mitochondrial content. Increasing mitochondrial fatty acid 
oxidation may be a strategy to offset the negative effect of lipid intermediates on insulin 
action potentially by clearing the excess lipid through oxidation.   In support of this 
hypothesis, studies which have induced mitochondrial uncoupling by overexpressing 
uncoupling protein 1 demonstrate resistance to the deleterious effects of a high fat diet 
[160]. There are studies which have demonstrated that obesity and type 2 diabetes 
lead to the reduction of mitochondrial function. Yet, high fat diets may actually lead to 
excessive beta-oxidation. Mice placed on a high fat diet for 5 or 20 weeks displayed 
increased rates of PA and Palmitoyl-CoA oxidation [136]. While in cultured myotubes, 
excess lipid availability resulted in increased beta-oxidation beyond the mitochondrial 
capacity to fully oxidise those lipids [161]. Indeed, PA exposure in culture can reduce 
mitochondrial function. For instance, the addition of PA (500µM-1mM) to myotubes 
increases reactive oxygen species whilst concomitantly reducing ATP levels [162]. 
Both PGC1 alpha expression and promoter activity were also reduced, all of the 
observed effects were attenuated by co incubation with oleate (500µM-1mM). Nisr & 
colleagues (2016) [163] also found that PA reduced oxygen consumption related to 
energy demand for cellular processes. Stearate (18:1) was also found to have similar 
properties to PA. Whilst oleate  and linoleate  had modest effects on ATP synthesis but 
did not reach statistical significance [163]. The effect of PA may depend on whether 
myoblasts or myotubes are used. Patkova et al (2014) [164] found that PA only reduced 
mitochondrial function in myoblasts, reducing ATP dependent oxygen consumption 
and maximal mitochondrial capacity. While in myotubes proton leak was increased but 
did not effect oxygen consumption related to ATP synthesis. It can be speculated that 
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these negative effects on cellular energy state could translate to impairments in 
anabolic processes such as muscle protein synthesis. 
 
 
Figure 1. 2 Accumulation of FFA and increased Palmitate can disrupt insulin signalling by attenuating PKB 
activity.  Fatty acids transported into the muscle cell are channelled towards storage in neutral lipid stores or 
oxidation. Accumulation of PA can provide a substrate for the production of Ceramide and DAGS which activated 
kinases and phosphatases that repress the action of PKB, this results in the loss of insulin stimulation glucose 
uptake.  Mitochondrial overload by fatty acids can increase reactive oxygen species which interfere with glucose 
uptake 
 
1.8. SFA and skeletal muscle anabolism 
 
 
In order to maintain homeostasis, skeletal muscle is continually integrating both 
extracellular and intracellular signals and altering cellular function to respond to 
changes in the cellular environment. There is some associational data to suggest that 
expanded adipose mass may modulate skeletal muscle protein turnover. Obese 
individuals from across the age spectrum display attenuated MPS responses to 
elevated plasma concentrations of amino acids and insulin [165], [166].  It has been 
proposed that fatty acid infiltration into skeletal muscle during obesity alters signalling 
networks that impair the protein synthetic response to feeding in rodents  [167], [168]. 
However, even acute exposure (6 hours) to elevated plasma lipids can lead to 
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impairments in muscle protein balance. Indeed, in young healthy men an acute lipid 
infusion (time) impairs the MPS response to infused amino acids + insulin [108]. This 
impaired MPS is associated with the complete attenuation of 4E-BP1 phosphorylation 
in response to feeding, suggesting the mechanism is via the disruption of upstream 
anabolic signalling. Furthermore, both acute high fat feeding (mixed) and longer term 
supplementation (omega-3) have been demonstrated to alter the activity of the kinases 
involved in muscle growth and energy sensing pathways in response to feeding and 
exercise [59], [169]. However, not all studies demonstrate a consensus. For instance, a 
similar study to Stephens et al observed no lipid dependent blunting of amino acid 
induced increases in MPS [170]. Although both Stephens and Katsanos used different 
doses of amino acids, one of the biggest methodological differences is the use of the 
hyperinsulinemc-euglycemic clamp by Stephens et al [108]. The mechanism of lipid 
action in the alteration of protein metabolic networks may therefore be regulated by 
insulin. Insulin additionally plays an important role in regulating skeletal muscle 
protein breakdown [171]. As a result, even if MPS is still sensitive to amino acids, 
insulin resistant muscle would fail to reduce protein breakdown in response to an 
anabolic stimulus. This reduction in insulin action would potentially lead to a reduction 
in total protein accretion, as protein breakdown would not be suppressed by feeding 
induced increases in insulin. These potential mechanisms are believed to partially 
explain the enhanced sarcopenia observed in older obese adults. 
The molecular mechanisms behind the above observations are still to be fully 
delineated. However, we know that increasing intracellular concentrations of PA 
induces stress on a number of functional networks. These include alterations in lipid 
metabolism and storage as well as attenuation of substrate transport (Glucose, amino 
acids) across the plasma membrane [19], [172]. PA exposure also disrupts intracellular 
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signalling, in particular the PKB signalling pathway.  Given that PA dysregulates PKB 
and downstream signalling it could be predicted that concurrent with the induction of 
insulin resistance that protein synthesis will also be attenuated. The currently available 
data on the effect of PA on muscle anabolism are limited, however, there are a number 
of known molecular effects of PA that are likely to interact with the regulation of 
protein synthesis. There is also data to suggest that fatty acids such as oleate and PAO 
do not have the same deleterious effects. 
Upon transport into the cell, PA is converted to palmitoyl-CoA which can then be used 
as a precursor for ceramide production. Evidence to suggests that PA is less efficiently 
stored in neutral lipids in muscle myotubes compared to more unsaturated lipids 
(oleate, linoleic, EPA, DHA) and this leads to the accumulation of lipid intermediaries 
such as ceramide and diacylglycerols (DAG) [112] . Previous work has shown that 
exogenous provision of C2 ceramide is sufficient to reduce the intracellular free amino 
acid pool through down-regulation of system A mediated amino acid transport, likely 
due to reduced membrane abundance [172]. Furthermore, downstream mTORC1 
signalling and protein synthesis were attenuated as a result [172]. The authors also 
showed that PA derived ceramides also reduced system A transport but did not couple 
this to measures of MPS. In contrast, the unsaturated fatty acid PAO did not blunt amino 
acid uptake and is, therefore, unlikely to reduce protein synthesis. The increase of 
amino acid uptake in response to insulin was not dampened by increased levels of 
ceramide which would suggest some divergent mechanisms of PA action on insulin 
responsive glucose and protein metabolism. In addition to noted effects on AA 
transport, PA has also been noted to regulate stress pathways such as the Endoplasmic 
reticulum stress signalling system. 
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The ER is an important organelle for protein folding and modification as well as lipid 
synthesis and calcium homeostasis. Disruption to the normal function, termed ER 
stress, can lead to the aggregation of misfolded proteins and induces what is known as 
the ‘unfolded protein response’ (UPR). The UPR initiates a transcriptional programme 
to restore homeostasis and failure to achieve this results in apoptosis. In response to 
ER stress multiple proteins are activated by release from the chaperone family (BiP). 
Of particular interest is the protein kinase R-like ER kinase (PERK) which 
phosphorylates eif2α (Ser51) which then becomes a competitive inhibitor of the 
guanine exchange factor eif2B reducing levels of  GTP loaded eif2 and inhibiting 
translation initiation [173].  This conserves energy and resources to mount an ATF6 
directed translational programme to enhance the levels of specific chaperone proteins 
required to prevent further stress induced damage. High fat feeding in animal and 
human models is associated with an induction of ER stress in the skeletal muscle [174]. 
In culture, PA is known to induce ER stress in a number of cell types, including skeletal 
muscle myotubes [175]. While inhibiting ceramide can prevent the development of 
insulin resistance, it may not be critical in SFA induced ER stress [176]. Inhibition of 
ceramide synthesis does not prevent the disruption of ER stress in hepatocytes [176]. 
Thus, PA may drive both ceramide dependant and independent reductions in protein 
synthesis. It could be predicted that in skeletal muscle, PA induces ER stress which 
leads to the phosphorylation of eif2a and subsequent inhibition of protein synthesis. 
Indeed, a study by  Tardif & colleagues (2014) [177] showed a PA (375 uM) driven and 
ceramide dependent reduction in muscle protein synthesis. Furthermore, PA also 
down-regulates MPS in L6 myotubes by a similar magnitude [163]. As we mentioned 
above there is also evidence that lipid overload can modify muscle protein breakdown. 
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The balance of protein synthesis and breakdown underpins changes in muscle protein 
balance.  Alterations in either parameter can push the muscle into a positive protein 
balance leading to hypertrophy, conversely a negative protein balance will lead to 
atrophy. Tissue culture studies show that PA can up-regulate the activity of proteolytic 
systems [178]. This up-regulation of protein breakdown leads to a reduction in muscle 
myotube diameter after a 48 hour incubation [179]. PA is known to reduce 
phosphorylation of PKB and this leads to sustained nuclear retention of the Forkhead 
box transcription factors(FoxO3) which induces the transcription of proteins involved 
in degradation pathways [178]. FoxO3 transcription factors control the expression of 
genes involved in processes such as apotosis, cell cycle arrest, oxidative stress 
resistance and muscle atrophy. In particular, expression of genes such as Murf1, 
atrogin-1 and Bnip3 are enhanced under atrophic conditions which lead to increased 
protein degradation, especially of muscle structural proteins [67], [180], [181]. The 
study by Woodworth-Hobbs & colleagues (2014) [178] showed that PA increased the 
mRNA abundance of atrogin-1 and Bnip3 when protein breakdown was also increased. 
This altered transcription of atrogenes is primarily driven by the attenuation of PKB 
phosphorylation which prevents the cytosolic sequestering of FoxO3 [178]. Another 
regulator of muscle atrophy is the NF-Kb pathway. NF-Kb is activated by the 
phosphorylation and subsequent proteasomal degradation of inhibitor of IKb kinase.  
Free NF-Kb then translocates to the nucleus and binds to DNA, initiating the 
transcription of a multitude of genes involved in cellular responses to stress. In 
particular, NF-Kb is known for the transcription of genes involved in inflammation.  
When L6 myotubes were exposed to PA NF-Kb was activated [182]. Activation of NF-
kb has been associated with muscle atrophy similar to cachexia [183]. 
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1.9. Summary of SFA/MUFA research 
In summary, while there is not a large body of data linking PA directly with 
perturbations in muscle anabolism it appears that increasing intracellular 
concentrations of PA can elicit an environment that leads to net protein loss and insulin 
resistance. PA attenuates protein synthesis while simultaneously increasing the rate of 
protein breakdown. There are a number of underlying mechanisms.  It appears that the 
PKB signalling pathway is a central node in the pathology of PA driven insulin and 
anabolic resistance. There are multiple mechanisms which feed in to attenuate the 
normal function of this axis. This overview has focused on the local factors determining 
muscle atrophy and growth however it has not considered systemic factors such as 
input from the immune system which is also known to be responsive to various fatty 
acids. Studies also show that PA induced perturbations in anabolic signalling are 
prevented by unsaturated fatty acids. It therefore remains to be seen how relevant this 
is in vivo where a diet of mixed fat sources are consumed regularly leading to a mix of 
circulating free fatty acids and triglycerides.  
1.10. Contrasting effects of fatty acid species 
Fatty acids display a diverse range of structures which lead to a highly diverse lipid 
pool. As demonstrated in the previous sections, fatty acids differing in carbon chain 
length and unsaturation levels can have both positive and negative effects on skeletal 
muscle metabolism and function. For example, EPA and DHA are very similar in 
structure, differing by only 2 carbons and 1 double bond, but appear to have different 
metabolic activities in skeletal muscle [184], [185]. DPA (22:5) is an intermediate of 
EPA and DHA   which may also have unique metabolic functions [186]. A recent study 
used computational modelling to demonstrate that EPA, DPA and DHA, differentially 
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alter membrane characteristics [187]. Similarly, PA and PAO, differ by a single double 
bond and this changes the way in which each fatty acid alters glucose uptake and 
metabolism. PA treatment of cultured myotubes attenuated insulins effect on glucose 
uptake, while PAO either does not alter, or increases, glucose uptake [188]. Although 
the role of specific fatty acids in altering skeletal muscle metabolic processes are well 
characterised, they mechanisms are still poorly understood. Some of the potential ways 
in which fatty acids can alter skeletal muscle function will be discussed in the next 
section. 
1.11. Remodelling the lipidome 
The composition of fatty acids within skeletal muscle is determined by a number 
factors. Mainly, dietary intake of fatty acids, uptake and oxidation of fatty acids in 
muscle and endogenous lipid production. Fatty acids can influence cell function 
through a number of ways. Fatty acids can alter the activity of transcription factors, 
such as PPARα and SREBP-1. Specific fatty acids also serve as substrates for lipid 
products such as eicosanoids, prostaglandins as well as lipid intermediates such as 
ceramides. Furthermore, fatty acids are incorporated into phospholipids, which are the 
main component of membranes. Cell membranes play a critical role in maintaining a 
barrier between the intra and extracellular environment and regulating the entry and 
exit of molecules. All external signals received must be propagated through the 
membrane. Altering membrane fatty acid composition and physical characteristics can 
impact cell function  
In 1972, Singer and Nicholson [189] proposed the fluid mosaic model which describes 
the behavior of cellular membranes.  Cellular membranes are composed of an 
asymmetric phospholipid bilayer in which cholesterol and proteins are embedded.  The 
membrane is not a static bilayer and membrane components can diffuse both laterally, 
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rotationally and flip between then inner and outer leaflets of the bilayer. These 
characteristics gives membranes physical properties such as fluidity and elasticity 
while still being structured enough to maintain the integrity of the membrane. 
Membrane fluidity and the movement of phospholipids is important for a number of 
reasons. It allows for the insertion of proteins and newly synthesized lipids into the 
bilayer and subsequent diffusion from the insertion point. Membrane fluidity is also 
important for the fusion with other membranes and mixing of the components, for 
example GLUT4 containing vesicles translocate to the plasma membrane in response 
to insulin and release GLUT4 proteins into the membrane which then diffuse laterally 
and open pores in the membrane.  Membrane bilayers can exist in two main states. The 
gel phase, where the membrane is more ridged and ordered and the liquid-crystalline 
phase where the membrane has a looser more fluid order. One of the key determinants 
of membrane fluidity is the carbon length and unsaturation length of fatty acids 
contained within phospholipids. Different fatty acids have different melting 
temperatures and this alters the temperature at which a membranes shift from a gel 
phase to the liquid phase. Increasing carbon chain length increases the melting 
temperature due to the increase in surface area. Lipids, such as PA, have a higher 
melting temperature and membranes rich in saturated fatty acids are maintained in a 
more gel like rigid structure. Increasing unsaturated bonds into the carbon chain 
decreases the melting temperature. Unsaturated bonds introduce kinks into the 
structure which prevent lipids from packing closely and form less structured 
membranes. Monounsaturated fatty acids have a more modest effect on membrane 
fluidity than more highly unsaturated fatty acids.  A modulator of fatty acid regulated 
membrane fluidity is the presence of cholesterol within membranes. The presence of 
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cholesterol causes tighter packing of lipids and can also segregate areas of different 
phases.  
Omega-3 PUFAs are long chain highly unsaturated fatty acids and given these 
characteristics are commonly used to assess the effects of fatty acid composition on cell 
membrane characteristics. Omega-3 lipids are highly incorporated into all cell 
membranes, such as the plasma and mitochondrial membranes [190]. Alterations in 
the membrane composition within cells are known to alter the physico-chemical 
properties. An increase in unsaturation of phospholipids will increase membrane 
fluidity whereas greater saturation of phospholipids will induce a more rigid structure. 
As such, insulin resistance is associated with decreasing concentration of PUFAs in 
serum and muscle phospholipids [191]. Theoretically, enhanced fluidity, looser 
packing of phospholipids, of the membrane may facilitate increased GLUT4 vesicle 
fusion with the plasma membrane. Membrane composition changes may alter the 
micro-environment of proteins localized within the membrane causing a modification 
in the function of the protein [29]. There is also evidence to suggest that DHA, and to a 
lesser extent EPA, play a role in the formation and composition of lipid rafts [192]. Lipid 
rafts are insoluble fractions of the membrane composed of sphingolipids, cholesterol 
and proteins and are formed in order to allow the compartmentalisation of the 
membrane for the coordination of function by providing scaffolding to stabilise 
protein-protein and lipid-lipid interactions involved in signal transduction and 
trafficking [193]. Studies have shown in a number of cell lines that DHA and EPA are 
incorporated into insoluble membrane fractions and lead to the ‘declustering’ of lipid 
rafts due to the poor affinity between omega-3 PUFAs and cholesterol, leading to the 
expulsion of cholesterol from the lipid rafts [192], [194]. However, EPA and DHA may 
have divergent effects on the structure of lipid rafts with EPA incorporated into non-
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raft regions and displacing cholesterol to raft regions making them more ordered, 
while DHA may have the opposite effect [195]. These structural changes may affect 
protein localisation within raft and non-raft regions, however, it is yet to be fully 
understood how this directly impacts on cell function. Given the important nature of 
signalling responses at the membrane, modification by omega-3 PUFAs could lead to a 
significant alteration in cellular function giving rise to changes in gene expression, cell 
signalling and release of bioactive metabolites. The current literature, however, 
focuses on immune cell lines and it remains to be studied in human skeletal muscle 
cells.   
 Given that omega-3 PUFAs interact with multiple cell signalling pathways changes in 
the membrane composition may be a potential convergence point for the effects of 
omega-3 PUFAs on metabolic outputs. The phospholipid pool also serves as the main 
substrate pool for production of eicosanoids. Enriching the phospholipid fraction 
specifically may, therefore, be necessary to elicit the beneficial effects on omega-3 
PUFAs. To date, few studies have fully characterised to what extent, or even which, 
phospholipid fractions (i.e phosphatidylcholines, phosphatidylerines, 
phosphatidylethanolamines and phosphatidylinositol) are enriched or displaced by 
omega-3 PUFAs in skeletal muscle and how this relates to skeletal muscle metabolism.  
Concurrent with the changes in membrane composition and physical characterstics, 
fatty acids can also serve as a substrate for lipid products and intermediates of lipid 
metabolism. In particular, omega-3 and omega-6 fatty acids EPA and AA are substrates 
for the production of protstaglandins, eicosanoids and thromboxanes. These are 
bioactive molecules that play a role in the modulation of inflammatory processes [196] 
.  Eicosanoids are synthesised from 20 carbon fatty acid chains which have been 
released from phospholipids by phospholipase A2 meaning both AA and EPA are 
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substrates for eicosanoid production. Incorporation of EPA and DHA into the substrate 
pool often occurs at the expense of AA reducing the potential for AA driven eicosanoid 
production. EPA, as a 20 carbon chain, competes with AA as a substrate for the 
cyclooxygenase (COX) and lypooxygenase (LOX) pathways and has also been seen to 
reduce the gene expression of COX-2 [197]. Dietary supplementations of omega-3 
PUFAs in humans have observed decreased production off AA eicosanoids such as 
Prostaglandin E2 while increasing the production of prostaglandin E3 [198], [199]. EPA 
derived eicosanoids also display a reduced affinity for eicosanoid receptors rendering 
them up to 50-80% less biologically active than AA derived eicosanoids [200]. Both 
EPA and DHA also serve as substrates for resolvins, protectins and maresins which 
display inflammation resolving properties in both cell culture and animal models of 
inflammation [201], [202]. However, a recent study has called into question the 
production of inflammatory resolving molecules and their role in mediating 
inflammatory challenges in healthy humans [203]. A short term supplementation 
period of 17.6 g EPA and DHA/day did not result in the detection of these inflammatory 
resolving mediators in plasma or urine [203]. One study found that the ability of EPA 
to reduce Prostaglandin E2 occurred between an intake of 1.35 and 2.75 g/day, 
suggesting a threshold for the anti-inflammatory effects [199]. The dose of EPA is 
typically lower in many studies which may be a possible factor in the equivocal changes 
in inflammatory markers seen in supplementation studies. Further study will be 
necessary to understand whether endogenous production of eicosanoids has a 
prominent role in the inflammatory process and if there is any potential role of 
eicosanoids in glucose and protein metabolism. 
Fatty acids can also bind to and alter the activity of transcription factors and proteins.  
Multiple fatty acid species have been identified as potential ligands of the transcription 
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factor peroxisome proliferate activated receptor alpha(PPARα). PPARα is a 
transcription factor involved in the regulation of fatty acid oxidation and energy 
homeostasis [204]. Long chain omega-3 PUFAs linoleic acid (18:3) and DHA (22:6), 
omega-6 PUFAs arachidonic acid (20:4) and saturated species myristic (14:0) and 
stearic acid (18:0) have all been identified as ligands for PPARα [205].  Prostaglandins 
synthesised from 20 carbon fatty acids have also been shown to be ligands for PPARα 
[205]. Sterol regulatory element binding protein 1 (SREBP-1) is another transcription 
factor that is affected by fatty acids. SREBP-1 plays a key role in expression of genes 
involved in lipogenesis. Upon insulin exposure SREBP1 is cleaved from the ER and 
translocates to the nucleus. It has been shown that omega-3 PUFAs supress the 
activation of  SREBP-1 in response to insulin through the liver X receptor [206]. As well 
as binding to transcription factors, some fatty acids also bind to proteins. The most 
common fatty acid modifications are the myristolation and palmitoylation of proteins. 
One of the main functions of this protein modification is the regulation of a proteins 
subcellular trafficking. Typically, palmitoylation of  a proteins targets a protein to the 
membrane and can specifically target a protein to lipid rafts and regulate cell signalling 
[207]. 
Collectively, this body of work demonstrates that fatty acids can alter cell function 
through a number of different mechanisms. Incorporation of fatty acids into complex 
lipid structures such as phospholipids can alter membrane characteristics and the 
response to extracellular stimuli. Furthermore, 20 carbon fatty acids act as a substrate 
for the production of prostaglandins and eicosanoids. Aside from changes in lipid 
structures, fatty acids can directly interact with transcription factors and induce 
changes in gene expression and subsequent protein abundance. Fatty acids, such as PA, 
can regulate protein membrane localisation by directly interacting with proteins. Thus, 
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fatty acids can alter the cellular environment on multiple levels. However, few studies 
have coupled measures of changes in lipid profiles with changes in proteomic and gene 
expression data. 
1.11. Mass spectrometry approaches in biology 
The generation of ‘omics’ datasets has been rapidly expanding in recent decades. The 
main concept is to better understand the underlying biology by taking a holistic view 
to measure the components of cells as universally as possible. This approach has been 
used to measure genetic sequence, mRNA, protein, lipids and metabolites. 
Underpinning the increase in omics studies is the advancement of available in 
technology. In particular, the development of mass spectrometry techniques allows the 
measurement of protein, lipids and metabolites with increasing resolution. The overall 
goal of this thesis was to further our understanding of how different fatty acyl 
structures alter the cellular microenvironment. To achieve this, we decided to utilise 
mass spec technologies to measure global changes in lipid profiles, specific changes in 
phospholipid composition and proteomic profiles.  
Many studies analyse the changes in abundance of a selected proteins, normally 
associated with a specific pathway. While this provides useful information, important 
changes in other proteins which may be mechanistically linked are missed. Coupling 
isotope labelling strategies with mass spectrometry analysis allows for a more global 
approach to protein abundance analyses. A typical workflow for proteomics analysis 
requires proteins to first be extracted from the sample, proteins are then separated by 
molecular mass to reduce sample complexity. Proteins then undergo tryptic digestion, 
separated by chromatography and injected into the mass spectrometer. Multiple 
strategies have been developed such as isotope coded affinity tag (ICAT), isobaric tags 
for relative and absolute quantification (iTRAQ) and stable isotope labelling of amino 
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acids in cell culture (SILAC). The ICAT technique involves labelling cysteine residues 
with an isotopic label conjugated to a biotin molecule. This biotin molecule is then used 
to pull down by affinity purification of peptides containing a labelled cysteine peptide. 
This limits the proteomic analysis to cysteine containing peptides and reduces the 
sample pool for analysis. Another drawback is that each sample is labelled individually 
prior to pooling. This could introduce different labelling efficiencies for each sample. 
iTRAQ is another commonly used proteomics method. iTRAQ introduces different 
isobaric tag to free amine groups post protein digestion. Samples can then be 
multiplexed and analysed simultaneously. A major limitation of the iTRAQ method is 
that accurate measurement of abundance changes is limited to large changes in protein 
abundance [208]. The SILAC strategy overcomes these issues by introducing the 
isotopic label during the proliferation of cells. This method uses labelled amino acids 
(heavy or light labelled argingine and lysine) – need to detail specific modification, 
known difference in mass. Cells are grown in modified media which is free of unlabelled 
arginine or lysine and supplemented with modified arginine or lysine. As these are non-
essential amino acid cells must use the labelled amino acid in the synthesis of new 
proteins. This ensures that after multiple cell population doublings, almost all proteins 
will contain a labelled arginine and lysine. This allows for more accurate quantification 
of abundance changes as multiple peptides from the same protein can be compared to 
ensure a similar level of change. These amino acids were also chosen as trypsin cleaves 
exclusively at arginine and lysine residues [209]. Thus, after tryptic digestion all 
peptides should contain either a labelled arginine or lysine. Prior to digestion samples 
are also pooled for all further steps which allows for experimental variability to be 
reduced. SILAC allows for the measurement of the relative change in abundance 
compared to both the unlabelled group and the other labelled group.  The SILAC 
 
General introduction                                                                                                                             43 
method has a number of strengths that overcome the limitations of other methods that 
makes it one the most effective ways to assess proteome changes. SILAC allows for the 
measurement of small changes in protein abundance as well as peptides not containing 
cysteine residues. Thus, SILAC proteomics provides a highly accurate method to assess 
relative changes in protein abundance between treatments 
 
1.12. Conclusion 
Overall, it appears that the metabolic effects of fatty acids are related to the presence 
of double bonds within the acyl chain structure. Double bonds alter the conformation 
of the fatty acid, altering membrane structure and lipid interaction with membrane 
proteins, cholesterol etc. Moreover, fatty acids are ligands for a number of 
enzymes/receptors. A change in the structure of the fatty acid will not only alter 
binding targets but also the efficiency by which those docking reactions occur [200]. 
Thus, different fatty acids have the capacity to substantially alter a number of cellular 
processes depending on the metabolic fate each fatty acid is channelled towards. Fatty 
acids have the capacity to alter gene expression [109], [147], [149], [210], so the 
metabolic activities may be reflected in the global proteomic signature of muscle cells. 
It is still poorly understood how fatty acids of differing chain length and unsaturation 
alter the myotube microenvironment by shifting lipidomic and proteomic profiles. 
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1.13. Aims and objectives 
The overall aim of this thesis is to further our understanding as to how minor 
differences in fatty acid structure can differentially alter various aspects of skeletal 
muscle metabolism. Specifically, by profiling myotube metabolic phenotypes and 
proteomic signatures. Because our primary output was to be 3 way SILAC screens, 
there are 2 main branches to this thesis (Figure 1.3). The comparison of two n-3 
PUFAs, Eicosapentaenoic acid and Docosahexaenoic acid and in another set of 
experiments a comparison of a saturated fat, Palmitate and an unsaturated fat 
Palmitoleate. The comparison of these fatty acids in two groups of experiments was 
necessitated by the limitation SILAC experiments being restricted to 3 way 
comparisons. 
The main objectives are: 
 
 
1. To characterise the incorporation of a) omega-3 fatty acids EPA and DHA 
and b) SFA PA and MUFA PAO into C2C12 myotube lipid pools and 
subsequent alterations in global lipid profiles using Gas 
chromatography/mass spectrometry analysis. Furthermore, analyse the 
storage pattern of EPA and DHA using a lipidomics approach to assess 
whether EPA and DHA are preferentially stored in neutral lipid stores or 
phospholipids. 
 
2.  To determine the impact of treating c2c12 myotubes with different fatty 
acids (EPA,DHA,PA,PAO) on myotube insulin sensitivity. Glucose uptake 
will be used as a key readout of insulin sensitivity. Measures of glucose 
uptake will be coupled to the assessment of PKB phosphorylation and 
protein abundance of key glucose transporters. Secondly, assess changes 
in mitochondrial respiration and protein abundance of mitochondrial 
complex proteins. 
 
3. To measure changes in protein metabolism by assessing basal protein 
synthesis and breakdown in c2c12 myotubes following treatment with a) 
EPA or DHA and b) PA or PAO using isotopic tracers. Phosphorylation of 
proteins involved in the mTOR signalling pathway will also be assessed. 
Changes in the abundance of individual proteins will be measured using a 
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SILAC proteomic screen to assess differentially regulated proteins. Where 
appropriate changes proteins associated with membranes will also be 
measured using SILAC proteomics. 
 
 
 
 
 
 
Figure 1. 3  Experimental design
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CHAPTER 2:  Lipid remodelling may influence the differential effects 
of EPA and DHA on skeletal muscle glucose uptake. 
 
Jeromson S, Mackenzie I, Doherty MK, Whitfield PD, Dick J, Shaw A, Ashcroft S, Philp 
A, Galloway SD, Gallagher IJ, Hamilton DL 
 
 
2.0. Abstract 
 
There is a great deal of interest in the potential metabolic benefits of increasing omega-
3 content in skeletal muscle. Studies have shown that omega-3 supplementation 
enhances muscle protein synthesis in response to hyperinsulinemia-
hyperaminoacidemia and may improve glucose metabolism. Omega-3 fatty acids are a 
heterogeneous mixture of fatty acids. There is evidence that the effects of omega-3 fatty 
acids on skeletal muscle function and metabolism may be dependent on the specific 
omega-3 fatty species. EPA and DHA are the most abundant n-3 species and have 
differential effects on protein and glucose metabolism but the mechanisms remain 
unclear.  
C2C12 myotubes treated with either 50µM EPA or DHA for 72 hours and subsequently 
subjected to assessment of lipid profiles, glucose uptake, mitochondria function and 
cell signalling.  Lipid profiling of skeletal muscle myotubes revealed that EPA and DHA 
are substantially incorporated into the lipid pool and are directed predominantly 
towards phospholipid species. EPA and DHA treatment increased total omega-3 
content (EPA: 951 ± 81%, DHA: 750±5 6%) with no significant difference between 
groups (p=0.115). Divergent effects of EPA and DHA on individual omega-3 fatty acids 
were observed. EPA treatment increased EPA content (1630 ± 23%) and DPA content 
(1318± 199%). DHA accumulated mainly as DHA (3050 ± 310%) with no significant 
changes in other omega-3 fatty acids. DHA decreased the abundance of the omega-6 
species, arachidonic acid (-22± 3%).  
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EPA increased basal glucose uptake (Con: 3.932±0.206 pmol/min/mg vs EPA: 
7.307±0.366 pmol/min/mg) and insulin stimulated glucose uptake (Con: 7.237±0.279 
pmol/min/mg vs EPA:9.996±0.350 pmol/min/mg compared to controls. DHA did not 
alter basal (5.041±0.38 pmol/min/mg) or insulin stimulated glucose uptake 
(7.270±0.3 pmol/min/mg). Insulin elicited a similar increase in PKBt308 
phosphorylation following EPA or DHA treatment. This increase was not the result of 
increased protein abundance of GLUT1 or GLUT4 (p>0.05). EPA or DHA treatment did 
not alter any aspect of mitochondrial respiration or abundance of respiratory complex 
proteins.  These results show that EPA and DHA have different metabolic activities in 
skeletal muscle and this may be related to changes in phospholipid content. 
 
2.1. Introduction 
 
Fatty acids in skeletal muscle serve as an important substrate for energy production 
and play an important role in cell functions, as critical components of cell structure and 
regulators of signalling pathways. The lipid stores within skeletal muscle are in 
constant flux and are reflective of dietary intake [21]. Ectopic lipid accumulation within 
muscle is linked with the onset of insulin resistance [154], [211], [212]. In particular, 
saturated fat is causally implicated in the loss of insulin sensitivity [19], [155]. A 
temporal disconnect exists between the lipid accumulation in muscle and the onset of 
insulin resistance, suggesting there is a progressive loss of regulatory mechanisms 
during a high fat diet [213]. There is promising evidence to assert that the addition of 
polyunsaturated omega-3 lipids to the diet can protect against the decline in glucose 
tolerance during high fat feeding. For example, the addition of 3.4% Kcals of omega-3 
lipids during a 10 week high fat diet offsets the decline in glucose control induced by 
high fat feeding [214]. Similar protective effects have also been observed in specific 
adipose tissue depots [215]. The marine derived omega-3 fatty acids eicosapentaenoic 
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acid (EPA 20:5) and docosahexaenoic acid (DHA 22:6) are thought to be the most 
bioactive omega-3 species. Supplementation of omega-3 above the recommended 
intake is known to enrich omega-3 content in skeletal muscle [23], [55], [59], [78]. 
Enrichment of EPA and DHA within skeletal muscle is known to have a number of 
metabolic effects. Muscle protein anabolism in response to simulated feeding is 
enhanced by omega-3 supplementation in both young and elderly subjects [55], [78]. 
Twelve weeks of omega-3 supplementation does not alter mitochondrial content but 
enhances ADP sensitivity [216]. While there is little consensus on the effects of omega-
3 on insulin sensitivity in human models [217], there are a number of studies from 
rodent and tissue culture studies which support a beneficial role of omega-3 lipids in 
skeletal muscle glucose metabolism   [83], [108], [214], [218]–[220]. A recent study in 
humans utilised a lipid infusion model to demonstrate that the addition of omega-3 
lipids to an infusion of a lipid mixture high in omega-6 fatty acids offsets the extent of 
lipid induced insulin resistance [108].  This body of research highlights that the omega-
3 lipid group can have both therapeutic and preventative characteristics 
 
Despite being very similar in structure, EPA and DHA may have divergent effects on 
skeletal muscle metabolism. In rodents EPA, but not DHA, attenuated the decline in 
mitochondrial function with ageing [142]. A key study observed that in cultured 
myotubes EPA increased MPS in response to anabolic stimuli and reduced muscle 
protein breakdown (MPB) while DHA had no effect [60]. The data from the studies by 
Smith & colleagues (33, 34) suggest that increased mTOR-p70S6K1 signalling 
underpins the enhanced MPS rate in response to omega-3 supplementation, however, 
Kamolrat & colleagues (2013) demonstrated that EPA in cultured cells increased MPS 
despite P70S6k1 phosphorylation being increased by both EPA and DHA. This study 
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did not couple measures of protein metabolism with measures of EPA and DHA 
concentrations in the myotube. This precludes the ability to tell if EPA altered protein 
synthesis as it concentration increased to a greater extent than that of DHA. Moreover, 
leucine was used to stimulate protein synthesis, however, leucine may not be an 
appropriate stimuli to assess changes in protein synthesis [61]. 
Both EPA and DHA have been shown in vitro to down-regulate Nuclear Factor-κappa B 
(NF-Kb) translocation to the nucleus leading to a reduction in Muscle RING finger 
protein-1 (Murf-1) expression, an important mediator of muscle atrophy in cultured 
myotubes [62]. This effect on NF-kb is dependent on PPARɣ, as knockdown of PPARɣ 
abrogates the down-regulatory effect of n-3 fatty acids [63], [64]. Given that both EPA 
and DHA exert these metabolic effects it appears unlikely that these effects would 
explain the observed divergent physiological effects [64], [70]. 
 
Effects of EPA and DHA may diverge from the commonly studied mTOR pathway. 
Multiple laboratories have also shown that EPA increases basal glucose uptake. These 
studies also show that insulin stimulated glucose uptake is higher following EPA 
treatment but the magnitude of change is similar to control treatments. In other 
striated muscle models such as cardiomyocytes, EPA but not DHA increases glucose 
and fatty acid uptake despite similar effects on cell signalling (12). To date, whether 
EPA and DHA have divergent effects on glucose uptake in skeletal muscle has not been 
investigated. Furthermore, these studies did not assess the incorporation of EPA and 
DHA into the lipid pools of the muscle cell lines. Thus, it is unknown If the observed 
differential effects between EPA and DHA are related to different rates of accumulation 
within the cell.  The molecular mechanisms of n-3 fatty acid action in skeletal muscle 
that underpin changes in glucose and protein metabolism are still poorly understood.  
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Given that one of the main cellular fates for fatty acids is incorporation into complex 
lipid species it seems logical that the differential action of EPA and DHA may be 
influenced by the differential effects on the cellular lipidome. To date no study has 
characterised the impact of EPA and DHA individually on lipidomic profiles in skeletal 
muscle. We therefore sought to characterize the skeletal muscle lipidome in response 
to EPA and DHA, assess the effects of EPA and DHA on glucose uptake and 
mitochondrial function. We hypothesized that EPA and DHA differentially remodel the 
skeletal muscle lipidome and influence downstream processes which may influence 
the previously observed divergent effects of EPA and DHA. 
 
2.2. Materials and methods 
2.2.1. Materials 
 
All plastic ware for tissue culture was purchased from fisher scientific (UK). Tissue 
culture media and sera were purchased from Invitrogen. Fatty acids EPA and DHA 
(>99%, liquid form) were purchased from Sigma Aldrich (Dorset, UK). H32-DG was 
purchased from Hartman Analytic. All solvents were LC-MS grade (Fisher Scientific, 
Loughborough, UK). 
 
2.2.2. Cell culture 
 
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 
20% foetal bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 
5% C02. Myoblasts were maintained at ~60% confluence. Differentiation was induced 
once confluence reached 80-90% by changing the media to differentiation media 
(DMEM supplemented with 2% horse serum and 1% Penicillin/Streptomycin) for 72 
hours. Following 72 hours differentiation cells were treated with 50 µM EPA or 50 µM 
DHA conjugated to 2% fatty acid free BSA,  2% fatty acid free (FAF) BSA alone was used 
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a control, for 72 hours. Fatty acids were conjugated to 2% fatty acid free BSA in DM by 
constant agitation for 1 hour at 37°C.  For lipid analysis, cell pellets were collected 
following 3 washes in 2% FAF BSA in PBS and centrifuged at 800 rpm for 4 minutes, 
excess liquid was removed and pellets were frozen in liquid nitrogen and stored at -
80°C until further analysis. 
 
2.2.3. FAME analysis 
 
Total lipids were extracted by homogenising in 20 volumes of chloroform/methanol 
(2:1 v/v). Total lipids were prepared according to the method of Folch et al. [221] and 
non-lipid impurities were removed by washing with 0.88% (w/v) KCl. The weight of 
lipids was determined gravimetrically after evaporation of solvent and overnight 
desiccation under vacuum. Fatty acid methyl esters (FAME) were prepared by acid-
catalysed transesterification of total lipids according to the method of Christie et al. 
Extraction and purification of FAME was performed as described by Ghioni et al. [222]. 
FAME were separated by gas-liquid chromatography using a ThermoFisher Trace GC 
2000 (ThermoFisher, Hemel Hempstead, UK) equipped with a fused silica capillary 
column (ZBWax, 60m x 0.25 m x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with 
hydrogen as carrier gas and using on-column injection. The temperature gradient was 
from 50 to 150oC at 40oC/min and then to 195oC at 1.5oC/min and finally to 220oC at 
2oC/min. Individual methyl esters were identified by reference to published data 
(Ackman, 1980). Data were collected and processed using the Chromcard for Windows 
(version 2.00) computer package (Thermoquest Italia S.p.A., Milan, Italy). All 
experiments were carried in duplicate from 4 independent experiments. Data were 
represented as fold change from the respective BSA control condition, logged to log2 
and significance was determined by t-test and corrected for false discovery rate.   
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2.2.4. Global lipidomic analysis of C2C12 myotubes 
 
Lipid extraction was performed according to the method described above. The lipids 
were analysed by liquid chromatography-mass spectrometry (LC-MS) using a Thermo 
Exactive Orbitrap mass spectrometer (Thermo Scientific, Hemel Hempstead, UK), 
equipped with a heated electrospray ionization probe and coupled to a Thermo Accela 
1250 UHPLC system. All samples were analysed in both positive and negative ion mode 
over the mass to charge (m/z) range 200-2000. The samples were injected (1µL) on to 
a Thermo Hypersil Gold C18 column (1.9 μm, 2.1mm x 100 mm,). Mobile phase A 
consisted of water containing 10 mM ammonium formate and 0.1% (v/v) formic acid. 
Mobile phase B consisted of 90:10 isopropanol/acetonitrile containing 10 mM 
ammonium formate and 0.1% (v/v) formic acid. The initial conditions for analysis were 
65%A/35%B. The percentage of mobile phase B was increased to 100% over 10 min 
and held for 7 minutes before re-equilibration with the starting conditions for 4 
minutes. The raw LC-MS data were processed with Progenesis QI v2.0 software (Non-
linear Dynamics, Newcastle, UK) and searched against LIPID MAPS 
(www.lipidmaps.org) and the Human Metabolome Database (http://www.hmdb.ca/) 
for identification. All experiments were carried out in duplicate from three 
independent experiments. 
 
2.2.5. Phospholipid profiling of C2C12 myotubes 
 
In order to assess the incorporation of EPA and DHA into cellular phospholipids the 
lipid extracts from C2C12 myotubes were analysed by electrospray ionisation-tandem 
mass spectrometry (ESI-MS/MS).  All analyses were performed in positive ion mode 
using a Thermo TSQ Quantum Ultra triple quadrupole mass spectrometer equipped 
with a heated electrospray ionization probe. Samples were directly infused into the ion 
source at a flow rate of 5 µL/min. Phosphatidylcholine and lysophosphatdilycholine 
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species were identified by precursor scanning for m/z 184 and 
phosphatidylethanolamine and phosphatidylethanolamine species were identified by 
neutral loss scanning for m/z 141. The data were expressed as a percentage 
composition of the relevant phospholipid fraction. 
 
2.2.6. Glucose uptake 
 
C2C12 myotubes were exposed to 50µM EPA or 50µM DHA for 48 h before a 2 h serum-
starve. Following the 2 h serum starve cells were exposed to insulin (100 nmol/l) or 
vehicle control for 30 mins. Myotubes were incubated (12 min) with 10 μmol/l 2-
deoxy-D-[3 H]glucose (2DG; 24.4 kBq/ml; Hartman Analytic) at 20°C. Non-specific 
uptake was determined using 10 μmol/l cytochalasin B (Sigma–Aldrich). After lysis, 
cell-associated radioactivity was measured (Beckman, High Wycombe, UK; LS 6000IC 
scintillation counter), and protein was quantified using the Bradford protein assay. 
Data represented are the average of six independent experiments carried out in 
duplicate. 
 
2.2.7. Cellular respiration. 
 
Cells were seeded in Xfe24-well cell culture microplates (Seahorse Bioscience, North 
Billerica, MA) at 1.0 x 104 cells/well in 100 µl of growth medium (high glucose DMEM, 
10% FBS, 1% penicillin/streptomycin) and allowed to rest at room temperature for 1 
h in order to promote an even cell distribution. Cells were then incubated at 37°C and 
5% CO2 for 3 h after which 150 µl of growth medium was added bringing the total 
volume to 250 µl. Cells were then returned to the incubator for a further 48 h. Upon 
reaching 90% confluence cells were then differentiated for 4 days using differentiation 
medium (high glucose DMEM, 2% horse serum, 1% penicillin/streptomycin). 
Differentiation medium was replenished every other day. Following 4 days of 
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differentiation cells were treated for 24 h with differentiation medium containing 50 
µM of either DHA, DPA, EPA or a 2% BSA control (n=5). Prior to the assay the cells were 
washed once and placed in 600 µl of Seahorse XF Base Medium (glucose 25 mM, sodium 
pyruvate 1 mM, glutamine 2 mM, pH 7.4) pre warmed to 37°C. The plate was then 
transferred to a non-CO2 incubator for 1 hour. Following calibration oxygen 
consumption measurements (OCR) were performed following the sequential addition 
of oligomycin (1 µM), carbonyl cyanide p-trifluoromethoxyphenylhydrazone (3 µM) 
and antimycin A/rotenone (1 µM). Upon completion of the assay cells were collected 
in lysis buffer (50 mM Tris pH 7.5; 270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 1% 
Triton X-100; 50 mM sodium fluoride; 5 mM sodium pyrophosphate decahydrate; 25 
mM beta-glytcerolphosphate; 0.4% protease inhibitor cocktail; 0.4% phosphatase 
inhibitor cocktail; 4.8% completeTM protease inhibitor cocktail EDTA free) and 
centrifuged for 10 min at 8,000 g and the supernatant was removed for protein 
determination. Protein concentration was determined using the DC protein assay (Bio-
Rad, Hercules, CA). Oxygen consumption rate (OCR) is reported relative to protein 
content (pmol/min/µg).  
 
 
2.2.8. Cell processing  
 
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 
mmol/l Tris·HCl pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 
1 mmol/l EDTA, 1% (vol/vol) Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 
mmol/l sucrose, and 0.1% (vol/vol) 2-mercaptoethanol and Complete protease 
inhibitor cocktail (Roche)] followed by snap freezing on liquid nitrogen. For 
preparation for western blotting samples were thawed and debris was removed by 
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and 
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protein concentration was determined using the DC protein assay according to the 
manufacturer’s instructions (Bio-Rad, Hercules,CA). 
 
2.2.9. Western blotting 
 
For WB, 100μg of supernatant was made up in Lamelli sample buffer, and 15 μg of total 
protein was loaded per well and run at 150 V for 1 h 15 min. Proteins were then 
transferred onto Whatman Immunobilon Nitrocellulose membranes (Fisher Scientific, 
Loughborough, UK) at 30 V for 2 h 15 min. Membranes were blocked in 3% BSA-Tris-
buffered saline (containing vol/vol 0.1% Tween 20) for 1 h at room temperature, 
followed by incubation in primary antibodies [PKBthr308 (#2965), total PKB (#4691) 
(New England Biolabs)], Glut1, Glut4 [Santa cruz biotech], Hekokinase1, Hekokinase2 
[Cell signalling] or OXPHOS mitoprofile at 4°C overnight. Membranes underwent three 
5 min washes in TBST followed by incubation in the appropriate secondary antibodies 
[secondary horseradish peroxidase conjugated antibody was purchased from ABCAM 
(#6721)] for 1 h at room temperature. Membranes were again washed three times for 
5 min followed by incubation in enhanced 55ntimycin55escence reagent (BioRad, 
Herts, UK). A BioRad ChemiDoc (Herts, UK) was used to visualize and quantify protein 
expression. Phospho proteins were normalized to the corresponding total protein. 
Data are representative of 3 independent experiments carried out in duplicate. 
 
2.2.10. Statistics 
 
Statistical analyses were carried out in Graphpad Prism. Glucose uptake was analysed 
with a two-way ANOVA followed by Tukey’s HSD test. A two-way ANOVA was used to 
determine the success of manipulating mitochondrial respiration. Differences in 
mitochondrial states between groups were assessed by a one-way ANOVA. For FAME 
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analyses data were assessed in R statistical packages using multiple t-tests and 
corrected by false discovery rate. Statistical significance was determined with a p<0.05. 
The global lipidomic data sets were subjected to principal component analysis (PCA) 
and orthogonal projection latent structure-discriminant analysis (OPLS-DA) using 
SIMCA-P v13.0 software (Utmetrics, Umea, Sweden). 
 
2.3. Results 
2.3.1. EPA and DHA substantially increase the abundance of omega-3 species but have 
different effects on individual omega-3 fatty acids 
 
After exposure to 50µM EPA or DHA for 72 hrs C2C12 myotubes were collected for 
FAME analysis to determine lipid profiles. EPA and DHA significantly increased omega-
3 fatty acid content from baseline values (EPA; 951 ± 81% p=0.0014, DHA; 750 ± 56% 
p=0.0009) with no significant difference detected between EPA and DHA treatment 
(p=0.115) (Figure 2.1A). The changes in omega-3 abundance are a result of 
differential shifts in specific omega-3 fatty acids caused by EPA or DHA treatment. The 
increase in omega-3 content by DHA is a result of accumulation of mainly DHA [22:6 n-
3, 3050% ± 310%. While, incubation of myotubes with EPA results in the accumulation 
of EPA [(20:5 n-3), 1630% ± 23.38] and DPA [(22:5 n-3), 1318% ± 199.8%] (Figure 
2.1B). These data suggest that EPA is elongated to DPA whilst DHA remains largely 
unmodified. 
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Figure 2. 1 EPA and DHA enhance n-3 abundance but differentially alter the abundance of 
individual omega-3 fatty acids. A) Fatty acid abundance following 72 hr treatment with either EPA or 
DHA determined by FAME analysis (n=4 in duplicate). B) Individual changes in omega-3 fatty acids (n=4 
in duplicate). Data is plotted as mean value ± S.E. * denotes significant difference between EPA and DHA 
groups (p<0.005). 
 
2.3.2. EPA and DHA divergently alter myotube lipid profiles 
 
Upon analysis of global lipid profiles, it is evident that both EPA and DHA alter the 
abundance of individual fatty acids are these changes are not exclusive to n-3 fatty 
acids. This increase in omega-3 content was associated with significant decreases in 
multiple species of monounsaturated fatty acids, omega-6 and omega-9 fatty acids, 
with a trend for increases in saturated fatty acids (Figures 2.1A and 2.2). In order to 
clearly distinguish differential shifts in fatty acid abundance we presented the 
complete fatty acid profiles as fold change [(log2) Figure 2.2]. The most clearly 
differentiated fatty acid is DPA (22:5 n-3) which demonstrates a significant 1318 ± 
200% increase with EPA treatment whilst DHA treatment induces a 17.83 ± 17.37% 
decrease in DPA content, although this was not a statistically significant effect. 
Additionally there is a trend (p=0.06) for EPA treatment to increase the DHA content 
of the cells (37.11 ± 12.62%) suggesting that only a small proportion of the EPA is 
converted to DHA.  Surprisingly arachidonic acid (20:4 n-6) was only significantly 
decreased by DHA treatment (-22.35 ± 3.174%) and remained unaffected by EPA 
treatment. Intriguingly we also observed that both EPA and DHA increased the content 
of the saturated fatty acid PA  (Fig 2.2). In order to build a more complete picture of 
the impact of EPA and DHA on the lipidome we proceeded with a global lipidomics 
assessment. 
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Figure 2. 2 Lipid alterations in response to EPA and DHA are not limited to omega-3 fatty acids. 
Fold change of individual fatty acid species (n=4 in duplicate). Data are expressed as log2 fold change ± 
S.E. 
2.3.3. EPA enhances basal and insulin stimulated glucose uptake independent of 
increased PKB phosphorylation 
 
Basal and insulin stimulated glucose uptake was determined by 2DG uptake. EPA 
incorporation significantly enhances both basal and insulin stimulated 2DG uptake 
indicating that EPA enhances the capacity for glucose uptake (p<0.05) (Figure 2.3A). 
DHA did not have any significant effects on 2DG uptake (Figure 2.3A). Simultaneous 
treatment with both EPA and DHA displayed similar effects to EPA alone. The data 
suggest that there are specific characteristics of EPA that enhance the capacity glucose 
uptake. The observed changes in glucose uptake was not related to changes in PKB 
phosphorylation as basal and insulin stimulated PKB phosphorylation were similar 
across groups (Figure 2.3B). Despite insulin stimulated glucose uptake being higher 
following EPA treatment, the magnitude of change from basal levels was not 
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significantly different between groups. This suggest that the insulin sensitive signalling 
response leading to GLUT4 translocation to the membrane remained unchanged 
following fatty acid treatment. 
 
 
 
Figure 2. 3 EPA and DHA have differential effects on muscle glucose uptake despite similar PKB 
signalling. A) Basal and insulin stimulated glucose uptake was measured by 2DG uptake. B) PKB 
phosphorylation was determined by western blots. Data are expressed as mean± S.E (n=6 in duplicate)  
 
2.3.4. EPA and DHA do not alter the  protein abundance of glucose transporters or 
hexokinase 
 
To further investigate the underlying mechanism behind the observed changes in 
glucose uptake, we assessed if n-3 fatty acid treatment altered the abundance of 
proteins involved in glucose transport and metabolism. Neither fatty acid treatment 
altered the protein abundance of glucose transporters GLUT1 and GLUT4 (p>0.05) 
(Figure 2.4A and B). These measures do not, however, rule out the possibility of 
changes in endo/exocytic cycling of glucose transporters with the plasma membrane. 
Upon uptake glucose is phosphorylated to glucose-6-phosphate by hexokinase. 
Hexokinase is thought to be constitutively active so changes in total abundance may 
reflect an increased capacity to process glucose, thus maintaining low intracellular 
glucose levels. Treatment with EPA or DHA did not alter the abundance of Hexokinase 
1 or 2 (p>0.05) (Figure 2.4C and D). 
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Figure 2. 4 EPA and DHA do not alter total protein abundance of glucose transporters and hekokinase 1 and 
2.   Protein content of A) Glut1 B) Glut4 C) Hexokinase 1 and D) Hexokinase2 were measured by western 
blotting. Representative images are shown in E) glucose transporters and F) Hexokinases. Data are 
presented as mean±S.E (n=3 in duplicate). 
 
2.3.5. N-3 fatty acids do not alter mitochondrial respiration 
 
As no changes in glucose transporters were detected we next assessed whether 
changes in mitochondrial oxygen consumption may explain the increase in glucose 
uptake following EPA treatment. C2C12 myotubes were treated with 50µM EPA or DHA 
for 24 hours. Following treatment with multiple inhibitors/uncouplers (Oligomycin, 
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FCCP, rotenone/ 61 ntimycin A) were used to probe various parameters of 
mitochondrial function using the seahorse XF mito stress test. A two way ANOVA found 
a significant interaction between oxygen consumption and inhibitor compound, 
indicating the successful manipulation of mitochondrial function. Following fatty acid 
treatment no changes in cellular oxygen consumption were observed in any parameter 
measured (Figure 2.5). There is evidence to suggest that fatty acids can induce 
mitochondrial uncoupling, however, the current doses used in this study may not have 
been sufficient to observe this effect. Consistent with the lack of changes in 
mitochondrial function, there were no alterations in the abundance of ATP synthase 
and UCQR2 (Complex V and Complex III respectively) (Figure 2.6). 
 
 
Figure 2. 5 N-3 fatty acids do not alter mitochondrial oxygen consumption. Mitochondrial function 
was assessed following treatment with 50µM EPA or DHA for 24 hours. B – baseline, C- coupled, Max – 
maximal respiration, proton leak, NMR – non mitochondrial respiration. Data are expressed as pmol of 
oxygen consumed/min/mg of protein.  
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Figure 2. 6  Omega-3 treatment does not alter the abundance of proteins involved in the electron 
transport complex. Protein abundance of proteins in the ETC were measured by western blot. A) 
relative abundance of ETC proteins. B) Representative western blot images. Upper panel – long 
exposure. Lower panel – short exposure. Data is presented as mean values relative to a loading control 
(n=3 in duplicate). 
 
2.3.6. Global lipidomic analysis reveals that EPA and DHA transition into phospholipids 
and divergently remodel the phospholipidome 
 
 
Figure 2. 7 PCA scores plots of lipid profiles generated by LC-MS in (A) positive ion and (B) 
negative ion modes. Cultured cells were incubated with either fatty acid free 2% BSA (green circles), 
fatty acid free 2% BSA pre-conjugated to 50 µM EPA (red triangles) or 50 µM DHA (blue squares) for 
72hrs. Each point represents a single cell sample (n=6). Samples exhibiting biochemical differences 
caused by fatty acid treatment are represented by points in regions away from the controls. 
 
Given that the mechanism underlying the EPA driven changes in glucose uptake was 
not readily apparent we assessed how the remodelling of the lipidome by fatty acid 
treatment may influence the observed results. Lipid extracts of myotubes treated with 
BSA (control), EPA or DHA were analysed by LC-MS in positive and negative ion modes, 
processed and subjected to multivariate data analysis. PCA of both the positive and 
negative ion data sets revealed that EPA and DHA supplementation caused a 
substantial divergence in the lipidome, effectively segregating control and treated cells 
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(Fig. 7A and 7B). Having established the existence of clustering behaviour between 
the sample cohorts more multivariate methods were used to characterise the specific 
lipid changes responsible for the observed shift in the lipidome of the EPA and DHA 
treated myotubes. The OPLS-DA scores and OPLS loadings ‘S’ curves of the positive ion 
data are shown in Fig. 2.8A and 2.8B. The results indicated that the observed variance 
between samples were best characterised by changes in the fatty acids contained in 
phospholipids, in particular PC and PE fractions. In EPA treated cells elevations in PC 
and PE species containing both 20:5 and 22:5 fatty acids (in agreement with FAME 
analysis) were observed, whereas there were relative increases in the abundance of 
phospholipid species with a 22:6 fatty acid in DHA treated cells. Interestingly, the 
analysis also revealed that both EPA and DHA treatments also resulted in an elevation 
of PC 32:0, a saturated species. DHA was also found to be incorporated into a number 
of triglyceride species. In order to fully understand the impact of EPA and DHA 
treatment we followed up these experiments through the targeted analysis of myotube 
phospholipid fractions.  
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Figure 2. 8. Positive ion OPLS-DA scores plots for (A) BSA vs DHA and (B) BSA vs EPA (n=6). Green 
circles indicate BSA treated C2C12 myotubes; blue squares indicate DHA treated C2C12 myotubes and red 
triangles indicate EPA treated C2C12 myotubes. The associated S-plots demonstrate the covariance 
versus the correlation in conjunction with the variable trend plots and allow easier visualization of the 
data. The variables that showed maximum change and, therefore strongly contributed to the class 
separation, are plotted at the top or bottom of the S-shaped plot. The variables that did not significantly 
vary are plotted in the middle. Each point represents a detected ion. 
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2.3.7. Targeted phospholipid analysis reveals that EPA and DHA increase the fraction of 
lipid species containing long chains and 5 or more double bonds at the expense of shorter 
chain less saturated species.  
 
Figure 2. 9 Targeted phospholipid analysis indicates preferential incorporation of long chain 
polyunsaturated fatty acids into specific phospholipid classes. C2C12 myotubes were solvent 
extracted and molecular species of (A) phosphatidylcholine and (B) phosphatidylethanolamines were 
detected by ESI-MS/MS in positive-ion mode by means of a precursor ion scan for m/z 184 and a neutral 
loss scan of m/z 141 respectively 
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ESI-MS/MS was utilised to characterise the profiles of myocyte phospholipid classes. 
Representative mass spectra of PC and PE are shown in Figure 2.9A and B. The general 
trends (Figure 2.10) in both EPA and DHA were similar with the displacement of 
shorter chain in apparent preference for longer chain highly unsaturated fatty acids. 
However, the magnitude of change for these displacements was often higher with DHA. 
EPA, DPA and DHA were also identified as being incorporated into the PS and PI 
fraction in a similar fashion. Caution should be taken when interpreting the lipid 
remodelling in PS and PI fractions as these fractions comprise a very small proportion 
of phospholipids. As a result, the ion intensities detected of PS and PI species are lower 
and subsequent results are less robust. Interestingly, EPA and DHA induced increases 
in species containing saturated fatty acids. For instance DHA induced a differential 
increase in the lysophosphatidylethanolamine (LPE 16:0), which contains a saturated 
fatty acid. Whilst EPA induced an increase in LPC 16:0, 18:0 and LPE 18:0 (For lyso-
phospholid analysis, see supplementary figure S1). It is therefore evident that in 
spite of significant increases in saturated fatty acids in these fractions EPA and DHA 
treatment still improve or maintain glucose uptake respectively. Overall, the trends 
directional shift towards either greater unsaturation or saturation of phospholipid 
classes were similar between EPA and DHA. In PC, there was an increased shift towards 
increased saturation of lipids. In PE species there was a decrease in saturation of 
phospholipids. Similarly, in PE the shift in unsaturated phospholipids was greater than 
the change in unsaturated PC phospholipids. Although overall trends were similar , 
differences emerged between EPA and DHA groups when individual phospholipids 
were analysed. 
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Figure 2. 10 EPA and DHA cause significant remodelling of phospholipid species. C2C12 myotubes 
were solvent extracted and molecular species of (A) lyso-phosphatidylcholine, (B) phosphatidylcholine, 
(C) lyso-phosphatidylethanolamine and (D) phosphatidylethanolamine were detected by ESI-MS/MS in 
positive-ion mode by means of a precursor ion scan for m/z 184 and a neutral loss scan of m/z 141 
respectively. Data are presented as % abundance  SEM. Bars not connected by the same letter are 
significantly different from one another (p<0.05). 
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2.4. Discussion 
 
This study is the first to carry out a comprehensive analysis of the lipidomic profiles of 
a skeletal muscle cell line in response to two differentially bioactive n-3 fatty acids. We 
demonstrate the differential metabolic activities of EPA vs DHA on glucose metabolsim 
in the C2C12 skeletal muscle cell line and provide data demonstrating the differential 
impact that EPA and DHA have on the skeletal muscle lipidome. Our data suggests that 
the bioactivity of EPA may be due to its preferential incorporation (and possibly 
elongation to DPA) into the phospholipid fraction where it substantially alters the long 
chain polyunsaturated fatty acid composition of major phospholipid classes. Increasing 
unsaturation of phospholipids will alter membrane organisation by maintain the 
membrane in a more liquid like state, increasing membrane fluidity and deformation. 
 
EPA has a positive effect on both basal and insulin stimulated muscle glucose transport 
while DHA shows no significant effect. The fold change in glucose uptake from the basal 
to the insulin stimulated state was similar between all groups. This finding suggests 
that insulin response was not altered by fatty acid treatment but the mechanisms by 
which EPA increased glucose uptake were maintained in response to insulin. In line 
with this finding, PKB phosphorylation was unchanged in response to insulin by either 
EPA or DHA. Thus the changes in glucose uptake following EPA treatment may be 
independent of PKB signalling. The change in glucose uptake was also not reflected in 
changes in protein abundance of GLUT1, GLUT4 and hexokinase proteins involved in 
glucose uptake and subsequent committal to metabolic pathways. Although we did not 
detect any changes in total content, changes in the activity of GLUT1 and GLUT4 cannot 
be discounted. Moreover, we did not assess GLUT1 or GLUT4 subcellular localisation. 
The shift in phospholipid composition induced by EPA may have sequestered GLUT1 
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or GLUT4 to the membrane or altered their pore forming activity. Hexokinases are 
considered constitutively active so it is unlikely there were any changes in kinase 
activity.  Furthermore, the significant remodelling of phospholipid may alter protein 
localisation within the cell. Alterations which bring Hexokinases within a closer 
vicinity to GLUT proteins may enhance the “functional coupling” of the system to 
sequester glucose within the cell.  
We next assessed whether changes in mitochondrial function may drive increased 
substrate uptake. Johnson & colleagues [142] demonstrated that EPA but not DHA 
prevented the declines in mitochondrial functions in an aged rodent model. In our 
cultured myotube model, we did not detect any changes in mitochondrial oxygen 
consumption. 
 
We hypothesised that the effects of EPA compared to DHA may be explained by 
differential remodelling of the lipidome. By coupling measures of lipid profiles with 
glucose uptake, we demonstrated that EPA increased glucose uptake and accumulated 
to a lesser extent than DHA. While total n-3 content was similar between treatments, 
EPA resulted in a larger variation in lipid species accumulating mainly as EPA and DPA 
and to a lesser extent DHA while DHA treatment mainly resulted in DHA accumulation 
with a decrease in DPA and a limited retro-conversion to EPA. The main differentially 
regulated fatty acids were DPA, increased in EPA and decreased in DHA, while only 
DHA decreased AA. It is speculated, that some of the beneficial effects of omega-3 are 
caused by the displacement of AA and concomitant reductions in PGF2α production. 
Our data suggests that in terms of glucose uptake, changes in AA content are not 
required. 
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Interestingly DPA accumulated to a similar extent as EPA [1630% (EPA) vs 1318% 
(DPA)], findings consistent with previous literature in other tissues [223], [224]. Given 
that DPA increased to a similar extent to EPA we are unable to determine whether it is 
EPA or DPA that is a driver behind the metabolic effects observed. These data suggest 
that upon intake into the cell EPA is elongated to DPA and to a lesser extent DHA. The 
elongation of EPA to DPA but not DHA may be explained by the differential affinities of 
the desaturases and elongases involved in fatty acid metabolism. In the n-3 pathway 
elovl2 catalyzes the conversion of EPA → DPA → 24:5 n-3, the precursor to DHA. 
However, increasing EPA concentrations is known to lower the saturation point in the 
conversion of DPA → 24:5 n-3 which may play a role the accumulation of DPA without 
being further metabolised to DHA [225]. Our data indicate that one of the primary fates 
of EPA and DHA was incorporation into the phospholipid fraction. In the global 
lipidomics screen we found EPA or DPA containing lipid species associated with the 
phospholipid pool whilst DHA containing species were often associated with the TAG 
pool, EPA containing species were rarely associated with the TAG pool. Fatty acids in 
the TAG pool are stored in discrete lipid droplets and therefore may be less 
metabolically active than the phospholipids associated with the membranes. This 
differential incorporation into the various lipid pools may partially explain the 
beneficial metabolic effects of EPA.  
 
The potential relevance of DPA as a mediator of many of the physiological effects of n-
3 supplementation is beginning to be further understood. DPA more potently inhibits 
platelet aggregation than EPA or DHA [226] as well as more potently stimulating 
endothelial cell migration than EPA or DHA [227]. In macrophages, EPA is a known 
inhibitor of the cyclooxygenase pathway and elongation to DPA is an important factor 
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in this inhibition (29). We would suggest that the elongation of EPA to DPA seen in our 
study may also have important physiological roles in the increase in skeletal muscle 
glucose transport by EPA. As with the global lipidomic analysis we observed the 
incorporation of long chain PUFAs into phospholipid species mainly at the expense of 
specific SFAs and MUFAs, however some specific SFAs were increased by both EPA and 
DHA. We identified multiple differentially regulated phospholipid species across PE, 
PC, LPE and LPC classes. In the EPA treated group a number of species were enriched 
by long chain PUFAs with 5 or more double bonds in addition to a number of EPA or 
DPA containing phospholipids in the PC, PE, PI and PS  fractions. In comparison, the 
DHA treated group increased the long chain PUFA containing phospholipids but did 
not increase or increase as much as EPA the content of species containing 22:5 or 40:5. 
Interestingly, with DHA treatment there was a trend for an increase in the PA 
containing lyso-PE content above that of control and EPA. Additionally, while it appears 
that many phospholipids containing saturated fatty acids are displaced in favour of 
polyunsaturated containing phospholipids we observe a rise in PC (32:0) with both 
EPA and DHA, which may reflect the rise in PA observed with FAME analysis. 
Incorporation of PUFAs into phospholipids is known to increase membrane fluidity 
and we speculate that this increase may be a compensatory mechanism to maintain a 
base level of membrane rigidity. A minimum level of membrane rigidity is necessary 
 To ensure a barrier is maintained around the cell and regulate the appropriate 
regulation of molecules crossing the membrane.  
An attractive mechanism for the differential effects of EPA and DHA may lie in the 
reduced production of different inflammatory eicosanoids. However, only DHA 
reduced the total amount of AA. Additionally, the displacement of phospholipids 
alongside a lack of inflammatory stimulus suggests it is unlikely that this would 
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mediate the metabolic differences seen in this model.  The G protein coupled receptor 
GPR120 has previously been identified as a general n-3 sensor in a number of tissues 
except skeletal muscle that elicits potent anti-inflammatory and consequently insulin 
sensitizing effects [219]. To our knowledge no such receptor exists in skeletal muscle 
that can discriminate between EPA and DHA deeming it unlikely that the observed 
differential effects are mediated by EPA or DHA through specific receptor activated 
signalling.   
 
Different phospholipid species are not merely inert structural components of cellular 
membranes and the various roles in intracellular processes are beginning to be further 
understood. The significant unsaturation of phospholipids will alter the membrane 
structural characteristics and alter the affinities of proteins associated with the 
membrane. We hypothesize that the incorporation of EPA into the lipid pool and 
subsequent incorporation into the phospholipid fraction alters the physical 
characteristic of the membrane and the distribution of proteins associated with the 
membrane which may explain the increases in glucose uptake. PS and PE are related 
phospholipid species found predominantly in the inner membrane and contribute to 
the membrane targeting and activation and modification of protein kinases [as 
reviewed [228]]. It has also previously been seen that the lyso-PC, a hyrdrolyzed form 
of phospholipid, stimulated adipocyte glucose uptake and with the effect dependent 
upon chain length and saturation of the acyl group [229]. We observed an 
incorporation of long chain PUFAs (possibly EPA and DPA) into the PC, PS, PE and 
certain lyso-PL species and therefore cannot discount that the change in acyl chain 
length and unsaturation level alters the function of these PL species and leads to an 
increase in glucose uptake through a currently unknown mechanism.   
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In summary, we demonstrate that EPA and DHA display divergent metabolic activities 
in a skeletal muscle cell line, which may be mediated by differential remodelling the 
lipidome. Additionally, we hypothesize that the elongation of EPA to DPA and 
subsequent incorporation into the phospholipid pool is a critical event mediating the 
divergent physiological effects of EPA and DHA. The specific role of DPA in skeletal 
muscle is not yet fully understood. Given that DPA is readily retro converted to EPA 
and is conserved from β-oxidation to a greater degree it may be possible that DPA may 
serve as a more stable reservoir of EPA. The mechanism underpinning the effect of EPA 
on glucose uptake remains unclear, however, differential remodelling of the lipidome 
may influence downstream effects. Similar to the divergence in the lipidome, n-3 fatty 
acids may also induce differential shifts in the proteomic profile which may explain the 
divergent effects on metabolism.    
 
 
 
 
Chapter 3: n-3 PUFAs and protein anabolism 74 
 
Chapter 3: EPA and DHA alter the membrane proteome and may 
drive the differential effects on protein turnover. 
 
Jeromson S, Martin CV, Rao F, Gallagher IJ, Hamilton DL 
 
3.0. Abstract 
 
In both young and older individuals, omega-3 supplementation improves muscle 
protein synthesis in response to simulated feeding. These anabolic effects may have 
clinical significance for the maintenance of muscle mass and strength, particularly for 
elderly individuals. There is evidence from in vitro studies that EPA and DHA have 
differential effects on protein anabolism in skeletal muscle cell lines. Furthermore, EPA 
and DHA significantly alter the lipidome and may alter the associations of proteins with 
cell membranes. We aimed to explore the impact of EPA and DHA on global proteomic 
profiles and changes in the membrane proteome. EPA treatment increased the total 
protein content in myotubes (Veh: 153±16.9 ug VS EPA: 237.7±44.9 ug). EPA and DHA 
did not alter protein synthesis (Veh:2.49±0.29 CPM/ug, EPA:2.47±0.27, DHA: 
2.4±0.37) or the phosphorylation status of key proteins in the mTOR signalling 
pathway. EPA treatment reduced protein breakdown, while, DHA had a neutral effect. 
SILAC analysis of the global proteome identified divergent shifts in protein expression 
following EPA or DHA incorporation. Analysis of the membrane proteome revealed a 
reduction in ribosomal proteins following DHA treatment. EPA increased association 
of proteins involved in protein folding with membranous regions . We speculate that 
EPA may increase protein fidelity, reducing protein breakdown and increasing total 
protein content. These data show that EPA and DHA differentially alter the proteomic 
profile of skeletal muscle and this may be caused by a shift in ribosomal localisation. 
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3.1. Introduction 
 
Chapter 2 of this thesis and several previous studies demonstrated that omega-3 fatty 
acids are readily incorporated into the skeletal muscle lipid pool. Evidence shows that 
manipulating skeletal muscle omega-3 content across a range of experimental models 
is associated with enhanced protein anabolism [55], [56], [60].  Four weeks of omega-
3 supplementation is associated with increases in mTOR and focal adhesion kinase, 
linked with mechanotransduction (FAK) [230], [231]. Changes in the content of 
anabolic proteins may sensitise skeletal muscle to anabolic stimuli. Indeed, eight weeks 
of omega-3 supplementation in both young and elderly subjects enhanced the muscle 
protein synthetic response to a hyperaminoacidemic-hyperinsulinemic clamp, without 
altering basal protein synthesis [2],[3]. Using a similar supplementation protocol, 
McGlory & colleagues (2016)[59] demonstrated that fish oil supplementation does not 
enhance MPS rates when resistance exercise is performed prior to amino acid feeding 
in young healthy males. Despite the lack of effect on combined exercise and nutrition, 
increasing omega-3 intake can have functional consequences for muscle function. 
Increased omega-3 intake over 6 months in older individuals offset declines in strength 
normally associated with ageing [232]. While in elderly women, fish oil 
supplementation enhanced strength gains during a programme of resistance exercise 
training [11].  
Alongside increments in MPS in response to feeding, omega-3 PUFAs have also been 
demonstrated to offset the deleterious effects of skeletal muscle disuse. Using a 
hindlimb immobilisation model, omega-3 PUFAs reduced the loss of muscle mass in 
rodents possibly through the preservation of the PKB-P70S6K1 anabolic signalling axis 
[52].  Proximal insulin signalling through the PKB-mTOR-P70S6K1 axis is also 
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enhanced in growing steers [79]. The fish oil supplements used in these studies are 
rich in EPA and DHA and despite the very similar structure, EPA and DHA may have 
differential effects on skeletal muscle protein metabolism. In C2C12 myotubes, EPA 
increased MPS after stimulation by leucine while simultaneously reducing protein 
breakdown [60]. Another in vitro study observed that both EPA and DHA reduced 
protein breakdown, although EPA and DHA were used at much higher concentrations 
than in these sets of experiments (400-600µM) [233].  
There is strong evidence that omega-3 PUFAs enhance anabolic processes in skeletal 
muscle which may have important clinical outcomes for populations at risk of 
significant loss of skeletal muscle mass, such as the elderly. However, the omega-3 
content in fish is declining which questions the sustainability of fish as the 
predominant source of omega-3 PUFAs. Current evidence suggests that EPA and DHA 
differentially alter protein turnover, however, it remains relatively unknown how EPA 
and DHA alter the proteomic signature that may provide mechanistic evidence for the 
observed effects of omega-3 on processes regulating protein turnover. Furthermore, 
the significant incorporation of EPA and DHA into phospholipids will alter the physico-
chemical properties of membranes and subsequent association of integral and 
peripheral membrane proteins with the membrane. This suggests that alteration in 
membrane associated proteins may alter the response to extracellular stimuli such as 
increased amino acid availability. Given the differential changes in the lipid pool, the 
effects of EPA and DHA may be mediated by membrane critical events. Therefore, the 
aim of this study was to assess the effects of EPA and DHA individually on protein 
turnover. We also sought to characterise how altered protein turnover may be 
reflected by changes in the abundance of individual proteins. This information will 
hopefully be used as a framework to identify target pathways that could be 
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manipulated by small drug compounds to mimic the molecular effects of omega-3 
PUFAs. A secondary aim of this study was to assess how altered membrane lipid 
composition influenced the proteins that are associated with the membrane.  
3.2. Materials and Methods 
 
3.2.1. Materials 
All plastic ware was purchased from Fisher scientific (UK). SILAC media was 
purchased from Dundee cell products. Dialysed foetal bovine serum was purchased 
from Sigma-Aldrich (Dorset, UK) and dialysed donor horse serum was purchased 
from Lab tech, (Sussex, UK). 
 
3.2.2. Cell culture 
 
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 
20% fetal bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 5% 
C02. Myoblasts were maintained at ~60% confluence. Differentiation was induced 
once confluence reached 80-90% by changing the media to differentiation media 
(DMEM supplemented with 2% horse serum and 1% Penicillin/Streptomycin) for 72 
hours. Following differentiation cells were treated with 50 µM EPA or 50 µM DHA 
conjugated  to 2% fatty acid free BSA or 2% fatty acid free (FAF) BSA as a control for 
72 hours for proteomics analysis. Protein synthesis and breakdown was assessed after 
24 hour incubation with EPA or DHA. Fatty acids were conjugated to 2% fatty acid free 
BSA in DM by constant agitation for 1 hour at 37°C.  
3.2.3. Cell preparation 
 
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 
mmol/l Tris·HCl pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 
1 mmol/l EDTA, 1% (vol/vol) Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 
mmol/l sucrose, and 0.1% (vol/vol) 2-mercaptoethanol and Complete protease 
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inhibitor cocktail (Roche)] followed by snap freezing on liquid nitrogen. For 
preparation for western blotting samples were thawed and debris was removed by 
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and 
protein concentration was determined using the DC protein assay according to the 
manufacturer’s instructions (Bio-Rad, Hercules,CA). 
3.2.4. Protein content 
 
 
Protein content following 72 h treatment with 50µM EPA or 50µM DHA conjugated to 
2% fatty acid free BSA as a carrier or 2% fatty acid free BSA alone as a control was 
determined by multiplying the concentration of the supernatant [as determined using 
the DC protein assay according to the manufacturer’s instructions (Sigma Aldrich, UK)] 
by the total volume of supernatant collected from a 6 well plate. Data are 
representative of 5 independent experiments carried out in triplicate. 
 
3.2.5. Muscle protein synthesis and breakdown 
 
Protein degradation was assessed by the quantification of the released L-[2,4,3H] 
phenylalanine into the culture media. Following 4 days of differentiation myotubes 
were incubated with media containing 2.5 µCi L-[2,4,3H] phenylalanine/ml and the 
label was maintained for 24 hours in order to label long lived proteins. Following the 
labelling pulse, cells were washed 2x in PBS and incubated in cold chase media (DMEM 
+ 2mM L-phenylalanine) for 3 hours to allow for degradation of short lived proteins. 
Myotubes were then treated with either 50µM EPA or DHA (DMEM, 2% horse sera, 
2mM L-phenylalanine, 2% FAF-BSA) for 24 hours. Following treatment an aliquot of 
the media was removed and radioactivity released was assessed by scintillation 
counting. The remaining myotubes were then thoroughly washed with ice cold saline 
(0.9%) and lysed with 50mM NaOH + 1% SDS for a minimum of 30 mins at room 
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temperature. Residual radioactivity in cell lysates was then assessed by scintillation 
counting. Total radioactivity was calculated as the sum of the L-[2,4,3H] phenylalanine 
released into the media and the residual cell retained L-[2,4,3H] phenylalanine. Protein 
breakdown is presented as the fraction of the total incorporated L-[2,4,3H] 
phenylalanine released into the media.  
Basal protein synthesis was assessed by the incorporation of L-[2,4,3H] phenylalanine 
into peptide chains. Following differentiation, myotubes were treated with 50µM EPA 
or DHA for 24 hours. At the end of the treatment period the media was removed and 
DMEM containing 1uCi L-[2,43H] phenylalanine (0.5 µCi/ml) was added for 180 mins. 
The reaction was stopped by 2x washes in ice cold saline (0.9%) before 3x washes with 
Tricholoroacetic acid (TCA) (10%) to remove any unincorporated tracer. Residual TCA 
was then removed by rinsing cells with methanol and plates left to dry.  Myotubes were 
then lysed in 50mM NaOH + 1% SDS for a minimum of 30 minutes. An aliquot was 
collected for liquid scintillation counting to assess 3H incorporation into proteins and 
the remaining lysate was used to determine protein content by the DC protein assay. 
Protein synthesis is presented as counts per minute/µg of protein. See 
supplementary data for assay validation. 
 
3.2.6. P70S6K1 signalling in response to a serum stimulus 
 
To assess the activation of the mTOR signalling pathway in response to a serum 
stimulus, the phosphorylation of P70S6K1 was measured. C2C12 myotubes were 
cultured as previously described. Following differentiation myotubes were treated 
with vehicle, EPA or DHA for 24 hours. Myotubes were then serum starved in serum 
free DMEM for 3 hours. Media was then changed to DMEM containing 20% foetal 
bovine serum for 30 or 60 minutes, cell lysates were then collected and prepared for 
western blotting. 
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3.2.7. Western blotting 
 
For western blots, supernatants was made up in Lamelli sample buffer, and 10-15 μg 
of total protein was loaded per well and run at 150 V for 1 h 15 min. Proteins were then 
transferred onto Whatman Immunobilon Nitrocellulose membranes (Fisher Scientific, 
Loughborough, UK) at 30 V for 2 h 15 min. Membranes were blocked in 3% BSA-Tris-
buffered saline (containing vol/vol 0.1% Tween 20) for 1 h at room temperature, 
followed by incubation in primary antibodies [pmTOR(ser2448), total mTOR, 
pP70S6K1(Thr389), total P70S6K1, p4E-BP1(Thr37/46), total 4E-BP1 [Cell signalling, 
USA]] at 4°C overnight. Membranes underwent three 5 min washes in TBST followed 
by incubation in the appropriate secondary antibodies [secondary horseradish 
peroxidase conjugated antibody was purchased from ABCAM (#6721)] for 1 h at room 
temperature. Membranes were again washed three times for 5 min followed by 
incubation in enhanced 80onlabelled80cence reagent (BioRad, Herts, UK). A BioRad 
ChemiDoc (Herts, UK) was used to visualize and quantify protein expression. Phospho 
proteins were normalized to the corresponding total protein. Data are representative 
of 3 independent experiments carried out in duplicate. 
 
3.2.8. Stable isotope labelling of amino acids in cell culture 
 
To assess changes in protein abundance, we used the SILAC method [234] .C2C12 
myoblasts were grown in Dulbeccos’ modified eagles medium (DM) supplemented 
with 20% dialysed (10 Kda) foetal bovine serum plus labelled amino acids lysine and 
arginine in a humidified atmosphere of 37°C and 5% CO2. Cells intended to act as the 
control group were grown in with unlabelled lysine and arginine(light), the EPA 
treatment group were grown in R6K4 media(l-arginine-13C6 hydrochloride, l-
lysine-4,4,5,5-d4 hydrochloride[medium]) while the DHA treatment group were 
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grown with R10K8 containing media (l-arginine-13C6, 15N4 hydrochloride, l-
lysine-13C6,15N2 hydrochloride [Heavy]). The use of combined labelled arginine 
and lysine ensures that nearly all peptides will contain a label after tryptic digestion. 
Cells were allowed to grow for at least 6 population doublings to ensure full 
incorporation of labelled amino acids. We observed that use of dialysed sera and 
labelled media did not affect doubling time, cell morphology or differentiation capacity. 
Upon reaching 90-100% confluence the media was replaced with DMEM containing 
2% dialysed donor horse serum (10 Da) to induce differentiation. After 3-4 days of 
differentiation, myotubes were treated with either control, 50µM EPA or 50 µM DHA 
for 72 hours (see treatment protocol). Changes in both the global proteome as well 
as proteins associated with membranes were assessed. For membrane proteome 
analysis, membranes were isolated using the Thermo scientific Mem per plus protein 
membrane extraction kit. Analysis of global and membrane proteins were then 
analysed by the same process. 
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Figure 3. 1 SILAC workflow. 
 
3.2.9. Treatment protocol 
 
Fatty acids EPA and DHA at a concentration of 50µM were conjugated to 2% fatty acid 
free BSA by constant agitation for 1 hour at 37°C. Fatty acid treatments were made in 
DMEM containing the appropriate label (con-light, EPA-medium, DHA- heavy) in order 
to maintain the labelled proteome. Treatment was maintained for 24 or 72 hours 
before cell pellets were collected and frozen in liquid nitrogen before being stored at -
80 until further analysis. Samples from each group were collected in triplicate and 
samples from each respective treatment group were pooled before processing for mass 
spectrometry analysis. 
3.2.10.  Mass spectrometry 
 
Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo 
Scientific) nanoflow LC system. On average 0.5µg of protein was loaded with a constant 
flow of 5 µl/min onto an Acclaim PepMap100 nanoViper C18 trap column (100 µm 
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inner-diameter, 2cm; Themro Scientific). After trap enrichment, peptides were eluted 
onto an Acclaim PepMap RSLC nanoViper, C18 column (75 µm, 15 cm; 
ThermoScientific) with a linear gradient of 2–40% solvent B (80% acetonitrile with 
0.08% formic acid) over 65 min with a constant flow of 300 nl/min. The HPLC system 
was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap 
Velos, Thermo Scientific) via a nanoelectrospray ion source (Thermo Scientific). The 
spray voltage was set to 1.2 kV, and the temperature of the heated capillary was set to 
250 °C. Full-scan MS survey spectra (m/z 335–1800) in profile mode were acquired in 
the Orbitrap with a resolution of 60,000 after accumulation of 1,000,000 ions. The 
fifteen most intense peptide ions from the preview scan in the Orbitrap were 
fragmented by collision-induced dissociation (normalized collision energy, 35%; 
activation Q, 0.250; and activation time, 10 ms) in the LTQ after the accumulation of 
10,000 ions. Maximal filling times were 1,000 ms for the full scans and 150 ms for the 
MS/MS scans. Precursor ion charge state screening was enabled, and all unassigned 
charge states as well as singly charged species were rejected. The lock mass option was 
enabled for survey scans to improve mass accuracy [209]. Data were acquired using 
the Xcalibur software. 
 
3.2.11.  Quantification and bioinformatics analysis 
 
The raw mass spectrometric data files obtained for each experiment were collated into 
a single quantitated data set using MaxQuant (version 1.2.2.5) [235] and the 
Andromeda search engine software [236]. Enzyme specificity was set to that of trypsin, 
allowing for cleavage N-terminal to proline residues and between aspartic acid and 
proline residues. Other parameters used were: (i) variable modifications, methionine 
oxidation, protein N-acetylation, gln  pyro-glu, Phospho(STY); (ii) fixed 
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modifications, cysteine carbamidomethylation; (iii) database: target-decoy human 
MaxQuant (ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS 
tolerance: FTMS- 10ppm , ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) 
maximum missed cleavages, 2; (viii) maximum of 84onlabel amino acids, 3; and (ix) 
false discovery rate, 1%. Peptide ratios were calculated for each arginine- and/or 
lysine-containing peptide as the peak area of 84onlabel arginine/lysine divided by the 
peak area of 84onlabelled arginine/lysine for each single-scan mass spectrum. Peptide 
ratios for all arginine- and lysine-containing peptides sequenced for each protein were 
averaged. Data is normalised using 1/median ratio value for each identified protein 
group per labelled sample.  
3.2.12.  Serum dialysis 
 
Dialysis of FBS and DHS was carried out in CelluSep-H1 dialysis bags (Membrane 
filtration products, inc., Texas, USA) with molecular weight cut off points of 1 Kda, 3 
Kda, 5 Kda, 10 Kda. The dialysis bags contained regenerated cellulose membranes, 
manufactured from natural cellulose reconstituted from cotton liners. These cellulose 
membranes are EDTA tested, heavy metal free, carry no fixed charge and do not adsorb 
most solutes. Prior to use, membranes were soaked in distilled water at room 
temperature for 30 minutes to remove the preservative solution. The membrane was 
then thoroughly rinsed with distilled water. Dialysis was carried out in independent 
dialysis bags with 1mL of serum per analysis. Dialysis was carried out at 4°C for 24 
hours using phosphate buffered saline as a buffer in at least 200 fold excess of dialysis 
buffer. The buffer was changed at 3 hours, 5 hours and once prior to leaving overnight. 
Following dialysis serum was recovered and filtered through sterile filter units (0.1µm, 
Pall, NY, USA) and frozen at -20. 1mL samples were taken in duplicate from 4 
independent experiments for fatty acid profiling. 
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3.2.13.  FAME analysis 
 
Lipid profiles of foetal bovine serum and donor horse serum which had undergone 
dialysis at various molecular weight cut offs (1 Kda, 3 Kda, 5 Kda, 10 Kda) were 
assessed by fatty acid methyl ester analysis (FAME). Total lipids were extracted by 
homogenising in 20 volumes of chloroform/methanol (2:1 v/v). Total lipids were 
prepared according to the method of Folch et al. [221] and non-lipid impurities were 
removed by washing with 0.88% (w/v) KCl. The weight of lipids was determined 
gravimetrically after evaporation of solvent and overnight desiccation under vacuum. 
Fatty acid methyl esters (FAME) were prepared by acid-catalysed transesterification 
of total lipids according to the method of Christie et al. (35). Extraction and purification 
of FAME was performed as described by Ghioni et al. (36). FAME were separated by 
gas-liquid chromatography using a ThermoFisher Trace GC 2000 (ThermoFisher, 
Hemel Hempstead, UK) equipped with a fused silica capillary column (ZBWax, 60m x 
0.32 x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with hydrogen as carrier gas and 
using on-column injection. The temperature gradient was form 50 to 150oC at 
40oC/min and then to 195oC at 1.5oC/min and finally to 220oC at 2oC/min. Individual 
methyl esters were identified by reference to published data (Ackman, 1980). Data 
were collected and processed using the Chromcard for Windows (version 2.00) 
computer package (Thermoquest Italia S.p.A., Milan, Italy). All experiments were 
carried out in duplicate from 4 independent experiments.  
3.2.14.  Data analysis and statistics 
 
Proteins were considered up-regulated or down-regulated with a minimum fold 
change cut off of 0.2, corresponding to a 20% change in protein abundance. Ingenuity 
pathway analysis software was used to assess over represented pathways and 
pathway activation predictions. Changes in fatty acid content of FBS and DHS were 
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assessed by one-way ANOVA, with a tukeys post hoc test used only if significant 
differences were detected, using Graphpad version 7.0. P-values were adjusted for 
multiple comparison testing where necessary. Membrane protein abundance was 
considered altered if fold change if lower than 0.75 or greater than 1.25 and a 
significant difference between EPA and DHA (p<0.05). Enrichment of biological 
processes was determined using gene ontology, using the whole genome of Mus 
musculus as a background reference list. Protein interactions were assessed using the 
STRING database (version 10). 
 
3.3. Results 
 
3.3.1. Serum dialysis increases the omega-3 content in donor horse serum 
 
To prevent the dilution of the amino acid tracer pool for the SILAC protocol, myotubes 
must be grown in media with a modified amino acid pool which necessitates the use of 
dialysed FBS and DHS during cell proliferation and differentiation.  Given that we 
aimed to assess how the modification of lipid composition affected protein expression 
we first sought to examine the effect of dialysis on serum lipid profiles. The lipid pool 
of cultured myotubes is largely dependent on the available fatty acids in the media and 
a significant change in the lipid profile may alter the baseline lipid profile and 
subsequent effects of EPA and DHA incorporation. No effect of dialysis on any lipid 
class in FBS was observed (supplementary figure S1.1). Interestingly, we found that 
in dialysis increased the omega-3 content in DHS (figure S1.1B, p value < 0.05). We 
used dialysed serum with a molecular weight cut off of 10 Kda (mean difference + 6.3 
µg/mg lipid) and hypothesise that a small increase would not have had a major impact 
on the myotubes baseline lipid profile.  
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Figure 3. 2 EPA enhances protein accretion. C2C12 myotubes were treated with either EPA or DHA 
for 72 hours. The total amount of cellular protein was assessed by multiplying the protein concentration 
by the total volume of lysate. Data are presented as mean ±S.E (n=5). * denotes significantly different 
from vehicle (p<0.05). 
 
3.3.2. EPA enhances protein accretion through a reduction in breakdown while DHA 
has a neutral effect. 
After a 72 hour incubation with EPA or DHA, myotubes were collected in order to 
determine total protein content. When myotubes were incubated with EPA total 
protein content was enhanced while incubation with DHA had a neutral effect (Figure 
3.2). Protein balance is determined by the balance between synthesis and breakdown 
of proteins. Thus, the observed protein accretion may be reflected in changes in either 
protein synthesis or breakdown. In order to understand the mechanisms underlying 
the changes in protein content we directly assessed protein synthesis and breakdown 
and related signalling. Neither fatty acid had any effect on basal protein synthesis after 
a 24 hour incubation (Figure 3.3A). Anabolic signalling assessed by the 
phosphorylation status of mTOR, P70S6K1 and 4E-BP1 was not different between 
groups, corresponding with lack of changes in protein synthesis (Figure 3.3C). EPA 
reduced protein breakdown compared to both the vehicle and DHA treatments (Figure 
3.3B). No changes were detected in the level of ubiquitin tagged proteins (Figure 
3.3D). 
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Figure 3. 3 The effect of EPA and DHA on muscle protein anabolism. A) Basal protein synthesis was 
measured by the incorporation of 3H L-Phenylalanine into muscle proteins (n=5). B) Protein breakdown 
was assessed by conditions C) basal phosphorylation status of key proteins in the mTOR signalling 
pathway (n=3). D) ubiquinated proteins tagged for degradation. E and F) Representative western blot 
images (n=3). P value <0.05. * denotes significant difference from vehicle and DHA. 
 
3.3.3. N-3 fatty acid treatment does not alter the P70S6K1 signalling response to a 
serum stimulus. 
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In order to measure the anabolic signalling response to serum stimulation, P70S6K1 
(T389) phosphorylation after a 3 hour serum starve 0, 30 and 60 minutes after addition 
of serum containing DMEM. Neither fatty acid treatment altered the activation or time 
course of P70S6K1 activation (Figure 3.4). These data indicate that not only has n-3 
supplementation not altered basal signalling responses, but it has not altered growth 
factor induced P70S6K1 activation. 
 
Figure 3. 4 EPA or DHA does not alter the P70S6K1 signalling response to a serum stimulus . 
Following treatment with EPA or DHA myotubes were stimulated with serum for 30 or 60 minutes and 
the anabolic signalling response was assessed by changed in P70S6K1 phosphorylation status (n=3).   
 
3.3.4. EPA and DHA differentially alter global proteome profiles 
To assess how omega-3 fatty acids altered the abundance of individual proteins we 
employed a SILAC model to identify changes in the global proteomic signature. The 
SILAC method is a semi-quantitative method that assessed relative fold changes in 
protein abundances from the unlabelled control group. 1563 proteins were identified 
and quantified in all 3 conditions (Figure 3.5). Proteins were considered altered if the 
abundance was changed by 20% (corresponding to ± 0.2 fold change). In order to 
discover how these alterations in protein abundance may alter cell function 
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overrepresentation analysis was performed. Proteins identified as altered (both up 
and down-regulated) were included in the same analyses. Figure 3.6 shows that EPA 
and DHA alter proteins involved in different signalling pathways. EPA largely altered 
pathways regulating protein synthesis and breakdown, as well as the cellular effects of 
sildenafil and RhoA signalling (Figure 3.6A.). While DHA altered proteins related to 
energy metabolism (TCA cycle), Protein ubiquitination, mitochondrial dysfunction as 
well as protein kinase A and integrin signalling (Figure 3.6B). Although this analysis 
does not indicate the direction of action on these pathways it does indicate the 
potential cellular processes affected by omega-3 incorporation.  
 
Figure 3. 5. Descriptive summary of global proteome. A) Frequency histogram of Log2 fold change 
B) Proportion of detected proteins altered by EPA and DHA. C) Number of proteins increased by EPA 
and DHA D) number of proteins decreased by EPA and DHA. 
 
Although this proteomic analysis assessed changes in total protein content, using 
currently available knowledge of positive and negative regulators, the activation or 
inhibition of some pathways can be predicted. Investigation of potentially activated 
pathways revealed a common influence of omega-3 fatty acids on actin cytoskeleton 
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signalling and the RhoGDI pathway. DHA incorporation is also predicted to inhibit a 
number of growth factor related pathways (Table 3.1.). The prediction of changes in 
the RhoGDI and actin cytoskeleton pathways may indicate a novel role of omega-3 fatty 
acids in GTP regulated processes in skeletal muscle. 
 
 
Figure 3. 6 Over representation analysis. A) Cellular processes overrepresented in EPA treatment 
group. B) cellular processes overrepresented in DHA treatment group. 
Table 3. 1 Pathway activation prediction analysis. 
EPA (z-score)  DHA (z-score)  
Activated 
pathways 
Inhibited pathways Activated 
pathways 
Inhibited pathways 
RhoGDI signalling 
(2.333) 
Regulation of actin 
based motility (-2.121) 
RhoGDI signalling 
(2.646) 
Actin cytoskeleton 
signalling (-3.71) 
 Actin cytoskeleton 
signalling (-2.041) 
Intrinsic 
prothrombin 
activation (-2) 
ILK signalling (-2.837) 
   CXCR4 signalling  (-2.646) 
   PAK signalling(-2.499) 
   PDGF signalling (2.499) 
   IL-8 signalling (-2.236) 
   EGF signalling (-2) 
   HGF signalling (-2) 
   VEGF signalling (-2) 
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3.3.5. Altered composition of phospholipids changes the membrane-associated 
proteome. 
 
Table 3. 2 Overrepresented biological processes in EPA membrane proteome. 
Go 
accession 
Biological 
process 
P-value Genes (mean fold change) 
GO:0006457 Protein folding 4.76E-03 Fkbp10 (1.49), Hspa4L (0.65), P3h1 (1.29), Txndc5 
(1.30), Prdx4 (1.30), Ppib (1.34), Ppic (1.45) 
 
Over 3000 proteins associated with the membrane compartment were identified in the 
SILAC screen. These results were filtered down to 625 proteins with a coefficient of 
variance ≤ 5% to describe consistent changes in membrane abundance.  Proteins were 
considered enriched or reduced in the membrane with a fold change cut off of 0.25. 
Proteins similarly affected by EPA and DHA were removed from analysis. Proteins with 
altered abundance were then subject to gene ontology analysis for biological 
processes.  Although a number of individual proteins were altered by EPA, there was 
not a major association of theses proteins with cell processes. 
Membrane proteins altered by EPA were associated with protein folding (p = 4.76E-
03) (Table 3.2). EPA also increased Calumenin in membranes which also plays a role 
in calcium sensitive protein folding. DHA altered proteins associated with a number of 
processes, primarily related to oxidative metabolism and ribosomal formation (Table 
3.3). Further examination of ribosomal proteins revealed that DHA induced the 
significant reduction in ribosomal proteins associated with both small and large 
subunits at the membrane. Conversely, EPA induced a small rise in ribosomal proteins 
(Figure3. 7). 
 
 
 
 
 
 
 
 
 
Chapter 3: n-3 PUFAs and protein anabolism 93 
 
Table 3. 3 Overrepresented biological processes in DHA membrane proteome 
Go 
accession 
Biological process P-value Genes (log2 mean fold change) 
GO:0015986 ATP synthesis coupled 
transport 
8.68E-04 Stoml2 (1.32), Tcirg1 (1.26), Atp5a1 (0.62), 
Atp5i (0.61), Atp5f1 (0.58), Atp5o (0.46) 
GO:0006084 Acetyl-CoA metabolic process 3.65E-02 Pdha1 (1.37), Acaa2 (0.67), Dld (0.65), Pdhx 
(0.60), Acat1 (0.64) 
GO:0042775 Mitochondrial ATP synthesis 
coupled electron transport 
1.55E-03 Uqcrc1 (1.54), Uqcrb (1.43), Cox4i1 (1.38), 
Coq9 (1.27), Dld (0.65), Ndufa10 (1.49), 
Mtch2 (1.36) 
GO:0042255 Ribosome assembly 6.05E-04 Rpsa (0.33), Rpl6 (0.58), Ddx3x (0.68), Rpl12 
(0.54), Rps2 (0.48), Rpl5 (0.31), Rpl24 (0.52), 
Rps5 (0.44) 
GO:0006412 Translation 7.24E-05 Rpl35 (0.59),Aars2 (0.58), Rps8 (0.49), 
Rpl10a (0.58), Rpl34 (0.56), Rpsa (0.33), 
Rps16 (0.50), Mrpl47 (0.59), Mrpl13 (0.55), 
Mrpl24 (0.54), RPl18 (0.55), Rpl6 (0.58), 
Rplp0 (0.61), Ddx3x (0.68), Tufm (0.5), Rps4x 
(0.47), Rpl4 (0.53), Rpl12 (0.54), Rpl14 
(0.57), Rpl15 (0.59), Rps11 (0.45), Rps9 
(0.49), Rps2 (0.48), Mrpl15 (0.52), Rpl5 
(0.31), Rpl19 (0.60), Rpl24 (0.52), Rps5 
(0.44), Mrpl21 (0.53), Rps13 (0.49) 
GO:0006417 Regulation of translation 2.33E-05 Hnrnpa2b1 (0.68), Ddx39b (0.67), Ddx3x 
(0.68), Srrt (0.33), Fxr1 (0.57), Rps9 (0.49), 
Ppp1ca (0.68), Elavl1 (1.35), GAPDH (1.87), 
Rps5 (0.44), Trap1 (0.67), Eif5 (0.75), Syncrip 
(0.63) 
GO:0046907 Intracellular transport 8.12E-03 Sar1a (1.63), Hnrnpa2b1 (0.68), Stoml2 
(1.32), Dctn2 (0.72), Rpsa (0.33), Ddx39b 
(0.67), Sptbn1 (0.62), Hspa4 (0.54), Nup62 
(0.54), Bicd2 (0.64), Timm44 (1.38), Anxa2 
(0.73), Ywhaq (0.73), Rab6a (1.32), Vcp 
(0.52), Trap1 (0.67), Uso1 (0.64), Actr2 
(0.62), Atp5o (0.46), Nup155 (0.42), 
Hsp90aa1 (0.64), Os9 (1.26), Copb2 (2.19), 
Anp32b (0.53) 
 
 
Figure 3. 7. Ribosomal protein association with membranes. Ribosomal proteins detected in the 
membrane proteome screen. Data is presented as fold change. Data is representative of n=3. 
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3.4. Discussion 
 
The aim of this study was to assess the differential effects of EPA and DHA on protein 
metabolism If changes in protein metabolism were reflected by changes in the 
proteomic profile of myotubes. We characterised the shift in global proteomic 
signatures following EPA or DHA incorporation and subsequently how omega-3 driven 
lipid remodelling altered the membrane associated proteome. We show that EPA and 
DHA also differentially alter the abundance of individual proteins and divergently 
changed proteins associate with different cell processes. Furthermore, we characterise 
the shift in proteins associated with the membrane in response to EPA or DHA. 
Our results show that a 72 hour incubation of C2C12 myotubes with EPA results in an 
increased accretion of protein. These changes were due to a reduction in protein 
breakdown and an unchanged rate of protein synthesis. Previous studies have shown 
that both EPA and DHA exert a protective effect when myotubes are in the presence of 
deleterious stimuli such as PA and TNF-alpha [64], [179].The present study 
demonstrates that EPA has effects on basal protein breakdown in the absence of a 
catabolic stimulus. These findings are in agreement with data from Kamolrat & 
colleagues (2013)[60]. While the magnitude of change in protein breakdown was 
moderate (approximately 5%) this measure was made after 24 hours for technical 
reasons. We speculate that a sustained decrease in protein breakdown for 72 hours 
while synthesis is maintained would confer an increased total protein content. One of 
the main pathways for protein breakdown is the ubiquitin/proteasome pathways. 
Ubiquitin molecules are added to proteins which tag them for degradation. We were 
unable to detect any changes in the amount of proteins tagged with ubiquitin. However, 
increased levels of P62 (gene – SQSTM1) were detected in the proteome screen and 
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differentially altered by EPA and DHA. P62 functions as an adaptor protein that links 
ubiquitin tagged proteins with the autophagy machinery [237]. Subsequently, P62 is 
degraded in the lysosome and may be used as an indicator of autophagic flux [238].  
However, EPA decreases protein levels of P62 while DHA increases P62 (Figure 3.8). 
This would be indicative of an increase and decrease respectively of autophagic flux, in 
contrast with observed changes in protein breakdown. Levels of P62 may also be 
affected by changes in gene expression and other cellular perturbations. We were 
unable to validate the changes in P62 by western blotting. More work is necessary to 
understand the mechanisms of the EPA induced depression of protein breakdown. One 
possible mechanism by which EPA may work is the maintenance of protein quality, 
reducing the targeted turnover of misfolded or damaged protein aggregates [107]. 
Atrophy is thought to be primarily driven by depression in protein synthesis so it 
remains to be seen how relevant small depressions in muscle protein breakdown 
would be in human models. 
 
We also assessed how EPA and DHA altered the individual abundance of proteins. 
Given, that DHA altered the abundance of a number of proteins without altering protein 
synthesis or breakdown, the results are not necessarily causally related. The 
abundance of proteins can be altered by both changes in the rate of turnover and gene 
expression. Both EPA and DHA are ligands for transcription factors such as PPARα and 
can inhibit the activation of SREBP-1 [205], [206]. The observed changes in the 
proteome may be due to alterations in the activity of transcription factors. Coupling 
our proteomic screen with micro array analysis would allow for the determination of 
whether changes in the proteomic profile are due to gene expression changes or 
turnover rates of proteins. 
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The proteins altered by EPA which associated with a number of pathways involved in 
protein metabolism. DHA associated with pathways involved in energy metabolism, 
integrin signalling and protein ubiquitination. Analysis of the proteomics revealed that 
proteins altered by EPA were associated with the processes regulating cell growth and 
protein turnover such as the mTOR and ubiquitin pathways. However, analysis of basal 
mTOR pathway activation by western blot did not reveal changes in the 
phosphorylation of mTOR or P70S6K. To test if these changes may only be observed in 
response to a stimulus, we performed a time course of P70S6K phosphorylation in 
response to a serum stimulus. This experiment did not show any changes in P70S6K1 
activation following EPA or DHA treatment. Kamolrat et al (2013)[184] observed that 
EPA and DHA enhanced P70S6K1 phosphorylation in response to leucine. In response 
to a serum stimulus consisting of amino acids and growth factors we did not observe 
any differences between groups on the phosphorylation of P70S6K1. In C2C12 
myotubes leucine stimulates anabolic signalling but not protein synthesis [61]. It is 
possible that the combination of amino acids and growth factors saturated the 
P70S6K1 signalling response in our study and prevented any differences from being 
observed. 
Human and trials have observed augmented signalling in response to amino acids and 
insulin in response to omega-3 fatty acids. It is possible that the effects are specific to 
these stimuli. Given that these stimuli converge on common pathways it is not known 
how this regulation would occur upstream of the mTOR pathway. Although we only 
assessed the abundance of proteins the IPA software can predict the activation or 
inhibition of pathways. Based on the protein expression profile it is predicted that EPA 
and DHA both inhibit actin cytoskeleton signalling. Omega-3 supplementation has been 
shown to alter the expression of cytoskeleton related genes in whole blood [239]. 
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Furthermore, actin remodelling is critical for insulin sensitive glucose uptake [240]. 
Given that no decline the insulin driven glucose uptake was observed, inhibition of this 
pathway did not have appear to have any effect (See chapter 2). Multiple growth factor 
receptor mediated signalling was predicted to be downregulated by DHA. Previous 
studies support a role for omega-3 fatty acids in reducing epidermal growth factor 
signalling and it appears this might extend to similar growth factor activated pathways 
in skeletal muscle [241].  This is thought to be one of the mechanisms by which omega-
3 fatty acids act to inhibit proliferation of cancer cells. Additionally, we observed a 
differential effect of EPA and DHA on the abundance of collagen proteins. EPA reduced 
collagen proteins while they were increased by DHA. The accumulation of collagen 
within the extracellular matrix is associated with insulin resistance [242] (Figure 
3.8A). However, DHA increased collagen protein abundance without altering insulin 
sensitivity, so changes in collagen abundance do not appear to have affected the 
phenotype observed in our work. One limitation of this proteomic approach is that due 
to running samples on gels prior to mass spectrometry analysis the data is biased 
towards the detection of cytosolic proteins.  Coupling changes in protein abundance 
with changes in post translational modifications and gene expression would give a 
more holistic view as to how individual fatty acids alter myotubes phenotypes 
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Figure 3. 8 Abundance of a) collagen proteins and b) P62, detected in the global proteomic screen. 
 
In the previous chapter, EPA and DHA were shown to be incorporated into 
phospholipid species. Phospholipids are found primarily in the membrane, these data 
indicate that EPA and DHA have the potential to alter membrane properties and 
potentially the membrane associated proteome. We show that EPA and DHA 
divergently alter the membrane associated proteome. This is likely due to the changes 
in phospholipid composition following EPA or DHA treatment. There are a number of 
mechanisms by which proteins can bind to the membrane which are influenced by the 
fatty acid composition of the lipid bilayers. Either by altering interactions between 
fatty acyl chains and proteins or the structure of lipid rafts. We hypothesised that the 
alteration of protein-membrane interactions may link lipid remodelling to 
downstream metabolic effects. Gene ontology analysis indicated that proteins 
associated with protein folding at the membrane were overrepresented following EPA 
incorporation (Table 3.1). There is experimental evidence that a number of the 
proteins identified with this process interact, as probed by the STRING database 
(Figure 3.9). Furthermore, analysis of ribosomal proteins indicated a small shift of 
ribosomal proteins at the membrane. We propose a mechanism in which protein 
folding is enhanced, reducing damaged or misfolded proteins and reducing protein 
breakdown which results in increased protein accretion. Further experimental work is 
needed to assess this hypothesis. Indeed, previous work has shown that EPA, but not 
DHA, maintained protein quality in aging mice [107]. In comparison, DHA significantly 
reduced the abundance of a number of ribosomal proteins with the membrane (Figure 
3.7). If total ribosomal content is unchanged then this would indicate an increase in 
cytosolic ribosomes. Proteins that enter the secretory pathways or integral membrane 
proteins are synthesised in the ER while other proteins are translated in the cytosolic 
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ribosome pool [243]. This differential shift in ribosomal compartmentalisation may 
partially explain the divergent changes in protein expression profiles.  
 
Figure 3. 9 STRING diagram representing protein-protein interactions. Levels of confidence key – 
curated database (Blue), experimental evidence (Pink), text mining (Yellow), Co-expression (Black) 
 
DHA also altered the abundance of proteins involved in ATP coupled proton transport 
and acetyl-CoA metabolism, in agreement with the global proteome analysis. The 
proteins identified with ATP synthesis coupled transport were mainly downregulated 
proteins in the ATP synthase complex. This would be expected to manifest as a reduced 
ability to generate ATP yet no changes were observed in ATP synthase dependent 
oxygen consumption, as measured in the previous chapter. The effects of DHA may not 
have been severe enough to observe at basal levels. Although maximal respiration is 
measured during the mito stress test, it is induced by uncoupling so would not detect 
any changes in ATP synthesis. Previous studies have observed that omega-3 fatty acids 
can alter mitochondrial function, altering ADP kinetics without altering maximal 
respiration [190]. It remains to be seen if this reduction in ATP synthase proteins 
would alter the mitochondrial response to cellular stress or changing substrate 
availability. 
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In summary, we demonstrate that protein turnover is differentially altered by EPA and 
DHA. EPA reduces protein breakdown which may be due to an increase in protein 
folding at the endoplasmic reticulum. No changes in protein synthesis or activation of 
the mTOR signalling pathway were observed with either EPA or DHA. Furthermore, no 
changes in the phosphorylation status of P70S6K1 following serum stimulation were 
detected. The changes in phospholipid composition described in the previous chapter 
induces a shift in proteins associated with cellular membranes. The changes in global 
or membrane specific proteome did not always reconcile with the metabolic measures 
such as mTOR activation with EPA or mitochondrial function with DHA. It may be that 
changes in these processes are only observable under specific stimuli that have not 
been explored in this work.  Building on this work, future experiments should 
investigate the mRNA transcripts associated with different ribosomal pools and the 
regulation of ribosomal protein localisation. The metabolic effects were not readily 
explained by changes in the global proteome but the membrane associated proteome 
may link lipid remodelling following omega-3 supplementation to the observed 
metabolic effects in human models.  
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3.5. Supplementary figures 
 
Figure S3 1. The effect of serum dialysis on the lipid composition of a) foetal bovine serum and 
b) donor horse serum. Graph represents N=4. Data expressed as mean ± SD. * indicates significant 
difference from control of that lipid class. 
 
Muscle protein synthesis/breakdown assay development: 
 
Linearity of L-[2,4,3H] phenylalanine incorporation into muscle proteins was 
determined by assessing the time course of labelled L-[2,4,3H] phenylalanine 
associated with proteins. Myotubes were serum starved for 2 hours in serum free 
DMEM. Media was then substituted for DMEM or Growth media + 10% FBS with 
labelled L-[2,4,3H] phenylalanine (0.5 µCi/ml) and measures of protein synthesis were 
taken at 60,120,180 and 240 minutes. Incorporation of L-[2,4,3H] phenylalanine was 
linear in both conditions over 240 minutes (R2 – DMEM (0.98), GM (0.97), Figure S1.). 
Although a divergence over time can be observed between both conditions, FBS 
contains an unknown amount of unlabelled L-Phenylalanine. This means the tracer 
pool is diluted, underestimating the true rate of incorporation over time. 
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Figure S3.2 Validation of muscle protein synthesis assay. Incorporation of L-[2,4,3H] phenylalanine 
in the basal state or in the presence of 10% growth serum. 
 
Protein breakdown: 
 
Protein breakdown was assessed in the presence of 3 different media compositions in 
order to ensure measures of protein breakdown were sensitive to changes in media 
composition. Protein breakdown was measured after incubation of myotubes with 
differentiation media (2% DHS), serum free DMEM or growth media (10% FBS + 
100nM insulin). DM was used as a baseline, DMEM alone increased protein breakdown 
while incubation with GM + insulin suppressed protein breakdown. These results 
demonstrate that the protein breakdown assay was able to detect expected changes in 
protein breakdown. 
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Figure S3. 3 Protein breakdown is sensitive to culture media. 
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Chapter 4: Palmitate induces insulin resistance despite conserved 
insulin driven PKB phosphorylation. 
 
Jeromson S, Shaw A, Cruz AM, Beall C, Gallagher IJ, Hamilton DL 
 
 
4.0. Abstract 
 
Saturated fatty acids have been linked with the development of metabolic disease and  
insulin resistance. The saturated fatty acid PA is a precursor of ceramides, which 
attenuate insulin action through a reduction in PKB activity. Studies have shown that 
PAO, a monounsaturated fatty acid that differs by a single double bond, can prevent the 
deleterious effects of PA. Few studies have assessed the impact of palmitate or PAO on 
the lipid composition of skeletal muscle myotubes. The aims of this study was to assess 
the effects of PA and PAO on myotube lipid profiles, glucose uptake and mitochondrial 
respiration. C2C12 myotubes were treated with PA or PAO (750µM) for 16 hours. PA 
and PAO abundance increased significantly (181±10% and 470± 41% respectively) 
after a 16 hour treatment with only modest effects on other fatty acid species. PA 
attenuated insulin dependent glucose uptake (Veh: 4.38±0.58 pmol/min/mg PA: 
2.88±0.57 pmol/min/mg) but did not decrease insulin stimulated PKB 
phosphorylation. A dose response study (250,500 and 750µM) of the effects of PA and 
PAO on mitochondrial respirations revealed that at 250µM palmitate (Control: 135% 
of baseline, PA: 165.3%) and PAO (181.1% of baseline) increased maximal 
mitochondrial respiration. Fatty acid concentrations of 500 and 750µM decreased ATP 
synthesis coupled respiration and increased proton leak. These data demonstrate that 
at lower concentrations PA and PAO can improve mitochondrial function. 
Furthermore, attenuation of PKB activation may not be critical for the deleterious 
effects of PA. 
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4.1. Introduction 
 
High fat diets are implicated in the onset of obesity and insulin resistance. In contrast 
to highly unsaturated long chain fatty acids, saturated fatty acids are associated with 
deleterious effect on a number of aspects of metabolism in skeletal muscle. In 
particular, PA (16:0) and PA derivatives are linked with the deterioration of insulin 
sensitivity. There is a large body of evidence from animal and tissue culture studies 
that implicate a causal role for saturated fat in the inhibition of aspects of skeletal 
muscle metabolic regulation [93], [244]. In vivo human studies, however, present a 
more ambiguous relationship between saturated fat intake and insulin sensitivity 
[145].   
One of the central mechanisms linking PA to the  attenuation of metabolic function lies 
in the conversion of PA to lipid intermediates such as ceramides and diacylglycerols 
(DAG) [157], [245], [246]. Both ceramides and DAGs act via different mechanisms but 
result in the inability of insulin to activate PKB, resulting in attenuated glucose 
uptake/glycogen synthesis [188]. DAGs act at the level of IRS/Pi3k, activating PKC 
isoforms which increase IRS serine phosphorylation, reducing IRS activation of PKB. 
While, ceramides inhibit PKB activation also by activating PKC isoforms and protein 
phosphatases (PP2A) which reduce phosphorylation of PKB [152], [159], [247].  
Additionally, PA disrupts signalling cascades involved in inflammation and reactive 
oxygen species [149], [248]. Co-treatment of cells with both PA and PAO is sufficient to 
prevent PA driven metabolic dysfunction [188].  Moreover, PAO alone has been shown 
to improve basal glucose uptake. Thus, PAO may have intrinsic benefits other than 
counteracting the effects of PA. The effects of PA and PAO on insulin sensitivity has 
been investigated by multiple laboratories. However, few studies have measured the 
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accumulation of PA and PAO within myotubes following treatment and changes in the 
abundance of other fatty acid species. 
 
Another factor that may impact on metabolic function and substrate utilisation, 
contributing to the accumulation of lipid intermediaries, is mitochondrial function. 
Prior studies have observed that muscle from obese individuals are more susceptible 
to the deleterious effects of PA than lean individuals [244]. This may be influenced by 
impaired mitochondrial function, reducing the ability to oxidise fat. Yet, insulin 
resistance may be characterised by excessive beta-oxidation [161]. However, high fat 
diets have been shown to increase mitochondrial biogenesis while concurrently 
inducing insulin resistance [136], [249]. This is thought to be due to increased CaMKII 
phosphorylation driven by an increase in reactive oxygen species [250]. Despite 
increases in mitochondrial content, incubation of muscle in vitro with PA at higher 
concentration (500-750µM) causes a decline in mitochondrial function [163], [164]. 
Another study observed that the effects of PA were dependent on whether 
mitochondrial function was assessed in myoblasts or myotubes  [164]. Furthermore, 
insulin improves mitochondrial function by reducing proton leak and this effect is 
prevented by PA [163]. These studies all used concentrations of PA ranging between 
500-750µM. Woodsworth-hobbs & colleagues [178] observed that PKB inhibition 
increases with increasing PA. It remains to be seen whether a similar effect on 
mitochondrial dysfunction occurs with lower doses of PA.  
 
The aims of this study were to establish how PA and PAO, differing in structure by one 
double bond, differentially altered lipid profiles and how PA or PAO altered insulin 
stimulated glucose uptake and PKB phosphorylation. In addition, we aimed to assess a 
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dose response effect of fatty acids on multiple parameters of mitochondrial function at 
three different doses (250µM, 500µM, 750µM). We hypothesise that the incorporation 
of PA into myotubes will compromise insulin sensitive glucose and PKB 
phosphorylation in addition to impairing mitochondrial function. We hypothesised 
that the addition of PAO would not however have the same deleterious effect on 
glucose uptake. 
4.2. Materials and methods 
4.2.1. Cell culture 
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 
20% foetal bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 
5% C02. Myoblasts were maintained at ~60% confluence. Differentiation was induced 
once confluence reached 80-90% by changing the media to differentiation media 
(DMEM supplemented with 2% horse serum and 1% Penicillin/Streptomycin) for 5-6 
days. Following differentiation, myotubes were treated with 750 µM PA or PA for 16 
hours. For fatty acid preparation, Palmitate (PA) or Palmitoleate (PAO) were dissolved 
in 100% ethanol at a stock solution of 100mM. Fatty acids were then added to the 
appropriate treatment media + 2% BSA to a working solution. Fatty acid-BSA 
complexes were prepared by constant vigorous shaking at 37°C for 1 hour prior to use 
in experiments. 
 
4.2.2. FAME analysis 
 
Total lipids were extracted by homogenising in 20 volumes of chloroform/methanol 
(2:1 v/v). Total lipids were prepared according to the method of Folch et al. [221] and 
non-lipid impurities were removed by washing with 0.88% (w/v) KCl. The weight of 
lipids was determined gravimetrically after evaporation of solvent and overnight 
desiccation under vacuum. Fatty acid methyl esters (FAME) were prepared by acid-
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catalysed transesterification of total lipids according to the method of Christie et al . 
Extraction and purification of FAME was performed as described by Ghioni et al. (36). 
FAME were separated by gas-liquid chromatography using a ThermoFisher Trace GC 
2000 (ThermoFisher, Hemel Hempstead, UK) equipped with a fused silica capillary 
column (ZBWax, 60m x 0.32 x 0.25 mm i.d.; Phenomenex, Macclesfield, UK) with 
hydrogen as carrier gas and using on-column injection. The temperature gradient was 
form 50 to 150oC at 40oC/min and then to 195oC at 1.5oC/min and finally to 220oC at 
2oC/min. Individual methyl esters were identified by reference to published data 
(Ackman, 1980). Data were collected and processed using the Chromcard for Windows 
(version 2.00) computer package (Thermoquest Italia S.p.A., Milan, Italy). All 
experiments were carried out in duplicate from 4 independent experiments.  
4.2.3. Glucose uptake 
 
C2C12 myotubes, were exposed to 750µM PA or PAO complexed with 2% fatty acid free 
BSA or 2% fatty acid free BSA as a control for 48 h before a 2 hour serum-starve. 
Following the 2 hour serum starve cells were exposed to insulin (100 nmol/l) or 
vehicle control for 30 mins. Myotubes were incubated (12 min) with 10 μmol/l 2-
deoxy-D-[3 H]glucose (2DG; 24.4 kBq/ml; Hartman Analytic) at 20°C. Non-specific 
uptake was determined using 10 μmol/l cytochalasin B (Sigma–Aldrich). After lysis, 
cell-associated radioactivity was measured (Beckman, High Wycombe, UK; LS 6000IC 
scintillation counter), and protein was quantified using the Bradford protein assay. 
Data represented are the average of 4 independent experiments carried out in 
duplicate. 
4.2.4. Cell respiration 
 
C2C12 myoblasts were cultured in XFe96 microplates at a density of 1600 cells/well. 
Differentiation was induced once cells had reached 80-90% confluence and media was 
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changed daily for 5 days, with myotubes being used for experiments on day 6. Cells 
were treated with 250µM, 500µM or 750µM PA or PAO in 1x Earle’s buffered saline 
solution (5.5 mM glucose) for 16 hours.  Myotubes were placed in base XF medium 
(5mM glucose, 2mM L-glutamine, 2.5mM sodium pyruvate and the pH adjusted (with 
sodium hydroxide) to 7.4 at 37oC) and supplemented with PA or PAO. The plate was 
then transferred to a non-CO2 incubator for 1 hour. Following basal measures of 
oxygen consumption Oligomycin (1µM), FCCP (2µM) and antimycin A/rotenone (1µM) 
were added sequentially. The data presented is the average of 4 cycles after each 
mitochondrial manipulation. Acute changes in oxygen consumption were assessed 
following the addition of either PA or PAO at the indicated concentrations. Cells were 
then lysed with 50mM NaOH and protein content determined by the Bradford method. 
Oxygen consumption rates are presented as pmol/min/mg. 
 
4.2.5. Cell processing 
 
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 
mmol/l Tris·HCl pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 
1 mmol/l EDTA, 1% (vol/vol) Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 
mmol/l sucrose, and 0.1% (vol/vol) 2-mercaptoethanol and Complete protease 
inhibitor cocktail (Roche)] followed by snap freezing on liquid nitrogen. For 
preparation for western blotting samples were thawed and debris was removed by 
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and 
protein concentration was determined using the DC protein assay according to the 
manufacturer’s instructions (Bio-Rad, Hercules,CA). 
 
4.2.6. Western blotting 
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For WB, 100μg of supernatant was made up in Lamelli sample buffer, and 15 μg of total 
protein was loaded per well and run at 150 V for 1 h 15 min. Proteins were then 
transferred onto Whatman Immunobilon Nitrocellulose membranes (Fisher Scientific, 
Loughborough, UK) at 30 V for 2 h 15 min. Membranes were blocked in 3% BSA-Tris-
buffered saline (containing vol/vol 0.1% Tween 20) for 1 h at room temperature, 
followed by incubation in primary antibodies [PKBthr308 (#2965), total PKB (#4691) 
(New England Biolabs) or OXPHOS mitoprofile at 4°C overnight. Membranes 
underwent three 5 min washes in TBST followed by incubation in the appropriate 
secondary antibodies [secondary horseradish peroxidase conjugated antibody was 
purchased from ABCAM (#6721)] for 1 h at room temperature. Membranes were again 
washed three times for 5 min followed by incubation in enhanced chemiluninescence 
reagent (BioRad, Herts, UK). A BioRad ChemiDoc (Herts, UK) was used to visualize and 
quantify protein expression. Phospho proteins were normalized to the corresponding 
total protein. Data are representative of 3 independent experiments carried out in 
duplicate. 
4.2.7. Data analysis and statistics 
Statistical analyses were carried out in GraphpadPrism v 7.0. Changes in lipid species 
were determined by two-way ANOVA followed by a bonferonni multiple comparisons 
test. Differentially changed lipid species were assessed by multiple t-tests corrected for 
false discovery rate (5%). A two-way ANOVA was used to determine the success of 
manipulating mitochondrial respiration. Changes in oxygen consumption rate in each 
mitochondrial state between groups at each concentration used were determined by a 
one-way ANOVA followed by a bonferonni multiple comparisons test where 
appropriate. 
4.3. Results 
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4.3.1. Palmitate and Palmitoleate exert similar effects on lipid profiles 
To assess incorporation of PA and PAO into muscle lipids, myotubes were collected 
following a 16 hour incubation and lipid profiles analysed by FAME analysis. Total 
saturated fat content was significantly increased following PA treatment (p < 0.05) 
while also decreasing monounsaturated species (p <0.05) (Figure 4.1A). The increase 
in total saturated lipid content was driven primarily by an increase in PAO alone (% 
change: 181% ± 10%, P < 0.0001) (Figure 4.1B). Although total MUFA species were 
decreased, PA actually increased the content of PAO, albeit modestly. Treatment of 
myotubes with PAO significantly increased total MUFA content and reduced saturated 
fatty acid content (Figure 4.1A). Again, the increase in MUFA was due to a substantial 
increase in PAO content (% change: 470%±41, P < 0.0001) (Figure 4.1B). Despite the 
larger relative change in PAO content, PA composed a larger proportion of total fatty 
acids in the lipid pool. This is largely determined by the greater PA content prior to 
incubation with PA or PAO. Given that changes in Saturated or MUFA content were 
primarily driven by changes only in the treatment fatty acids suggests that PA or PAO 
are not readily converted to other fatty acid species. The different relative changes in 
relative changes of PA and PAO content treatment groups may be explained by 
different rates of uptake or oxidation. 
 
Figure 4. 1 Palmitate and Palmitoleate induced lipid profiles in C2C12 myotubes. A. Incorporation 
of PA and PAO were assessed by FAME analysis. Data is expressed as % of lipid pool and representative 
of n=3 in duplicate. . B Relative change in PA(16:00) and PA (16.1n-7) abundance. * denotes significantly 
different from control and treatment group. δ indicates significant difference between PA and PAO. 
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To determine differential changes in individual fatty acid species following PA or PAO 
treatments, log2 fold changes were plotted and divergent responses assessed by 
multiple t-tests (Figure 4.2). The only differential response between the two fatty 
acids were the expected increases in PA and PAO in each respective treatment group. 
Both PA and PAO decreased a number of saturated and monounsaturated fatty acids 
and polyunsaturated fatty acids. Given the high concentrations of PA and PAO used 
[750µM] it is likely that the decreases in a number of fatty acid species are due to 
reduced uptake of these fatty acids from the cell media.  
 
 
Figure 4. 2. Differential changes in fatty acids species following PA or PAO incorporation. Changes 
in fatty abundance were plotted as log2 fold to assess divergent changes in fatty acid species. * denotes 
significant difference between groups. Data are representative of n=3 (in duplicate). 
 
4.3.2. Palmitate causes insulin resistance despite normal PKB phosphorylation 
Insulin sensitivity was assessed by measuring glucose uptake and PKB 
phosphorylation following treatment with either PA or PAO. PA or PAO did not have 
any effect on basal glucose uptake. PA attenuated the increase in glucose uptake driven 
by insulin while myotubes treated with PAO were unaffected (p<0.05) (Figure 4.3A). 
The attenuation of PKB phosphorylation in response to insulin is often associated with 
a reduction in glucose uptake. In this study PKB(thr308) phosphorylation (basal and 
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insulin stimulated) was unchanged by PA or PAO despite the loss of insulin sensitive 
glucose uptake in the PA condition (Figure 4.3B). 
 
Figure 4. 3  Palmitate inhibits insulin sensitive glucose uptake with no change in PKB 
phosphorylation. A) glucose uptake was measured by uptake of 3H-Deoxyglucose. Data is 
representative of n=6 (in duplicate). Bars that do not share a letter are considered significantly different. 
B) PKB(thr308) phosphorylation was assessed by western blotting. Data are representative of n=3( in 
duplicate). 
4.3.3. Palmitate disrupts mitochondrial function 
 
 
Figure 4. 4. Acute changes in oxygen consumption. Changes in the rate of oxygen consumption were 
measured immediately after exposure to varying doses of PA and PAO. Data are representative of n=20. 
* denotes significant difference from control (p-values < 0.05).  
 
Both PA and PAO were administered at the same concentration yet the capacity to exert 
effects on cell metabolism may be related to how readily oxidised each fatty acid is. The 
intracellular concentration of fatty acids will reflect the balance between uptake and 
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oxidation. Measurement of oxygen consumption after the acute exposure reflects the 
oxidation of exogenous free fatty acids/uncoupling of respiration. A dose response 
relationship was assessed in OCR changes following the additions of PA or PAO up to a 
concentration of 100µM (Figure 4.4). A significant % change in OCR in BSA and PAO 
groups was observed compared to PA (p<0.05, 5.7 mean % change between PA: PAO) 
was observed at 25µM. At 100 µM, oxygen consumption was increased by both PA and 
PAO above that of the BSA control suggesting an increased oxidation of exogenous fatty 
acids. However, no differences between PA and PAO were observed. 
 
 
Figure 4.5. Mitochondrial oxygen consumption traces. C2C12 myotube oxidative capacity was 
assessed using a seahorse bioanalyser and mitochondrial stress test. A) Changes in mitochondrial 
respiration following PA treatment. B) Mitochondrial respiration following PAO treatment. 
 
We next assessed how a 16 hour incubation with PA and PAO altered parameters of 
mitochondrial function. Following treatment of C2C12 myotubes with 250µM, 500µM 
and 750µM PA or PAO for 16 hours mitochondrial function was assessed using the XF 
Seahorse mito stress test. Due to technical difficulties we were unable to obtain 
readings for mitochondrial function at doses of 500 and 750µM PAO. PA caused the 
progressive decline in mitochondrial function with increasing concentration (Figure 
4.5A). Oxygen consumption related to ATP synthesis was reduced by all doses with 
concomitant increases in proton leak (Figure 4.6A, E). The most deleterious effects 
were observed at doses of 500 and 750µM PA. Maximal respiration was reduced, as a 
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result, mitochondria had very little spare respiratory capacity. Interestingly, 250µM PA 
actually increased maximal respiration and spare respiratory capacity. Similarly, 
250µM PAO also enhanced maximal respiration (Figure 4.5B). Unlike PA, PAO did not 
alter ATP synthase dependent OCR indicting that PAO was not negatively affecting 
mitochondrial function. There was a significant increase in proton leak in the PAO 
group, however, this was a small increase and is unlikely to have major effects on 
mitochondrial function.  
Abundances of proteins in the electron transport chain were assessed by western blot 
to assess if the reduction in ATP synthase activity was due to a decreased abundance 
of critical proteins (Figure 4.6). The protein abundances of ATP synthase (subunit 
alpha) and a complex 3 protein UQCRC2 were unaltered by either fatty acid treatment. 
This suggests either an intrinsic default with the energy producing machinery or a 
reduced attenuation of energy consuming processes reducing energy demand for 
metabolic processes. 
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Figure 4. 6.Effects of Palmitate and Palmitoleate on parameters of mitochondrial function. (A,C,E) 
effect of Palmitate on ATP synthesis, spare respiratory capacity and proton leak, respectively. (B,D,F) 
Effect of Palmitoleate on ATP synthase, spare respiratory capacity and proton leak, respectively. Data 
are representative of n=26-28. Data is presented as % of baseline OCR. Number of * denotes smaller p 
value. 
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Figure 4. 7 . Protein abundances of electron transport chain complexes. A – ATP synthase alpha 
(Complex V). B – UQCRC2 (Complex III). Data are representative of n=3 in duplicate. Data are presented 
as mean ± S.E.M 
 
4.4. Discussion 
This study demonstrates that incubation of C2C12 myotubes with 750µM PA or PAO 
leads to a significant incorporation of these fatty acids into the lipid pool and results in 
divergent metabolic responses. One of the key findings of this study demonstrated that 
PA can supress insulin stimulated glucose uptake without attenuating PKB 
phosphorylation. Basal glucose uptake was not altered by PA but insulin failed to 
stimulate an increase in glucose uptake. PAO did not alter glucose uptake or PKB 
phosphorylation. Interestingly, assessment of mitochondrial function following PA or 
PAO treatment revealed that at 250µM, maximal and spare respiratory capacity were 
both increased. At higher doses (500-750µM) PA increased proton leak significantly. 
This disruption in mitochondrial function by PA may play a role in reducing energy 
availability and reducing the myotubes capacity to modify glucose uptake 
appropriately in response to insulin. 
We observed that both PA and PAO were significantly incorporated into the myotube 
lipid pool following a 16 hour incubation with a 750µM bolus of either PA or PAO. 
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Compared to previous chapters, neither fatty acid induced substantial changes in the 
abundance of other saturated and unsaturated fatty acid species. The only 
differentially altered fatty acids were the expected changes in PA and PAO.  Myotubes 
were treated with PA and PAO in PBS + 5mM glucose, meaning no other fatty acids 
were present in the media. Given the treatment media and lack of substantial changes 
in lipid profiles, the data suggests that neither PA or PA is readily converted to other 
fatty acids through elongation and unsaturation reactions. The change in abundance 
likely reflects the balance between uptake and oxidation. PA is the most abundant fatty 
acids in C2C12 myotubes and PA abundance doubled following treatment. PAO had a 
lower concentration in the vehicle group but increased to a greater relative extent 
following PAO treatment than PA.  The different changes in abundance following 
treatment using the same fatty acid concentrations may be explained by differential 
changes in oxidation of PA and PAO. To assess potential differences in oxidation we 
measured acute changes in oxygen consumption following the addition of increasing 
doses of either PA or PAO. The only difference in OCR between PA and PAO was 
observed at 25µM. At doses of 100µM both PA and PAO increased OCR above control 
but no difference was detected between PA and PAO. These data suggest that oxidation 
of exogenous PA and PAO are similar in C2C12 myotubes. Fatty acid uptake is largely 
mediated by transporter proteins, given the media used, the uptake of PA or PAO would 
not be limited by competitive uptake [251]. A recent study has demonstrated that 
addition of the unsaturated fatty acid ALA to the diet alters the abundance of fatty acid 
transporters at the membrane in mouse skeletal muscle [252]. It has yet to be 
investigated if MUFAs such as PAO exert similar effects on fatty acid transporter 
membrane localisation. 
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Following the addition of PA we observed that insulin stimulated glucose uptake was 
attenuated with no effect of PA on basal glucose uptake. This finding is in agreement 
with a number of previous studies which observed a deleterious effect of 750µM PA on 
insulin stimulated glucose uptake [151], [188]. In contrast to these studies, however, 
we did not observe any suppression in insulin stimulated PKB phosphorylation by PA.  
This is a curious finding as PKB activation by insulin and downstream signalling is key 
for initiating the translocation of GLUT4 containing vesicles to the membrane. The lack 
of suppression of PKB phosphorylation would also suggest that in our model PA did 
not activate PKC isoforms or PP2A which inhibit PKB activation either directly or by 
inhibiting upstream signalling.  This led us to speculate that the deleterious effects of 
PA may lie downstream of PKB. PKB phosphorylates AS160 and inhibits its GTPase 
activity resulting in the movement of GLUT4 vesicles to the myotube membrane. Under 
the experimental conditions used, PA may act directly on AS160. Alternatively, the 
inhibition of glucose uptake in response to insulin may be mediated by an increased 
saturation of phospholipids. Although we did not directly measure PA content in 
phospholipids, the large rise in PA content would likely mean an increased 
incorporation in phospholipids. Increasing phospholipid saturation would cause the 
denser packing of phospholipids and a more gel-like membrane structure. The denser 
packing would decrease membrane deformability and interfere with the fusion of 
GLUT4 vesicles with the membrane [253]. More rigid packing could also interfere with 
the lateral diffusion of GLUT4 molecules along the membrane and their pore forming 
activity. If downstream PKB signalling is intact, then this may explain the loss of insulin 
stimulated glucose uptake. More comprehensive profiling of PKB pathway activation 
will be necessary to corroborate this hypothesis. 
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While many previous studies observe attenuated PKB phosphorylation, the PKB 
response to insulin is not completely ablated. To the author’s knowledge, only 
Woodworth-hobbs et al (2014) demonstrate complete suppression of PKB 
phosphorylation at 750µM PA [178]. For instance, Dimopolous & colleagues (2006) 
observe an increase in PKB phosphorylation after insulin stimulation, albeit reduced 
compared to the control group [188]. Given that GLUT4 abundance at the membrane 
saturates at 5% of maximal insulin stimulated PKB phosphorylation, the suppression 
of PKB activation by PA may not be the driver of decreased glucose uptake [254]. 
Furthermore, PA does not induce insulin resistance when co-incubated with a lipid 
mixture ([148] . These data question whether a reduction in PKB activation is critical 
to the disruption of GLUT4 translocation to the membrane induced by PA. Since we did 
not observe an interaction between reduced PKB phosphorylation and glucose uptake, 
the mechanism by which glucose uptake is suppressed may lie downstream of PKB or 
intrinsic defects in glucose transport.  
PA is known to induce reactive oxygen species production, of which mitochondria are 
a major source of production [255]. There is now available data that demonstrate the 
effect of individual fatty acids on multiple parameters of mitochondrial function [163], 
[164]. We utilised the Seahorse analyser to perform a mitochondrial stress test 
following pre-treatment with 3 different doses of PA and PAO (250µM, 500µM, 
750µM). Technical issues prevented the assessment of PAO at doses above 250µM. We 
observed the progressive decline in mitochondrial function with increasing doses of 
PA. In particular, PA caused a large increase in mitochondrial proton leak. Increased 
proton leak can lead to the increase in reactive oxygen species.  Reactive oxygen 
species have been linked with a reduction in glucose uptake[256]. Our results are in 
agreement with previous findings in cultured skeletal muscle myotubes that PA 
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reduced ATP synthesis related oxygen consumption, with a concomitant increase in 
proton leak [163]. Although not directly measured, we predict the ATP availability 
would be reduced following PA treatment.  In contrast, other studies have observed 
that PA only altered mitochondrial respiration when C2C12 cells were in the myoblast 
stage [164]. Reconciling experimental differences is difficult but the contrasting results 
may be due to differences in mitochondrial capability and basal energy demand. Unlike 
PA, PAO (250µM) induced a significant but small rise in proton leak that did not 
compromise ATP linked oxygen consumption. We speculate, however, that at higher 
doses a decline in mitochondrial oxygen consumption would occur. Interestingly, at the 
lowest dose used (250µM) both PA and PAO increased maximal respiration and 
therefore spare respiratory capacity. The increase in maximal oxygen consumption 
could not be fully explained by increasing proton leak. Myotubes would treated with 
these relatively lower doses of fatty acids would therefore likely have an increased 
capacity to alter metabolic rate in response to cellular stress. While the mechanism 
underlying the increase in maximal respiratory capacity is poorly understood it may 
not be related to changes in mitochondrial abundance. The protein content of proteins 
involved in oxidative phosphorylation were unchanged by PA or PAO treatment. The 
increase in maximal capacity may be related to changes in mitochondrial 
fission/fusion. 
Insulin stimulated glucose uptake requires the translocation of GLUT4 containing 
vesicles and fusion of those vesicles with the membrane [257]. Membrane fusion is a 
multistep process involving the movement, docking and fusion with the membrane, 
key to this process are SNARE proteins [258], [259]. Multiple SNARE complexes are 
present in each vesicle fusion event and requires approximately 10 ATP molecules per 
SNARE complex. Extrapolating to the large number of vesicles containing GLUT4, this 
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would be an energetically costly process [260], [261]. With mitochondrial function 
being severely compromised at 750µM PA, vesicle movement and fusion may have 
been compromised. The signal for vesicle translocation lies downstream of PKB so 
would potentially explain how glucose uptake is attenuated despite PKB 
phosphorylation being unaffected. 
In summary, we show that both PA and PAO are significantly incorporated into the lipid 
pool but only PA is associated with the reduction in insulin stimulated glucose uptake. 
Both basal and insulin stimulated PKB phosphorylation were unaffected by fatty acid 
treatment. Instead, we speculate that compromised mitochondrial function or altered 
phospholipid compositions may disrupt insulin stimulated glucose uptake. Our data is 
in contrast to a number of previous studies. The major difference between this study 
and others is the treatment media used. Prior data from our lab showed that PA driven 
insulin resistance was only detectable when PBS+ 5mM glucose was used as a 
treatment media. Other substrates in the media may influence the effect of fatty acids 
on myotube metabolism. Given the significant disruption of metabolic processes by PA 
but not PAO, we next sought to examine the effect of these fatty acids on protein 
metabolism and proteomic profile to further understand the metabolic changes. 
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Chapter 5: Palmitate attenuates protein synthesis despite an 
increase in anabolic signalling. 
Jeromson S, Shaw A, Martin CV, Gallagher IJ, Hamilton DL 
 
5.0. Abstract 
Maintenance of skeletal muscle mass is critical for metabolic health and activity. 
Obesity and ectopic accumulation of lipids within skeletal muscle is associated with 
areduction in the MPS response to insulin and amino acids. There is still little 
understanding in how individual fatty acids can alter muscle anabolism. PA and PAO 
differ in structure by a single double bond but there is evidence to suggest that these 
fatty acids may have different effects on protein turnover. The primary aim of this 
study was to study the effect of incorporation of PA or PAP on protein synthesis, 
breakdown, anabolic signalling and shifts in protein expression in C2C12 myotubes. 
Treatment of C2C12 myotubes with PA resulted in attenuated basal protein synthesis 
(62.9± 12.6% of control) while PAO did not have a significant effect (79.2±15% 
compared to vehicle). Rates of protein breakdown were unaltered by PA or PAO 
treatment. Assessment of anabolic signalling revealed that PA increased 
phosphorylation of ribosomal protein S6. Neither PA nor PAO affected measures of 
endoplasmic reticulum stress. Proteomic analysis also revealed that PA and PAO 
differentially alter the proteomic profile of skeletal muscle. PA and PAO altered the 
expression of proteins involved in purine nucleotide synthesis and cell-cell adhesion. 
These results show that PA attenuated protein synthesis despite an increase in 
anabolic signalling and no change in endoplasmic reticulum stress. Despite being very 
similar in structure PA and PAO have differential effects on protein turnover and 
protein expression. 
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5.1. Introduction 
Skeletal muscle mass maintenance is determined by the balance between protein 
synthesis and breakdown. Maintaining muscle mass is crucial for locomotion, 
metabolic health and longevity [262]. Conditions such as obesity and type 2 diabetes 
have been associated with the accelerated loss of muscle mass [263], [264]. Dietary fat 
has been implicated as playing a role in attenuated protein anabolism. Ectopic lipid 
accumulation within skeletal muscle is thought to contribute to the attenuation of 
muscle anabolism. In rodents, fatty acid accumulation impairs activation of signalling 
pathways and subsequently attenuates protein synthesis [202],[203]. Moreover, obese 
individuals display an attenuated MPS response to elevations in plasma insulin and 
amino acids [165], [166]. Activity of protein kinases within skeletal muscle is sensitive 
to regulation by different fatty acids [59], [169]. In young healthy men, an acute lipid 
infusion impaired the MPS response to insulin and amino acids [265]. This suppression 
of  MPS was associated with the downregulation of 4E-BP1 phosphorylation with 
increasing amino acid concentration. However, not all studies observe an effect of fat 
on protein synthesis. Katsanos & colleagues (2011) [166] did not observe any effect of 
a high fat infusion on rates of MPS. Thus, there is still not a strong consensus on how 
fat or individual fatty acids alter protein synthesis in humans. Given, that saturated fat 
is linked with a negative effect on insulin action, it is logical to hypothesise that 
saturated fat could also causally disrupt in protein turnover. 
There is evidence from in vitro models that PA  can alter multiple aspects of cellular 
function that would serve to supress protein synthesis. PA is known to inhibit glucose 
uptake and this effect extends to other substrates, such as amino acids [172]). System 
A transport facilitates the sodium dependant uptake of neutral amino acids [266]. 
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Exogenous provision of C2 ceramide reduces system A mediated amino acid transport, 
an effect mimicked by PA [172] .  This may lead to a reduction in amino acid availability 
for incorporation into peptide chains. Furthermore, PA can induce ER stress which 
leads to the phosphorylation of Eif2α (Ser51) inhibiting translation initiation [173], 
[175]. Similar to insulin sensitivity, unsaturated fatty acids do not have the same effect. 
It has yet to be investigated if the structurally similar fatty acid PAO has the same effect 
on protein metabolism as PA. As well as altering the synthesis of proteins, fatty acids 
can also affect the rate at which proteins are broken down. PA inhibition prevents the 
sequestering of Fox0 proteins within the cytoplasm by PKB. As a result, Fox0 proteins 
translocate to the nucleus and initiate expression of atrogenes; Murf1, atrogin-1 and 
Bnip3 [67], [178]. Furthermore, a 48 hour incubation with PA resulted in decreased 
muscle myotube diameter, likely linked to the increased protein degradation of muscle 
structural proteins [179]. This shift in protein metabolism following PA treatment has 
been shown to alter the expression of a number of proteins involved in cellular 
processes such as lipid metabolism, protein synthesis and ER stress [267]. The co-
incubation of PA with oleate can counteract the changes in protein expression caused 
by PA. Given that saturated fatty acids and polyunsaturated fatty acids can 
differentially alter protein expression it is likely that monounsaturated fats will have 
independent effects on the abundance of proteins. The alteration in the proteome 
profile may contribute to the understanding of how different fatty acids differentially 
alter skeletal muscle cellular function. 
PA has the potential to influence multiple aspects of protein turnover. Thus, PA may 
induce a shift in the proteomic signature of individual protein abundance. This shift in 
protein abundance could alter the metabolic phenotype of skeletal muscle which 
would serve to alter changes in metabolism in response to intra/extracellular stimuli. 
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Previous studies have only assessed the proteome following PA alone and co-
incubation with oleate treatments [267]. We therefore aimed to investigate the 
proteomic profile in response to PA and PAO using SILAC labelling. Furthermore, we 
investigated the effects of different fatty acid species on measures of protein synthesis 
and breakdown and associated signalling. We hypothesised that PA would induce a 
negative protein balance by altering protein synthesis and breakdown, while PAO 
would display a neutral effect. 
 
5.2. Materials and methods 
5.2.1. Cell culture 
C2C12 myoblasts were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 
20% foetal bovine serum and 1% penicillin/streptomycin and incubated at 37°C and 
5% C02. Myoblasts were maintained at ~60% confluence. Differentiation was induced 
once confluence reached 80-90% by changing the media to differentiation media 
(DMEM supplemented with 2% horse serum and 1% Penicillin/Streptomycin) for 5-6 
days. Following differentiation, myotubes were treated with 750µM PA or Palmitoleate 
for 16 hours. For fatty acid preparation, Palmitate (PA) or Palmitoleate (PAO) were 
dissolved in 100% ethanol at a stock solution of 100mM. Fatty acids were then added 
to the appropriate treatment media + 2% BSA to a working solution. Fatty acid-BSA 
complexes were prepared by constant vigorous shaking at 37°C for 1 hour prior to use 
in experiments. 
5.2.2. Cell processing 
Cell lysates were collected from 6 well plates by scraping on ice in RIPA buffer [50 
mmol/l Tris·HCl pH 7.5, 50 mmol/l NaF, 500 mmol/l NaCl, 1 mmol/l sodium vanadate, 
1 mmol/l EDTA, 1% (vol/vol) Triton X-100, 5 mmol/l sodium pyrophosphate, 0.27 
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mmol/l sucrose, and 0.1% (vol/vol) 2-mercaptoethanol and Complete protease 
inhibitor cocktail (Roche)] followed by snap freezing on liquid nitrogen. For 
preparation for western blotting samples were thawed and debris was removed by 
centrifugation at 4°C for 15 min at 13,000 g. The supernatant was then removed, and 
protein concentration was determined using the DC protein assay according to the 
manufacturer’s instructions (Bio-Rad, Hercules,CA). 
5.2.3. Western blotting 
For western blotting, 100μg of supernatant was made up in Lamelli sample buffer, and 
15 μg of total protein was loaded per well and run at 150 V for 1 h 15 min. Proteins 
were then transferred onto Whatman Immunobilon Nitrocellulose membranes (Fisher 
Scientific, Loughborough, UK) at 30 V for 2 h 15 min. Membranes were blocked in 3% 
BSA-Tris-buffered saline (containing vol/vol 0.1% Tween 20) for 1 h at room 
temperature, followed by incubation in primary antibodies [PKBthr308 (#2965), total 
PKB (#4691) (New England Biolabs) or OXPHOS mitoprofile at 4°C overnight. 
Membranes underwent three 5 min washes in TBST followed by incubation in the 
appropriate secondary antibodies [secondary horseradish peroxidase conjugated 
antibody was purchased from ABCAM (#6721)] for 1 h at room temperature. 
Membranes were again washed three times for 5 min followed by incubation in 
enhanced chemiluninescence reagent (BioRad, Herts, UK). A BioRad ChemiDoc (Herts, 
UK) was used to visualize and quantify protein expression. Phospho proteins were 
normalized to the corresponding total protein. Data are representative of 3 
independent experiments carried out in duplicate. 
 
5.2.4. Muscle protein synthesis and breakdown 
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Protein degradation was assessed by the quantification of the released L-[2,4,3H] 
phenylalanine into the culture media. Following 4 days of differentiation myotubes 
were incubated with medium containing 2.5 µCi L-[2,4,3H] phenylalanine/ml and the 
label was maintained for 24 hours in order to label long lived proteins. Following the 
pulse the cells were washed 2x in PBS and incubated in cold chase media (DMEM + 
2mM L-phenylalanine) for 3 hours to allow for degradation of short lived proteins. 
Myotubes were then treated with either 750µM PA or PAO (PBS+ 5mM glucose, 2mM 
L-phenylalanine, 2% FAF-BSA) for 24 hours. Following treatment an aliquot of the 
media was removed and radioactivity released was assessed by scintillation counting. 
The remaining myotubes were then thoroughly washed with ice cold saline (0.9%) and 
lysed with 50mM NaOH + 1% SDS for a minimum of 30 mins at room temperature. 
Residual radioactivity in cell lysates was then assessed by scintillation counting. Total 
radioactivity was calculated as the sum of the L-[2,4,3H] phenylalanine released into 
the media and the residual cell retained L-[2,4,3H] phenylalanine. Protein breakdown 
is presented as the fraction of the total incorporated L-[2,4,3H] phenylalanine released 
into the media.  
Basal protein synthesis was assessed by the incorporation of L-[2,4,3H] phenylalanine 
into peptide chains. Following differentiation, myotubes were treated with 750µM PA 
or PAO for 16 hours (PBS + 5mM glucose). DMEM + fatty acids were used for the last 2 
hours of the fatty acid treatment in order to prevent the stimulation of protein 
synthesis by the addition of amino acid containing DMEM. At the end of the treatment 
period the media was removed and DMEM containing 1µCi L-[2,43H] phenylalanine 
(0.5 µCi/ml) was added for 180 mins. The reaction was stopped by 2x washes in ice 
cold saline (0.9%) before 3x washes with tricholoroacetic acid (TCA) (10%) to remove 
any unincorporated tracer. Residual TCA was then removed by rinsing cells with 
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methanol and plates left to dry.  Myotubes were then lysed in 50mM NaOH + 1% SDS 
for a minimum of 30 minutes. An aliquot was collected for liquid scintillation counting 
to assess 3H incorporation into proteins and the remaining lysate was used to 
determine protein content by the DC protein assay. Protein synthesis is presented as 
counts per minute/µg of protein. 
 
5.2.5. Stable isotope labelling of amino acids in cell culture 
 
Proteomic profiles were profiled using the SILAC labelling method [234]. C2C12 
myoblasts were grown in differentiation media (DM) supplemented with 20% dialysed 
(10 KDa) foetal bovine serum plus labelled amino acids lysine and arginine in a 
humidified atmosphere of 37°C and 5% CO2. Cells intended to act as the control group 
were grown in with unlabelled lysine and arginine(light), the PA treatment group were 
grown in R6K4 media(l-arginine-13C6 hydrochloride, l-lysine-4,4,5,5-d4 
hydrochloride[medium]) while the PAO treatment group were grown with R10K8 
containing media (l-arginine-13C6, 15N4 hydrochloride, l-lysine-13C6,15N2 
hydrochloride [Heavy]). The use of combined labelled arginine and lysine ensures 
that nearly all peptides will contain a label after tryptic digestion. Cells were allowed 
to grow for at least 6 population doublings to ensure full incorporation of labelled 
amino acids. We observed that use of dialysed sera and labelled media did not affect 
doubling time, cell morphology or differentiation capacity. Upon reaching 90-100% 
confluence the media was replaced with DMEM containing 2% dialysed donor horse 
serum (10 Da) to induce differentiation. Following differentiation, myotubes were 
treated with either PA or PAO for 16 hours and collected for proteome analysis. 
5.2.6. Mass spectrometry 
Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo 
Scientific) nanoflow LC system. On average 0.5µg of protein was loaded with a constant 
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flow of 5 µl/min onto an Acclaim PepMap100 nanoViper C18 trap column (100 µm 
inner-diameter, 2cm; Themro Scientific). After trap enrichment, peptides were eluted 
onto an Acclaim PepMap RSLC nanoViper, C18 column (75 µm, 15 cm; 
ThermoScientific) with a linear gradient of 2–40% solvent B (80% acetonitrile with 
0.08% formic acid) over 65 min with a constant flow of 300 nl/min. The HPLC system 
was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap 
Velos, Thermo Scientific) via a nanoelectrospray ion source (Thermo Scientific). The 
spray voltage was set to 1.2 kV, and the temperature of the heated capillary was set to 
250 °C. Full-scan MS survey spectra (m/z 335–1800) in profile mode were acquired in 
the Orbitrap with a resolution of 60,000 after accumulation of 1,000,000 ions. The 
fifteen most intense peptide ions from the preview scan in the Orbitrap were 
fragmented by collision-induced dissociation (normalized collision energy, 35%; 
activation Q, 0.250; and activation time, 10 ms) in the LTQ after the accumulation of 
10,000 ions. Maximal filling times were 1,000 ms for the full scans and 150 ms for the 
MS/MS scans. Precursor ion charge state screening was enabled, and all unassigned 
charge states as well as singly charged species were rejected. The lock mass option was 
enabled for survey scans to improve mass accuracy [209]. Data were acquired using 
the Xcalibur software. 
5.2.7. Quantification and bioinformatics analysis 
The raw mass spectrometric data files obtained for each experiment were collated into 
a single quantitated data set using MaxQuant (version 1.2.2.5) [235] and the 
Andromeda search engine software  [236]. Enzyme specificity was set to that of 
trypsin, allowing for cleavage N-terminal to proline residues and between aspartic acid 
and proline residues. Other parameters used were: (i) variable modifications, 
methionine oxidation, protein N-acetylation, gln  pyro-glu, Phospho(STY); (ii) fixed 
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modifications, cysteine carbamidomethylation; (iii) database: target-decoy human 
MaxQuant (ipi.HUMAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS 
tolerance: FTMS- 10ppm , ITMS- 0.6 Da; (vi) maximum peptide length, 6; (vii) 
maximum missed cleavages, 2; (viii) maximum of labeled amino acids, 3; and (ix) false 
discovery rate, 1%. Peptide ratios were calculated for each arginine- and/or lysine-
containing peptide as the peak area of labeled arginine/lysine divided by the peak area 
of nonlabeled arginine/lysine for each single-scan mass spectrum. Peptide ratios for 
all arginine- and lysine-containing peptides sequenced for each protein were averaged. 
Data were normalised using 1/median ratio value for each identified protein group per 
labelled sample. 
5.2.8. Data analysis and statistics 
Statistical analyses were carried out using Graphpad Prism (V7). Changes in protein 
synthesis, breakdown and signalling between groups were assessed using a One-way 
ANOVA followed by multiple comparisons tests. SILAC proteomics results were 
initially filtered for experimental replicates within 1 standard deviation. Protein 
abundance was considered altered with a fold change ≥ 1.2 or ≤ 0.8. 
Overrepresentation analysis was assessed using gene ontology. The whole mus 
musculus genome was used as a background list. 
5.3. Results 
5.3.1. Palmitate attenuated protein synthesis but not protein breakdown 
To assess protein metabolism we utilised tritiated L-phenylalanine as a tracer to 
measure both synthesis and breakdown of skeletal muscle proteins. Protein synthesis 
is assessed by the incorporation of labelled phenylalanine into amino acid chains. In 
order to accurately assess protein synthesis, the fatty acid treatment protocol had to 
be slightly modified in order to prevent the amino acid stimulation of MPS when the 
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tracer media was used. Only the first 14 hours of the PA/PAO treatment were 
completed in PBS + 5mM glucose with the last 2 hours being completed using DMEM +  
750µM PA/PAO. This was to allow protein synthesis to return to basal levels following 
the introduction of amino acids. Moreover, L-phenylalanine is not an essential amino 
acid, therefore any changes in protein synthesis are unlikely to be driven by the 
addition of the small amounts of this tracer. Following fatty acid treatment, PA 
significantly reduced basal protein synthesis by approximately 40% (Fig 5.1). PAO also 
induced a small decline in MPS but was not significantly different from control. 
Surprisingly, despite MPS being attenuated RpS6 phosphorylation (a readout of 
P70S6K1 activity) was increased by PA. Eif2α (Ser51) phosphorylation, a marker of ER 
stress, was unchanged by any fatty acid treatment. 
 
Figure 5. 1 Effect of PA and PAO on protein metabolism. A) muscle protein synthesis was assessed 
by L-[2,4,3H] Phenylalanine into protein chains. Data is representative of n=5 and presented as % of 
baseline ± S.E.M. B) protein breakdown was assessed by measuring release of L-[2,4,3H] Phenylalanine 
into media. Data is representative of n=8 and presented as % of total radioactivity ± S.E.M. C) 
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Phosphorylation of RpS6 (Ser240/244) as assessed by western blotting. Data is representative of n=3 
and presented as mean fold change ± S.E.M. D) phosphorylation of Eif2α (Ser51) was assessed by 
western blotting. Data is representative of n=3 and presented as mean fold change ± S.E.M. 
5.3.2. Altered rates of protein turnover results in divergent proteomic profiles 
Due to the finding that PA downregulated protein synthesis and PAO had no effect, we 
hypothesised that this change in protein turnover would result in divergent proteomic 
profiles. We therefore examined if changes in protein turnover altered the abundance 
of individual proteins and subsequently what cell processes these altered proteins 
were associated with. We identified 2079 proteins in the SILAC screen. Due to the high 
variability between replicates, only proteins with replicates within one standard 
deviation were used for further analysis, leaving 532 proteins. Proteins altered in 
abundance by ± 20% were considered to be changed by fatty acid treatment. We 
observed that only a small number of proteins were altered in abundance by either 
fatty acid treatment (Figure 5.2). In the PA group ATR serine/threonine kinase 
displayed the biggest relative change with a 7-fold reduction in abundance.  In the PAO 
treatment group, Cytochrome P450, subfamily F had the largest magnitude of all 
proteins with a log2 fold change of 1.59. A full list of genes altered by both fatty acid 
treatments can be seen in Table 1 and 2. Gene ontology analysis on proteins altered 
revealed that purine nucleotide synthesis was overrepresented (P = 3.07E-02). 
Proteins altered after PAO treatment associated with cell-cell adhesion (p =2.16E-02) 
and cell organisation (p= 1.09E-02). 
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Figure 5. 2 Venn diagram of common and divergent changes in protein abundance following PA/PAO 
treatment. A) comparison of proteins upregulated in each fatty acid treatment B) comparison of proteins 
downregulated by each fatty acid treatment. 
 
Table 5. 1 List of proteins altered by PA 
PA  
Upregulated RPL19, VCAN, ADSL, CYP2F1, EPB41L1, 
PSME2, RPL18, BPNT1, NDRG1, CNOT1, 
LRBA, SORCS2 
 
Downregulated  CYC1, CTSA, CANX, ATP1B3, SEC63, SUCLG1, SYPL1, NCSTN, BAG3, PSMD3, 
KIAA1033,  SAE1, NME1, DNAJA1, TRAP1, SCCPDH, Crip2, HSD11B1, 
Pdlim3, MT-ND5, ATP5J2, ATP2A1, CTSD, TIMM50, PBXIP1, NAP1L1, 
GCDH, POR, PRKAR1A, ATP5L, ZMPSTE24, XRN2, ATR 
 
Table 5. 2 List of proteins altered by PAO 
PAO  
Upregulated CYP2F1, BZW1, EIF4G, RENBP, DLG1, Tpm4, STIP1, HGS, PTGFRN, 
HSD11B1 
Downregulated HDLBP, PRKACB, ENO3, MAT2A, CTSD, HDGF, SCCPDH, UPF1, STRAP, GBA, 
Slc25a1, MT-ND5, RSU1, PPA1,CKM, CKAP5, PEBP1, PGLS, ITGB1, TM9SF3, 
MAP1B, UNC45B, TIMM50, AMCAR, C12orf10, Cyb5r3, PPP1CA, EIF3I, 
PURB, LAP3, AIMP2, KIAA1033, MAP7D1, ATP5J2,PSME4, CSNK2A1, 
PARVB, ATP2A1, DYSF, DRG2, POR, CDH13, SUGT1, ADPRH, CRYAB, 
SYPL1, FLOT1, ITGA7, APOBEC2, BASP1, ARL6IPS, TRIM72, ANKDR2, 
TRIP12, GPC1, ZMPSTE24, AP2M1, CACNG1, SERBP1, ACSL4, YBX3, CDH2, 
ABCC1, NID1, NAP1L1, SORBS2, TRAP1, DIAPH1, Pdlim3, ATP2A3, KLH41 
5.4. Discussion 
Previous studies have shown that PA can have deleterious effects on myotube diameter 
and amino acid transport, which indicate a disruption in protein anabolism [172], 
[179]. In this study we provide some mechanistic insight into how PA can inhibit 
aspects of protein turnover. We show that following a 16 hour treatment PA reduces 
rates of basal protein synthesis. PAO treated myotubes displayed a small decline in 
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protein synthesis but was not significantly different from control. These of different 
effects of PA and PAO on protein metabolism mirror the differential effects on insulin 
sensitivity. The attenuation in protein synthesis by PA was unlikely to be due to 
changes in ER stress. Surprisingly, PA enhanced phosphorylation of ribosomal protein 
S6, a downstream marker of P70S6K1 activation. Furthermore, we show that PA and 
PAO alter the proteomic profile of C2C12 myotubes. 
In muscle tissue, protein is in a constant state of turnover. Protein expression is 
regulated by a number of different variables but ultimately acts to coordinate changes 
in protein abundance in order to appropriately respond to both internal and external 
changes in environment. The loss of protein content can result in the development of 
metabolic dysfunction. In skeletal muscle, factors that result in a negative protein 
balance leads to atrophy. Fatty acid infiltration into muscle can have a negative impact 
on glucose metabolism. We show here that PA attenuates protein synthesis but does 
not impact protein breakdown, while PAO has a no effect.  A previous study observed 
that PA treatment induced a progressive loss of myotube diameter in C2C12 cells [178]. 
Our results indicate that the loss of myotube diameter may be due to a reduction in 
protein synthesis rather than elevated protein breakdown. Hyde & Colleagues 
(2005)[172] observed that PA derived ceramides reduced system A amino acid 
transport so it is logical  that PA incorporation results in the attenuation of protein 
synthesis. To understand the mechanism underlying the reduced protein synthesis we 
assessed signalling markers of anabolic signalling and ER stress. In response to ER 
stress the unfolded protein response is initiated which halts initiation of protein 
synthesis to restore cell homeostasis. In particular, the kinase PERK is activated which 
phosphorylates EiF2α (Ser51) which subsequently inhibits protein translation. We did 
not observe any changes in Eif2α (Ser51) phosphorylation following treatment with 
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either PA or PAO.  Our data contrasts with that of previous reports which observed that 
PA treatment induced ER stress in skeletal muscle myotubes [175]. Our study used PBS 
+ 5mM glucose while [175] used typical differentiation media (2% Serum in DMEM). 
The differences in the available exogenous substrate pools and substrate utilisation 
will alter the effects of PA on protein and glucose metabolism.  ER stress can be induced 
by the aggregation of misfolded proteins. the reduction in the rate of newly synthesised 
proteins caused by PA would reduce the load on the protein folding machinery and 
may offset a reduction in protein folding capacity, thus preventing ER stress.  Measures 
of mTORC1 pathway activity were assessed by measuring phosphorylation of 
downstream targets. We hypothesised that since protein synthesis was reduced that 
mTORC1 related signalling would be similarly reduced. Surprisingly, phosphorylation 
of RpS6, a downstream target of P70SK1, was enhanced following PA activation. The 
uncoupling of protein synthesis to anabolic signalling is not without precedent. 
Termed the “muscle full effect”, anabolic signals remain elevated despite changes in 
MPS being transient [268]. This work shows that protein synthesis does not always 
follow the same pattern as signalling pathway activation. In Beta-cells acute PA 
treatment increased mTORC1 signalling and mRNA translation. However, a 72 hour PA 
treatment resulted in ER stress and the initiation of the unfolded protein response 
[269]. We assessed MPS and signalling after 16 hours and it is possible that we missed 
an acute rise in MPS prior to MPS declining below control. Given that PA can reduce 
amino acid transport and basal protein synthesis is reduced. We also hypothesise that 
the increase in MPS in response to anabolic stimuli would also be attenuated compared 
to control and PAO treated myotubes. Future experiments should aim to assess the 
temporal nature of the effect of PA on muscle anabolism. In a skeletal muscle model, 
PA was observed to only phosphorylate P70S6K1 without having any effect on 4E-BP1. 
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We did not assess the phosphorylation status of 4E-BP1 but our findings would likely 
be in agreement given that RpS6 is a downstream target of P70S6K1. A recent study 
found that PA attenuated MPS by a similar magnitude, using a different methodological 
approach [163]. This study did not couple changes in protein synthesis to anabolic 
signalling measures. Similar to insulin stimulated glucose uptake, protein synthesis is 
also an energetically costly process. In the previous chapter we showed that at the dose 
of PA used for protein anabolism measurements mitochondrial function is severely 
compromised, in particular ATP synthase dependent OCR. As a result of the reduced 
capacity to meet energy demands, protein synthesis may have been reduced in 
accordance with energy availability, despite the activation of anabolic signalling 
pathways. Due to the significant uncoupling of mitochondrial respiration to ATP 
synthesis it is unlikely that the changes in mitochondrial function are due to a reduced 
energy demand for protein synthesis. Treatment media lacking amino acids would 
have led to myotubes relying on intracellular recycling of amino acids to generate new 
proteins. If PA disrupted autophagy then this would result in a reduced rate of protein 
synthesis. In order to further understand the phenotype of PA and PAO treated 
myotubes we followed up these experiments with a SILAC global proteome analysis. 
  
Overall, the effects of PA and PAO on protein abundance identified in the SILAC screen 
revealed changes in a small number of proteins. PAO altered the most proteins, mainly 
through a reduction in protein abundance. Gene ontology analysis did not identify 
many cell processes that would be affected by changes in the abundance of these 
proteins. Analysis of proteins altered by PA revealed enriched processes for purine 
nucleotide biosynthesis. While PAO proteins associated with cell-cell adhesion and 
organelle organisation. Yet analysis of these singular proteins may indicate critical 
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changes in some cellular processes. Indeed, the largest protein downregulated by PA 
was the serine/threonine kinase ATR. This kinase plays a critical role in the DNA 
damage response and activates signalling cascades to repair DNA [270]. The 7-fold 
decrease in this kinase may prevent the appropriate response to DNA damage and 
increase apoptosis.  PA is known to induce mitochondrial DNA damage due to an 
increase in ROS production and if ATR also functions on mitochondrial DNA then this 
may prevent mtDNA repair [164]. Moreover, Protein kinase A was reduced by 30%. It 
is unknown if this loss of PKA would have an observable effect on metabolism. A recent 
study by Chen & colleagues (2016) [267] used a similar SILAC design. This work 
assessed the proteome following incubation with PA and a co-incubation of PA and 
Oleic acid. This study identified Cox-2, a prostaglandin synthase, as a potential effector 
of PA effects. The increase in Cox-2 was reversed by co-incubation with OA. Thus, the 
protective effects of unsaturated fatty acids may be due to the reversal of changes in 
protein abundance induced by PA. Furthermore, given that PA can alter RpS6 
phosphorylation in the absence of any stimulus we speculate that the effects may also 
be driven by changes in post translational modifications (PTM) and repression of 
changes in PTM, as is the case with PKB.  The different experimental methods used by 
this study and Chen et al was the different vehicle media used. This key difference 
prevents a full comparison of the effects of PA on global protein expression. One 
limitation to our model is that the vehicle media did not contain amino acids. This 
means that the cells would have to rely on internal protein recycling as a source of 
amino acids for synthesis of new proteins. The design of the MPS assay means that 
would not have detected any detrimental effect of reduced amino acid availability on 
rates of protein turnover. Therefore, we may have missed changes in gene expression 
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induced by PA and PAO that were not seen at the protein level due to limited substrate 
availability for new proteins.  
In summary, PA incorporation into C2C12 myotubes alters protein metabolism by 
attenuating muscle protein synthesis. In contrast, PAO does not significantly alter any 
aspect of protein synthesis or breakdown. These findings contrast with some of the 
previous literature which observe that PA can increase protein breakdown. 
Surprisingly, the attenuation in protein synthesis was not reflected by decreased 
anabolic signals but RpS6 phosphorylation was actually enhanced. We also did not 
detect any changes in the phosphorylation of ER stress marker Eif2a which inhibits 
protein synthesis. PAO did not alter any measured aspect of anabolic or ER stress 
signalling. It appears that the addition of a single bond into the fatty acid chain is 
sufficient to attenuate the deleterious effect of PA on skeletal muscle protein 
anabolism. 
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Chapter 6: General discussion 
 
 
6.0. General discussion 
 
There is a great deal of interest in the how the composition of dietary fat can elicit 
alterations in glucose and protein metabolism. In the past few decades, the proportion 
of individuals diagnosed with conditions such as type-2 diabetes has risen 
dramatically. Up to 10% of the UK population are estimated to be living with diabetes 
(Diabetes UK)..  The consumption of a diet high in fat has been associated with the 
accumulation of lipids in peripheral tissues which subsequently disrupts normal 
metabolic function. Furthermore, animal and cell studies have linked a high fat intake 
with insulin resistance, altered protein turnover and defects in lipid metabolism [165], 
[265]. The composition of the fat in the diet can also modify the impact of fat on 
metabolism. SFA are implicated as having deleterious effects on insulin sensitivity and 
protein metabolism. While, mono and polyunsaturated fatty acids can offset the 
negative effects of SFA and intrinsically improve aspects of glucose and protein 
metabolism. This supposition is strongly supported by molecular data from cell culture 
and rodent models. However, human studies have provided a more ambiguous 
relationship between dietary fatty acid composition and alterations in metabolic 
function. In particular, there is a great deal of interest in understanding the beneficial 
effects of omega-3 incorporation into skeletal muscle. There have also been multiple 
human trials which have attempted to tease out the relationship between SFA and 
insulin resistance.  
 It is still not fully understood how the fatty acid composition of the diet interacts with 
other environmental variables to impact on metabolic function. The discussion of this 
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work will be split into 2 main parts; part A will discuss the effects of n-3 fatty acids 
EPA and DHA on glucose and protein metabolism, while part B will discuss the effects 
of PA and PAO on glucose and protein metabolism. The common and differential effects 
of EPA,DHA,PA and PAO will be examined in part C 
The body of experimental work presented in this thesis was undertaken in order to 
add to the understanding of how subtle differences in fatty acid structure and 
unsaturation can elicit divergent effects on insulin sensitivity and protein metabolism. 
In order to achieve those aims we designed experiments to meet the following 
objectives: 
 
1. To characterise the incorporation of a) omega-3 fatty acids EPA and DHA 
and b) SFA PA and MUFA PAO into C2C12 myotube lipid pools and 
subsequent alterations in global lipid profiles using Gas 
chromatography/mass spectrometry analysis. Furthermore, analyse the 
storage pattern of EPA and DHA using a shotgun lipidomics approach to 
assess whether EPA and DHA are preferentially stored in neutral lipid 
stores or phospholipids. 
 
2.  To determine the impact of treating c2c12 myotubes with different fatty 
acids (EPA,DHA,PA,PAO) on myotube insulin sensitivity. Glucose uptake 
will be used as a key readout of insulin sensitivity. Measures of glucose 
uptake will be coupled to the assessment of PKB phosphorylation and 
protein abundance of key glucose transporters. Secondly, assess changes 
in mitochondrial respiration and protein abundance of mitochondrial 
complex proteins. 
 
3. To measure changes in protein metabolism by assessing basal protein 
synthesis and breakdown in c2c12 myotubes following treatment with a) 
EPA or DHA and b) PA or PAO using isotopic tracers. Phosphorylation of 
proteins involved in the mTOR signalling pathway will also be assessed. 
Changes in the abundance of individual proteins will be measured using a 
SILAC proteomic screen to assess differentially regulated proteins. Where 
appropriate changes proteins associated with membranes will also be 
measured using SILAC proteomics. 
 
These three aims were addressed through two sets of parallel experiments. In the first 
set of experiments we examined the effects of two n-3 PUFAs EPA and DHA on lipid 
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profiles and metabolic measures such as glucose uptake, protein anabolism and 
mitochondrial function in C2C12 myotubes. To explore the mechanism underlying the 
observed changes, we coupled these experiments to global and membrane specific 
proteomic assessments. In the second branch of experiments, we examined the effects 
of the saturated fatty acid PA and mono unsaturated fatty acid PAO on glucose uptake, 
protein metabolism and mitochondrial function. We also examined the proteomic 
profile following PA or PAO treatment of C2C12 myotubes. 
Part A 
It is now well characterised that omega-3 consumption results in the incorporation of 
n-3 fatty acids into the skeletal muscle pool [23], [55], [56], [59]. These studies 
collectively demonstrate that 4-8 weeks of supplementation (5g n-3, 3g EPA, 2g DHA) 
result in the significant incorporation into the muscle lipid pool and the phospholipid 
specific pool. It appears that omega-3 content saturates after an approximate two-fold 
increase in both total and phospholipid pool.  This incorporation of n-3 PUFAs into 
skeletal muscle is thought to bring about positive health outcomes such as increased 
strength, and increased anabolic sensitivity to aminoacidemia and hyperinsulinemia 
[11], [55], [56], [232] . These health benefits are thought to be the result of potentiated 
activation of the mTOR-P70S6K1 signalling axis in skeletal muscle. In young trained 
individuals omega-3 supplementation did not augment the MPS in response to 
combined feeding and resistance exercise [59]. A surprising finding of this study was 
that the activities of PKB, P70S6K1 and AMPKα2 were supressed by fish oil 
supplementation [59]. In an animal model of hindlimb suspension omega-3 fatty acids 
ameliorated the loss of muscle mass, however recovery after reloading was delayed 
[52], [74]. These studies collectively demonstrate that omega-3 fatty acids can have a 
significant physiological impact on skeletal muscle protein metabolism. Omega-3 fatty 
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acids comprise a heterogeneous mixture of fatty acids of which EPA and DHA are the 
prominent fatty acids. Commonly, supplementation studies use a combination of EPA 
and DHA to demonstrate the effects of n-3 PUFAs on physiology. This prevents the 
ability to decipher whether EPA or DHA are, individually or in combination, driving the 
observed metabolic effects. An interesting study using C2C12 myotubes compared the 
anabolic effects of EPA and DHA individually [184]. The results of this study suggest 
that in skeletal muscle EPA is increases protein synthesis and reduces protein 
breakdown, DHA had no effect. In Chapters 2 and 3 of this thesis the potential 
mechanisms underlying the differential effects of EPA and DHA were explored. 
Work using C2C12 myotubes and cardiomyocytes demonstrate that EPA and DHA 
differentially alter both protein and glucose metabolism [184], [271]. In 
cardiomyocytes EPA, but not DHA, increased glucose uptake [271]. Two independent 
labs have observed that in skeletal muscle EPA increases basal and insulin stimulated 
glucose uptake but it was not previously known if DHA had a similar effect [109], [272]. 
It is demonstrated in Chapter 2 that in line with previous findings EPA enhances 
glucose uptake, in contrast, DHA does not alter basal or insulin stimulated glucose 
uptake. We show that EPA elicits an increase in glucose uptake at even lower 
concentrations than used by Aas & colleagues and Figueras et al (2011) [109], [272]. 
The divergent effect on glucose uptake are curious findings given the similarities in the 
structure of EPA and DHA. Changes in the mRNA abundance of glucose transports 
GLUT1 and GLUT4 have been previously observed following EPA treatment of cultured 
myotubes [109], [272]. However, in the experiments in Chapter 2, any increase in 
glucose transporter expression was not reflected at the protein level. Assessing the 
localisation of GLUT1 and GLUT4 after treatment with EPA or DHA would have 
provided stronger evidence that alterations in glucose transporters did not play a role 
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 Changes in glucose uptake were unlikely to be explained by increased conversion of 
glucose to glucose-6-phosphate as hexokinase 1 and 2 abundance were not altered. 
Hexokinases are considered constitutively active, so a change in HK content would 
indicate changes in kinase activity. Thus, protein abundance can be used as a readout 
of abundance and activity [273]. A recent study in older women observed a significant 
relationship between circulating levels of DHA and insulin dependent glucose uptake 
in skeletal muscle. Our data and that of others would suggest that DHA does not play a 
causal role in this association in muscle and cardiac tissue [274]. Although DHA did not 
alter glucose uptake or PKB phosphorylation, it cannot be discounted that DHA may 
alter glucose utilisation in human models. No changes in mitochondrial respiration 
were observed in Chapter 2 but substrate utilisation was not assessed. The mechanism 
explaining how EPA increased glucose uptake was not readily apparent from measures 
of glucose transporter abundance, PKB signalling or mitochondrial function. 
 
Given that fatty acids are either broken down for energy or stored in complex lipid 
species as an energy reserve and as membrane components it was hypothesised that 
the metabolic effects of n-3 fatty acids are dependent on the incorporation into 
complex lipid species. Therefore, the divergent physiological effects of n-3 PUFAs may 
be explained by differential remodelling of the lipidome. Following extensive measures 
of global lipid profiles, our data are in line with this hypothesis. A major difficulty in 
lipid remodelling experiments is directly linking changes in multiple lipid species in 
various lipid compartments with physiological effects.  
 
Following EPA and DHA treatment of myotubes, total omega-3 content increased up to 
10-fold. This is significantly higher enrichment than has typically been observed in vivo 
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in human skeletal muscle.  Both EPA and DHA resulted in the significant increase in 
total n-3 content, with up to a 10-fold increase each. There are multiple plausible 
reasons as to the ability of myotubes to incorporate n-3 PUFAs to a greater degree than 
in vivo skeletal muscle. N-3 PUFAs are known to be incorporated into a number of 
tissues such as red blood cells, adipose tissue and skeletal muscle. Therefore, there is 
“competition” between tissues for the uptake of available n-3 fatty acids. Moreover, 
differences in lipid turnover rates and uptake capacity can alter the accumulation of n-
3 PUFAs within tissue. Rates of fatty acid oxidation are known to differ depending on 
fibre type composition [26]. Studies looking at the impact of n-3 PUFAs in human 
muscle are largely conducted in the vastus lateralis, a mixed fibre type muscle. It is 
possible that n-3 content and metabolic effects may act in a fibre type dependent 
manner. Furthermore, we used EPA and DHA at a concentration of 50μM. This 
concentration is within the physiological range of omega-3 concentrations in 
individuals who consume regular oily fish [275]. Although 50μM is not a supra-
physiological concentration the available n-3 PUFA pool for uptake into skeletal muscle 
is unlikely be as high as 50μM.  Speculatively, It is possible that in order to have an 
impact on glucose uptake and insulin sensitivity, the intracellular omega-3 
concentration may need to be higher than the concentration needed to elicit changes 
in protein anabolism . This could contribute to the explanation as to why human studies 
show a beneficial effect on protein anabolism in the fed state but not on insulin 
sensitivity. We used EPA and DHA in the free fatty acid form bound to albumin. There 
is evidence that the method of delivery (i.e in TAGs or phospholipids) can affect the 
bioavailability and physiological effects [276]. In this study EPA and DHA 
concentrations in plasma rose to a greater extent when omega-3 PUFAs were provided 
as phospholipids rather than TAGs. This greater rise in plasma concentration was 
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correlated with greater reductions of steatosis and improvements in glucose 
metabolism. 
 
Although both EPA and DHA induced significant increases in n-3 content, the 
composition of individual n-3 fatty acids differed between both treatment groups. We 
observed the expected changes in EPA and DHA with each respective treatment but 
EPA induced the increase in DPA (22:5), an intermediate fatty acid between EPA and 
DHA. There is interesting mechanistic data to explain why EPA can be elongated to DPA 
without being further converted to DHA [225]. The elongases’ affinity for DPA 
saturates with increasing accumulation of DPA. In DHA treated myotubes retro 
conversion to EPA was observed without accumulating as DPA. The remaining 
question, is whether DPA can play a role in the metabolic effects of n-3 PUFAs in 
skeletal muscle. We speculate that the conversion of EPA to DPA may be a critical factor 
in the beneficial effects of EPA. Corroborating this hypothesis, Norris & colleagues 
(2012)[277] observed the blunting of EPAs effect in macrophages when the conversion 
to DPA was inhibited. Inhibiting this conversion in our model is difficult due to the lack 
of specificity of elongases and desaturases. While certain enzymes have a higher 
affinity towards different fatty acids, they are not exclusive. Thus, we could not be 
confident that any effects seen by blocking the conversion of EPA to DPA were not due 
to off target effects. Furthermore, other experimental work from our lab showed that 
treatment of C2C12 myotubes with DPA resulted in the similar accumulation of both 
DPA and EPA, with limited conversion to DHA (Data not shown). Indeed, in vivo work 
in rats demonstrated that DPA supplementation results in the accumulation of DPA and 
EPA in a number of tissues [278]. A parallel study from the same group then 
demonstrated using radioactively labelled fatty acids that DPA accumulates to a 
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greater extent than EPA in skeletal muscle [279]. Likely due to the reduced oxidation 
of DPA compared to EPA. These studies suggest different incorporation patters hint at 
potential differential metabolic effects. N-3 PUFAs are known substrates for 
conversion to bioactive lipid intermediates such as prostaglandins, maresins and 
resolvins. A short supplementation study with EPA, DPA and DHA caused a differential 
shift in plasma levels of resolvins and maresins with little overlap between groups 
[280]. This may partially explain a mechanism for the differential effects of n-3 PUFAs. 
There is, however, little current understanding of the role lipid mediators could play in 
enhancing glucose metabolism. However, it should be noted that a group did not 
observe any changes in n-3 derived lipid mediators after a short term supplementation 
with a very high dose of n-3 PUFAS  [203]. Given that EPA and DPA are interconvertible, 
it is difficult to tease out divergent physiological effects. One study collected a time 
course of EPA and DHA levels in hepatic tissue and observed that after 8 hours of 
incubation DPA has accumulated significantly without interconversion to EPA. Using 
this time point the authors demonstrated that DPA down-regulated expression of 
lipogenic genes such as Sterol regulatory element binding protein (SREBP-1), fatty acid 
synthase (FASn) and acetyl-CoA carboxylase 1 (ACC1) [281]. These effects are similar 
to previous reports that EPA and DHA both downregulate lipogenic gene expression 
[282], [283] . Surprisingly in our model, lipid profiling revealed that both EPA and DHA 
treated myotubes had elevated levels of saturated fatty acids. 
The observation that both EPA and DHA treatment resulted in an increase in saturated 
fatty acids was unexpected. Most predominant, was an approximate 20% shift in the 
saturated fatty acid PA.  Although we cannot confirm the underlying cause of this shift 
we speculate that it may be a compensatory mechanism due to the significant increase 
in myotube unsaturation levels. PA is often linked with a reduction in insulin 
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stimulated glucose uptake. Yet, an increase in PA did not appear to have any negative 
effects on glucose uptake or protein turnover in the context of incubation in EPA/DHA. 
As mentioned previously, n-3 PUFAs downregulate lipogenic genes in hepatic tissue 
[282], [283]. It is unlikely that EPA and DHA promote lipogenesis in skeletal muscle.. 
The membrane proteome screen conducted in Chapter 3 detected a significant 
decrease in SREBP-1 association with the membrane following DHA treatment. The 
cleavage of SREBP-1 from the membrane is a significant step in producing the mature 
form of the protein [284]. If expression is unchanged then DHA may activate SREBP-1 
and subsequent lipogenic gene transcription. Another plausible scenario for the 
accumulation of saturated fats, is the reduction in saturated fat oxidation due to the 
large increase in the presence of n-3 fatty acids. Due to the increased number of double 
bonds, n-3 fatty acid species are more susceptible to oxidation [285]. We did not 
observe any changes in mitochondrial oxygen consumption but that does not discount 
that there were any shifts in substrate utilisation. Increased n-3 availability may have 
shifted fat utilisation to preferentially oxidise n-3 fatty acids. However, both EPA and 
DHA increased substantially (~10-fold increase) so it is unlikely that both fatty acids 
were metabolised for energy production to a great extent.  Another potential reason 
that PA levels increased globally and at the phospholipid level is the compensatory 
response to the increased unsaturation levels. The regulatory mechanisms that control 
phospholipid fatty acid composition remain to be fully defined. 
Incorporation of n-3 PUFAs into phospholipid species is known to induce a shift in 
physico-chemical properties such as membrane fluidity and melting temperature.  
Furthermore, both EPA and DHA are both incorporated into lipid raft like domains 
[195]. Lipid raft domains are highly ordered structures high in sphingomyelin and 
cholesterol that are thought to act as scaffolding domains for protein signalling [286]. 
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Therefore, modulation off lipid raft composition has the capacity to alter downstream 
signalling. Indeed, in colonocytes, DHA supressed  downstream endothelial growth 
factor signalling to ERK1/2, STAT3 and mTOR signalling pathways [287]. It has been 
previously shown that PUFAs are incorporated into lipid rafts and modify the structure 
of these microdomains [288]. PUFA rich lipid rafts have a poor affinity with cholesterol 
and depending on the specific PUFA species, membranes can have both PUFA 
rich/sterol poor and sterol rich/PUFA poor micro domains [288]. Follow up work 
observed that EPA and DHA differentially integrate into lipid rafts, with DHA 
demonstrating a higher incorporation capacity [195].  The phospholipid species that 
n-3 PUFAs are incorporated in can also determine spatio-location within the 
membrane and segregation in raft regions [289]. DHA incorporated into PC segregate 
into raft regions, while incorporation into PE increases incorporation into non raft 
regions [195]. Not only do n-3 PUFA alter the fatty acid composition but also the 
function of phospholipid species. In Chapter 2 we observed the significant 
incorporation of EPA and DHA into all lipid fractions. However, we observed 
differences in the relative abundance of n-3 containing phospholipids between species. 
Of the two most abundant phospholipid groups, PE and PC, we observed that PE had 
the highest abundance of unsaturated species and displayed the greatest relative 
increase in species containing unsaturated fatty acids. In contrast, PC species had the 
highest saturated content and largest decrease in saturated content, with the exception 
of PC 30:00 and PC 32:00. In light of these data and the observed phospholipid 
remodelling, we hypothesised that the incorporation of EPA and DHA into 
phospholipids would alter the membrane associated proteome. Differential shifts in 
proteins associated with the membrane may explain the contrasting effects of EPA and 
DHA. 
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To understand how changes in membrane phospholipid altered the membrane 
associated proteome we utilised a SILAC labelling model followed by the isolation of 
membranous regions. Despite the similar patterns in phospholipid composition the 
membrane association of a number of proteins were differentially altered. The most 
striking results from this screen was the reduction in membrane associated ribosomal 
proteins following DHA treatment. There was a small increase in membrane ribosomal 
proteins following EPA treatment. Changes in membrane association likely reflect 
shifts in the ER and to a lesser extent mitochondrial ribosomal pool. Siekavitz & Palade 
(1956) [290] demonstrated that mRNA transcripts associated with ER bound ribosome 
largely code for secreted and integral membrane proteins while cytosolic ribosomes 
translate cytosolic/nuclear proteins [291], [292]. If total ribosome abundance 
remained stable, then this may represent a divergent shift in the type of proteins being 
translated following EPA or DHA incorporation. Indeed, in Chapter 2, a global SILAC 
protein screen identified a number of differentially expressed proteins in EPA or DHA 
treated myotubes.  Complementing these data with microarray analysis would help to 
identify whether changes in protein abundance are due to increased transcription or 
changes in the turnover of these proteins. 
As well as changes in gene expression, the rate at which individual proteins are 
recycled influence the total abundance of any given protein within the cell. Using a 
global SILAC screen we observed a number of differentially expressed proteins 
following either EPA or DHA treatment. Further analysis of these data revealed that 
differentially altered proteins were associated with different cellular processes.  Thus, 
differential shifts in the proteome in response to EPA and DHA incorporation may 
explain the observed divergent effects on metabolism.  
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Overall, our data on protein turnover agree with previous literature [293].  In response 
to an increased availability of leucine, EPA but not DHA, increases the protein synthesis 
response in C2C12 myotubes. Here we show that in the basal state, neither EPA nor DHA 
alters protein synthesis. Following serum starvation, myotubes were stimulated with 
20% FBS growth media and P70S6K1 phosphorylation was assessed as a marker of the 
anabolic response. In contrast to previous reports, neither fatty acid altered P70S6K1 
phosphorylation. This suggests the effect of omega-3 on muscle anabolism is 
determined by the nature of the anabolic stimulus. We also observed a reduction in 
protein breakdown, again in agreement with previous reports. This change in protein 
turnover resulted in a significant increase in protein content after 72 hours of 
treatment. In an animal model, omega-3 fatty acids offset the loss of muscle mass 
following hind limb immobilisation [52]. Our work and the work of others in tissue 
culture models suggest that this protective effect may be driven mainly by EPA. 
Following resuspension in the same cohort, the fish oil group displayed a delayed 
response in muscle growth. This delayed recovery was associated with a reduction in 
prostaglandin F2α compared to the control group [74]. This may be the result of 
phospholipid remodelling reducing the precursor pool for production of this 
prostaglandin species. It should be noted, that by the end of the experimental period, 
mice in the omega-3 supplementation group had recovered to a similar extent than 
control mice. Thus omega-3 PUFAs may only be detrimental in the early phases of 
recovery when acute inflammation is a necessary stimulus for recovery.  Under 
atrophic conditions, the attenuating effect of EPA on protein breakdown may lead to 
the accumulation of damaged proteins. A reduction in protein breakdown may not be 
advantageous for effective recovery. 
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In summary, we provide evidence to suggest that EPA is the main driver of the 
beneficial effects of n-3 fatty acids on protein accumulation and glucose uptake in 
skeletal muscle. The elongation of EPA to n-3 DPA may be a critical step in eliciting 
effects on cell metabolism. In contrast, DHA does not mediate any observable 
differences from the vehicle treatment and does not appear to have any deleterious 
effect in respect to the metabolic parameters measured. These effects may be 
influenced by the EPA specific alteration of fatty acids species contained in 
phospholipids and the changes in proteins associated with phospholipids. 
Part B 
In the second experimental arm of this thesis the effects of saturated fatty acid PA and 
mono unsaturated fatty acid PAO on glucose and protein metabolism were assessed. 
This comparison allows for the assessment of the importance of double bonds within 
a fatty acid carbon chain. PA is often associated with deleterious effects on muscle 
glucose metabolism. It is often thought that PA treatment disrupts normal metabolic 
function through the accumulation of lipids. Yet PAO, when used at the same 
concentration does not induce the same defects [19]. Moreover, when PA and PAO are 
co-incubated the deleterious effects of PA are attenuated. These antagonistic effects 
make it difficult to assess the effect of PA or PAO on insulin sensitivity in vivo.  Doubling 
the saturated fat content of the diet can alter gene transcription [147] but does not 
alter insulin sensitivity. Ex vivo assessment of muscle glucose uptake showed that PA 
reduced insulin stimulated glucose uptake and obesity increased sensitivity to this 
effect [244]. To date, the understanding of PA effect in muscle has relied on information 
from tissue culture models.  
Very little information is available regarding the effects of PA and PAO on the overall 
lipid profiles in skeletal muscle. Multiple studies present data regarding the metabolic 
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effects of PA but it is not known how well it is incorporated into the lipid pool. We first 
assessed the remodelling of the lipid pool following treatment with 750μM PA or PAO 
for 16 hours. Unlike n-3 fatty acids neither PA nor PAO had a major impact on the 
abundance of other fatty acids. Generally, MUFA species are displaced in favour of 
accumulation of PA or PAO. Although, the magnitude of these changes were smaller 
than the changes observed in the omega-3 lipid profiling experiments. This is 
surprising given that PA and PAO were used at a significantly higher concentration. 
Although differences in the relative fold change were observed between PA and PAO, 
the absolute incorporation was significantly greater in the PA group. This would not 
suggest that fatty acid transporters have different affinities for fatty acid species.  
Although we did not make a direct measure, it is likely that the two-fold increase in 
total lipid content would induce an increase in saturated fatty acid containing 
phospholipid species. Increasing the saturated fatty acid of membrane phospholipids 
would theoretically increase the rigidity of phospholipids due to the increase in 
melting temperature of the membrane. This could reduce the fusion of proteins 
translocating to the membrane. This is one of the potential mechanisms by which PA 
could downregulate glucose uptake in response to insulin.  
Following these measurements, we made assessments of glucose uptake in the basal 
state and insulin stimulated state, alongside PKB phosphorylation. In agreement with 
previous reports, PA attenuated insulin stimulated glucose uptake but did not affect 
basal uptake. However, unlike these studies we did not observe any changes in PKB 
phosphorylation in response to insulin. This demonstrates that there are multiple 
mechanisms by which PA attenuates insulin driven glucose uptake. As discussed in 
Chapter 4 PKB activation may not be the most critical factor in PA’s reduction in 
glucose uptake. Multiple studies show that the capacity to phosphorylate PKB is still 
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maintained following PA treatment, albeit to a lesser extent ([19], [247], [294]). PKB 
may only require a small increase in phosphorylation to saturate GLUT4 translocation 
to the membrane [254]. Common in phosphorylation amplification cascades, a small 
increase in the activity of an upstream regulator can still have significant downstream 
effects on downstream signalling. Thus, the critical deleterious effect of PA may lie 
downstream of PKB. Current thinking suggests that the conversion of PA to ceramides 
activate PKC isoforms and protein phosphatases which disrupt PKB activation. We did 
not assess ceramide levels but given that there were no changes in PKB 
phosphorylation it could be speculated that ceramides did not impact PKB 
phosphorylation or did not increase enough to interfere with PKB phosphorylation.  
These results also highlight that PA may act downstream of PKB or through PKB 
independent mechanisms to interfere with insulin stimulated glucose uptake. One such 
possibility may be the down regulation of Sortilin, which regulates GLUT4 cycling in 
C2C12 myotubes [295]. Following these experiments, we assessed the effect of PA and 
PAO on mitochondrial oxidative capacity. At 750µM PA significantly attenuated 
oxidative capacity, with increasing proton leak and compromised ATP synthesis. It 
could be hypothesised that the reduction in ATP production would activate energy 
stress pathways, such as AMPK activation, which increase glucose uptake and shift 
energy production to rely on glycolysis. Due to the acidic nature of fatty acids it is 
difficult to measure the rate of extracellular acidification to assess changes in 
glycolysis. We did not assess any changes in glucose transporter capacity or 
localisation following PA or PAO treatment which may play a role. It remains to be seen 
whether defects in oxidative phosphorylation precede decrements in protein 
synthesis.  
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The decrements in insulin sensitivity caused by PA may only be present in the context 
of energy overload within skeletal muscle [296]. For example, providing 2DG, a non-
metabolizable for of glucose, instead of glucose in culture media abrogates the 
deleterious effect of PA on insulin sensitivity. In our experimental model, PA and PAO 
treatment were given in media lacking serum, amino acids and low in glucose (5mM). 
Given these conditions, we are able to show that in C2C12 myotubes PA induces insulin 
resistance in conditions of reduced energy availability. Thus, the insulin resistance 
induced in our model is due to specific properties of PA and not energy overload of the 
myotubes. 
While there has been a significant amount of investigation into the effects of PA and 
PAO on glucose metabolism, there is little information regarding the effects of these 
fatty acids on muscle protein anabolism in human models. PA is known to induce ER 
stress in myotubes and this subsequently induces a signal which feedbacks to inhibit 
protein synthesis [175]. Thus, it was hypothesised that PA would inhibit protein 
synthesis. Indeed, we and other groups have recently shown that in skeletal muscle 
myotubes PA attenuates basal protein synthesis [163]. Our data suggest that the 
reduced protein synthesis was not due to ER stress as EIF2α (ser51) phosphorylation 
was unchanged following PA treatment. Interestingly, the attenuation in synthesis of 
new proteins was also not due to reduced P70S6K1 signalling as RpS6 phosphorylation 
was increased. There are data to suggest that a negative feedback loop following 
P70S6K1 activation which inactivates the upstream regulators which can negatively 
affect glucose uptake [297]. However, if this was the case then it would be expected to 
manifest as a reduction in PKB phosphorylation. Since we did not see any changes in 
PKB phosphorylation it does not appear that this feedback loop is having any effect. 
From our data it is not readily apparent the disconnect between anabolic signalling and 
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protein synthesis. We did not detect any changes in protein breakdown in either fatty 
acid treatment group, It may be that PA enhances the protein breakdown response only 
in the presence of catabolic stimuli such as TNFα.  
Similar to Chapter 3, we performed a global SILAC analysis to build a more complete 
picture of the protein expression changes. Gene ontology analysis did not reveal any 
enrichment for major anabolic or glucose metabolic pathways. It could be the case that 
proteins identified in the screen may have novel functions in the regulation of glucose 
uptake. Chen & colleagues (2016) using a similar experimental design, showed that PA 
upregulated Cox-2 and this effect was reversed by co-incubation with oleic acid. It 
remains to be seen if changes in prostaglandin synthesis plays a causal role in the 
metabolic effects of PA. We were unable to detect Cox-2 or perilipin proteins in our 
screen so it is difficult to compare results. This is likely due to the different treatment 
medias used to deliver PA and PAO in myotubes. The effects of PA and PAO are likely 
to be different when in the presence of lipids, growth factors and amino acids. 
However, this experiment was designed to understand the changes in glucose and MPS 
observed using PBS + 5mM glucose as a vehicle media. We propose that the effects of 
PA are largely driven by changes in post translational modifications (PTM). EPA and 
DHA have been shown in vivo to have differential effects on PTMs and it is likely that 
comparing unsaturated fatty acids with saturated fatty acids would demonstrate even 
larger differences [107]. Further work should assess the phospho-proteome to assess 
changes in kinase signalling following insulin treatment. 
Part C 
Although direct experimental comparisons are difficult using these fatty acids we can 
compare the overall effects. From the data gathered it suggests that EPA and PA have 
unique effects on skeletal muscle myotube function. There is now a large amount of 
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evidence that longer chain, highly unsaturated fatty acids have beneficial and 
protective effects against shorter chain saturated fatty acids. In particular, the n-3 
PUFA EPA both increases glucose uptake and reduces protein breakdown while DHA 
which differs by 2 carbons and 1 double bond does not display any of these effects (in 
our hands). The MUFA PAO, similar to DHA, did not have any effect on glucose uptake 
or protein metabolism. It appears that the previously observed protective effects may 
only be evident in the presence of an inflammatory or catabolic stimulus. Interestingly, 
both PA and PAO increased maximal mitochondrial capacity when used at 
concentrations of 250µM. The effects of EPA and DHA on mitochondrial function were 
only assessed at 50µM. It would be interesting to assess if EPA and DHA had similar 
effects on maximal mitochondrial respiration when used at higher concentrations. 
 Our main hypothesis was that the divergent effects of different fatty acid species were 
driven in part by the fatty acid specific shift in the myotube lipid pool. Both PA and PAO 
treatment results in increases in those fatty acid species, however, very few other fatty 
acids were displaced or increased as a result. In contrast, EPA and DHA had a significant 
impact on the abundance on MUFAs (decrease) and SFA (increase in some fatty acids). 
Moreover, there were divergent effects between EPA and DHA in important species 
such as arachidonic acid (AA) and DPA. The differences in lipid remodelling between 
experimental branches may have been related to the length of fatty acid treatment (72 
vs 16 hours). However, prior studies have observed changes in lipid content after a 
short incubation with fatty acids [298] and we do not predict that extended incubation 
with PA or PAO would alter the observed effects. Assessing the time course of each 
individual fatty acid incorporation would assist in answering this question. 
A shift in the lipidomic profile influences the proteins associated with the membrane 
which has the potential to alter the cellular response to extracellular stimuli such as 
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insulin and amino acids. The fatty acid composition of skeletal muscle can also 
determine the rate of protein turnover. EPA increases protein accumulation over 72 
hours, largely due to a reduction in protein breakdown. The data from this thesis 
suggest that shorter chain SFA do not alter protein breakdown but attenuate basal 
rates of protein synthesis. In light of the body of data, increasing the unsaturated fatty 
acid content, in particular with EPA and DPA, can have protective and beneficial effects 
on skeletal muscle metabolism. While saturation of the lipid pool can have deleterious 
effects on muscle metabolism. 
We also profiled the proteome of myotubes following treatment with EPA, DHA, PA or 
PAO. We then assessed the association of altered proteins with biological processes. 
Treating myotubes with omega-3 PUFAs EPA and DHA elicited alterations in a large 
number of proteins which associated with the mTOR pathway, EIF2 signalling, protein 
ubiquitination and actin cytoskeleton dynamics. Namely, processes all involved in cell 
growth and protein turnover. In contrast, proteomic profiling of PA and PAO treated 
myotubes revealed changes in the abundance of only a few proteins. Furthermore, gene 
ontology analysis of these proteins revealed that these proteins did not associated with 
a substantial number of cell processes. Only purine nucleotide biosynthesis was 
enriched by PA and cell-cell adhesion by PAO. These proteomic profiles suggest that 
highly unsaturated fatty acids EPA and DHA have a greater impact on protein 
expression and turnover. The different treatment medias used in each experimental 
arm preclude definitive evidence of this. 
Limitations and future approaches 
 
This thesis has added novel information about the effects of fatty acids of differing 
chain length and saturation. It is however, important to acknowledge that there are 
limiting factors to every experimental model. Two of the main physiological outputs 
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we assessed in this thesis were glucose uptake and muscle anabolism. In order to 
further explore the mechanisms underlying the observed changes we utilised a global 
SILAC labelling proteomics approach with the hypothesis that alterations in protein 
abundance may sensitise or desensitise muscle to extracellular glucose or protein. This 
approach is a highly sensitive way to assess changes in the abundance of proteins 
[234]. Global proteomics are often labelled as an unbiased approach compared to 
western blotting for individual protein abundance, however, there are certain caveats 
to this point. Proteomic screens are unlikely to capture the entire proteome, thus this 
approach only reduces bias. Labelled lysine and arginine amino acids are added to the 
cell media during proliferation and differentiation and are subsequently incorporated 
into proteins with high efficiency. Light, medium and heavy labels are used which 
allows up to 3 groups to be compared at one time. Prior to infusion into the mass 
spectrometer proteins undergo tryptic digestion. Trypsin cleaves at lysine and arginine 
residues which results in every peptide containing a labelled lysine or arginine. While 
there are a number of strengths of using this method there are some drawbacks. Prior 
to tryptic digestion the samples are separated on a 2D gel. Due to many membrane 
proteins containing hydrophobic domains, it can lead to the formation of protein 
aggregates and subsequent mobility issues when ran on a gel. Furthermore, proteins 
with isolelectric points and molecular weight outwith the median of the proteome can 
be difficult to quantify. This biases protein detection to that of cytosolic proteins and 
may impact or mask the detection of potential changes in protein abundance that may 
explain the phenotype of cells following fatty acid treatment. Given this bias, following 
our finding that omega-3 incorporation resulted in significant phospholipid 
remodelling we conducted a membrane proteomic screen. By isolating the membrane 
fraction prior to separation, membrane proteins are enriched thus allowing for easier 
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identification. This screen revealed a number of differentially altered proteins that 
were not detected in the global proteomic screen (Chapter 2). 
Skeletal muscle has a number of mechanisms that couple extracellular stimuli with the 
appropriate signalling and physiological response. Responses to extracellular stimuli 
such as insulin and amino acid availability are governed by post translational 
modifications[250], [268], [299].  We chose to initially assess global changes in protein 
abundance to identify gene expression networks sensitive to fatty acids with subtle 
differences in structure. Moreover, we observed that EPA and PA altered aspects of 
basal glucose and protein metabolism. We also observed that in response to insulin 
EPA enhanced glucose uptake compared to DHA while PA inhibited glucose uptake. 
Future studies should couple the observed changes in protein abundance with 
phospho-proteomics in the basal and insulin stimulated state. Furthermore, in 
Chapter 2 we observed that protein breakdown is altered by EPA.. Unlike previous 
reports, we did not observe any potentiating effect of EPA or DHA on P70S6K1 
phosphorylation in response to a serum stimulus. It is possible that this effect may be 
dependent on the presence of insulin [170], [265]. These experiments were completed 
in a C2C12 cell line which were insulin sensitive in terms of glucose uptake but protein 
synthesis was not responsive to increased insulin availability.  This replicates the 
observation in human skeletal muscle that MPS is not sensitive to increasing 
concentrations of insulin [171].  Previous studies in C2C12 myotubes have shown an 
effect of insulin on MPS and this highlights that even immortalised cell lines are not 
always homogeneous. Furthermore, studies in humans have shown that omega-3 fatty 
acids can induce modest changes in gene expression but it remains to be seen if gene 
expression is specific to either EPA or DHA [210].  
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One of the most significant limitations of this thesis is the inability to directly compare 
the effects of all four fatty acids. The experimental design necessitated that the project 
be completed in two independent arms. This also meant that different concentrations 
and vehicle media were used in each experimental arm. Using the same fatty acid 
concentrations and media conditions across all experiments would that some of the 
observed metabolic changes would not have been observed. Furthermore, at 
concentration of 750µM, EPA and DHA would be toxic to the cells while at 50µM PA 
and PAO would be unlikely to have any significant effects. Moreover, previous media 
testing from our lab was only able to detect a PA induced reduction in glucose uptake 
when PBS+5mM glucose was used as the vehicle media. Each set of experiments 
required different media conditions which further precludes running a 4-way 
comparison in the same set of experiments. Furthermore, the maximum number of 
groups that can be compared in one SILAC experiment is three. This limits the 
conclusions of these studies about the function of different fatty acid structures, it is 
difficult to design a direct metabolic comparison without confounding variables such 
as lipotoxicity induced cell death. One strength of these experiments is that DHA and 
PAO had neutral effects, acting as a secondary fatty acid control group. This allowed us 
to delineate that the observed effects were due to differences in fatty acid structure 
and not simply fatty acid overload. 
To address these limitations, future experiments should aim to validate the main 
results of the mass spectrometry experiments.  The SILAC proteomic screen identified 
a number of differentially altered proteins. Western blotting for some of the main 
targets identified in this screen would validate these results.  Additionally, one of the 
main trends that emerged from the membrane proteomic data suggested a shift in 
ribosomal protein abundance. Subcellular fractionation of the cytosolic and membrane 
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compartment followed by western blotting for ribosomal proteins would add further 
insight into these results.  If this shift in ribosomal content was confirmed then 
ribosomal profiling would allow for the identification of mRNA transcripts associated 
with specific ribosomal pools. Due to the lack of changes in the lipidome following PA 
or PAO treatment, we did not follow this work up with the assessment of phospholipid 
analysis. Coupling the metabolic changes in PA/PAO treated cells with extensive 
phospholipid analysis may allow for a better comparison with EPA/DHA treated cells. 
 
Future philosophy 
The body of experimental work presented in this thesis demonstrates that different 
carbon chain lengths and number of double bonds of fatty acid species can have a 
significant impact on skeletal muscle myotube metabolic function. We provide further 
evidence that EPA is more metabolically active in skeletal muscle than DHA, when 
assessing glucose and protein metabolism. We provide novel data that suggest these 
differential effects are driven by lipid specific remodelling of the lipidome and changes 
in phospholipid structure and associated proteome. Moreover, by comparing PA and 
PAO we show that a single double bond can influence the metabolic effects of fatty acids 
in skeletal muscle. These results, whilst interesting, raise a number of questions that 
will hopefully be resolved in the future. 
1. How are specific fatty acid species channelled towards different metabolic 
fates? 
 
2. How does EPA increase glucose uptake independently of changes in PKB 
phosphorylation and glucose transporter abundance? 
 
3. Do n-3 fatty acids modify the actions of insulin on signalling pathway 
activation and gene expression? 
 
4. Do EPA and DHA differentially alter protein turnover in human models 
under conditions of suboptimal anabolic stimuli? 
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5. Further define how PA supresses protein synthesis despite increases in P70 
related signalling 
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